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ABSTRACT 
Identification of HIV-1 genetic associations with  
coreceptor usage and neurocognitive impairment 
 
Gregory C. Antell 
 
The low fidelity of HIV-1 reverse transcriptase results in a high frequency of 
mutation and generates extensive genetic variation both within and between 
infected individuals. Importantly, many of these mutations can contribute to 
disease presentation and progression despite the overall efficacy of antiretroviral 
therapy (ART). Of particular interest to the studies herein was the relationship 
between HIV-1 genetic diversity, tropism, and the development of HIV-1 
associated neurocognitive disorders (HAND), a comorbidity of increasing 
prevalence in the HIV-1 infected population. These studies explored two 
interrelated avenues of research: developing a strategy to identify genetic 
signatures of HIV-1 co-receptor utilization during entry that extends beyond 
proteins forming the viral envelope, and utilizing the genetic variation of the 
accessory HIV-1 protein Tat to assess the likelihood of neurocognitive impairment.  
Jensen-Shannon divergence was applied to compare multiple sequence 
alignments and identify signature positions that are most distinct between X4- and 
R5-utilizing HIV-1 genotypes or quasispecies, for the accessory proteins Tat and 
Vpr. Additionally, within the HIV-1 long terminal repeat (LTR), predicted 
 xi 
transcription factor binding sites demonstrated statistically different binding affinity 
scores for X4 and R5 LTR sequences.  
Finally, we developed a statistical learning approach utilizing regularized 
logistic regression for the prediction of neurocognitive impairment, integrating 
patient-derived HIV-1 genetic information as well as standard clinical 
measurements such as CD4+ T cell count and viral load. Here, we demonstrated 
that genetic-based models of neurocognitive impairment can outperform models 
utilizing standard clinical data based on the analysis of receiver operating 
characteristic (ROC) curves. This performance provides strong support that the 
integration of next generation sequencing data of HIV-1 Tat and other genes may 
yield improvements to clinical screening tools, as well as allow the statistical 
inference of genetic variants associated with neurocognitive impairment. 
 These studies have shown that the naturally occurring genetic variation that 
exists throughout the genome associates with coreceptor usage and hence cell 
phenotype.  This may play a role in disease pathogenesis as macrophages are 
classically implicated in bringing virus to the central nervous system (CNS) and 
infection of the T cell compartment is classically related to worsening of disease 
progression.  In line with this thought, viral proteins made from infected cells in the 
CNS, like Tat, may play a role in CNS dysfunction leading to impairment.  Taken 
together, viral sequences found in patients may have the ability to be used as a 
biomarker for disease progression and neurocognitive impairment. 
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in Neuroinflammatory Disease 
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1.1 Abstract 
Human immunodeficiency virus type 1 (HIV-1) and human T-cell leukemia virus 
type 1 (HTLV-1) lead to acquired immunodeficiency syndrome (AIDS) and adult T-
cell leukemia, respectively, and these viruses have also been identified as the 
etiologic agents of HIV-associated neurocognitive disorders (HAND) and HTLV-1-
associated myelopathy/tropical spastic paraparesis (HAM/TSP). Pathogenic 
processes associated with these diseases are due to HIV-1 and HTLV-1 infecting 
not only cells of the host immune system but also cells of the central nervous 
system (CNS). For each of these viruses (HIV-1 and HTLV-1), the major viral 
regulatory proteins, Tat and Tax, respectively, have been shown to be implicated 
as extracellular neurotoxic proteins. This chapter will provide an overview of the 
structure and function of Tat and Tax and describe their role in viral replication 
focusing on their interaction with their viral promoters. Information will then be 
presented that describes known modifications of these important regulatory and 
neurotoxic proteins and the current understanding with respect to how these 
proteins are secreted into the extracellular environment. The specific roles that Tat 
and Tax play as extracellular proteins especially their role in neuropathogenesis 
are discussed with a focus on comparing their functional similarities and 
differences. Finally, the review will discuss the immune response in the CNS with 
respect to these two essential viral transactivator proteins. 
  
 3 
1.2 Introduction 
Human immunodeficiency virus type 1 (HIV-1) and human T-cell leukemia virus 
type 1 (HTLV-1) have both been shown to infect not only cells of the host immune 
system but also cells of the central nervous system (CNS) (Jacobson 2002, 
Gonzalez-Scarano and Martin-Garcia 2005). As members of the retrovirus family, 
HIV-1 and HTLV-1 contain RNA genomes and hijack the host cell transcriptional 
machinery in order to synthesize viral proteins and replicate within human host cell 
targets. Infection with HIV-1 and HTLV-1 can lead to acquired immunodeficiency 
syndrome (AIDS) and adult T-cell leukemia, respectively, and these viruses have 
also been identified as the etiologic agents of HIV-associated neurocognitive 
disorders (HAND) and HTLV-1-associated myelopathy/tropical spastic 
paraparesis (HAM/TSP). While HIV-1 and HTLV-1 CNS infection do not cause 
acutely fatal diseases, the resulting neurological problems persist as chronic 
conditions that cause a wide range of neurological abnormalities and remain 
relevant medical concerns (Sacktor, McDermott et al. 2002, McArthur 2004, Pillat, 
Bauer et al. 2011). With no successful vaccine existing for HIV-1 or HTLV-1 and 
antiretroviral drugs having a reduced efficacy on targets within the CNS, 
investigation into the causes and consequences of retroviral-induced 
neurodegeneration remains a prominent research focus (Walker and Burton 2008, 
Goncalves, Proietti et al. 2010, Churchill and Nath 2013). 
1.2.1 HIV-1-associated neurological disorders (HAND) 
Since the adoption of highly active antiretroviral therapy (HAART), the 
symptomology of HIV-1 disease has been increasingly transformed from a 
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devastating attack on the peripheral immune system to a chronic disease that 
continues to involve pathogenesis in the CNS (Sacktor, McDermott et al. 2002, 
McArthur 2004). As a result, most AIDS-defining illnesses have seen a dramatic 
decrease in both severity and frequency, in addition to reduced viral loads and 
increased CD4+ T-cell counts in HIV-1-infected individuals (Li, Tubiana et al. 1998, 
Hunt, Deeks et al. 2003). In contrast to this trend, HAND has increased in 
prevalence although the most severe form of HAND, HIV-1-associated dementia 
(HAD), has become much less common (McArthur 2004, Nath, Schiess et al. 
2008). The other manifestations of HAND consist of asymptomatic neurocognitive 
impairment and HIV-associated mild neurocognitive disorder (Cherner, Cysique et 
al. 2007). These conditions are distinguished on the basis of the severity of 
cognitive dysfunction, with symptoms including memory loss, impaired 
coordination, and reduced adherence to medication regimens (Andrade, Deutsch 
et al. 2012). HAND is also often accompanied by HIV encephalitis (HIVE), a brain 
pathology caused by immune activation of microglia and macrophages in response 
to HIV-1 infection and associated with poor prognosis (Gray, Adle-Biassette et al. 
2001). In addition to activating an antiviral immune response within the CNS, the 
production of HIV-1 proteins also leads to neurotoxicity through direct and indirect 
mechanisms. Of particular interest is the HIV-1 transactivator protein Tat, which in 
addition to driving viral transcription also functions as an extracellular neurotoxic 
protein, as discussed below (Li, Li et al. 2009). 
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1.2.2 HTLV-1-associated myelopathy/tropical spastic paraparesis  
HAM/TSP is a chronic and progressive inflammatory disease of the CNS 
(Gessain and Mahieux 2012). The disease is primarily a demyelinating disease of 
the spinal cord caused by the overstimulation and dysfunction of the immune 
compartment (Irish, Khan et al. 2009). Especially prominent in the 
neuropathogenesis of HAM/TSP is the cytotoxic T-lymphocyte (CTL) response to 
the HTLV-1 transactivator protein, Tax, and increased expression of inflammatory 
cytokines and chemokines (Kannagi, Shida et al. 1992, Parker, Daenke et al. 1992, 
Guerreiro, Santos et al. 2006, Ahuja, Lepoutre et al. 2007). HAM/TSP does not 
present in all HTLV-1-infected patients and the pathogenesis of the disease 
remains poorly understood (Pillat, Bauer et al. 2011). A wide variety of factors likely 
contribute to whether an HTLV-1-infected individual will develop HAM/TSP 
including the mode of infection, viral strain, and human leukocyte antigen (HLA) 
subtype (Daenke, Nightingale et al. 1990, Niewiesk, Daenke et al. 1994, Jeffery, 
Siddiqui et al. 2000, Grant, Barmak et al. 2002, Sabouri, Saito et al. 2005, 
Rafatpanah, Pravica et al. 2007). Clinically, HAM/TSP may result in a variety of 
symptoms including urinary incontinence, lower back pain, sexual dysfunction, and 
weakness of the lower limbs (paraparesis), for which it is named (Shibasaki, Endo 
et al. 1988, Nakagawa, Izumo et al. 1995). These symptoms are consistent with 
the majority of neuronal damage being found in the corticospinal tract (Araujo, 
Andrade-Filho et al. 1998). The disease typically progresses through two stages, 
an initial inflammatory disorder and a chronic long-term degenerative stage 
(Araujo, Leite et al. 1995). The acute phase is characterized by infiltrating 
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lymphocytes and the release of proinflammatory cytokines, while chronic disease 
is marked by the accumulation of CD8+ T cells in the cerebrospinal fluid (CSF) and 
peripheral blood and at lesions within the spinal cord (Lepoutre, Jain et al. 2009). 
1.2.3 Significance of HIV-1 Tat and HTLV-1 Tax in neurodegenerative 
disease 
The molecular and cellular mechanisms responsible for neurodegenerative 
disease during HIV-1 and HTLV-1 infections are complex and multifaceted (Irish, 
Khan et al. 2009). In particular, the viral transactivator proteins Tat and Tax play 
significant roles due to their requirement in viral replication and known toxic 
properties to a wide variety of CNS cells (Park, Haseltine et al. 1988, Cowan, 
Alexander et al. 1997, New, Ma et al. 1997, Karn and Stoltzfus 2012). Notably, Tat 
can be continually produced by HIV-1-infected cells located in the CNS despite the 
widespread use of HAART, demonstrating that neurologic vulnerability to this 
protein persists in the HAART era (Li, Li et al. 2009). It has also been demonstrated 
that HIV-1 Tat can contribute to HAND by modifying amyloid precursor protein 
processing and increasing amyloid beta production (Kim, Yoon et al. 2013). 
Because Tat and Tax are essential for viral replication, in addition to demonstrating 
neurotoxic properties, both proteins remain central to the development of effective 
HIV-1 and HTLV-1 therapies. This review will focus on the multidimensional roles 
and requirements of Tat and Tax in pathogenesis in the CNS, with a particular 
focus on their functional similarities and differences. 
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1.3 Structure of HIV-1 Tat and HTLV-1 Tax proteins 
1.3.1 Tat structure and functional domains 
HIV-1 Tat is a predominantly nuclear, multifunctional protein that is essential 
for productive viral replication and processive transcription from the HIV-1 
promoter, termed the long terminal repeat (LTR). The protein typically consists of 
101 amino acids encoded by two exons, the first encoding residues 1-72 and the 
second encoding residues 73-101 (Ruben, Perkins et al. 1989, Jeang, Xiao et al. 
1999). Notably, while 86 amino acid laboratory strains of Tat (LAI, HXB2, NL4-3) 
are most commonly used for in vitro experimentation, this form represents a 
truncated protein relative to the majority of clinical isolates that maintain a 101 
amino acid full-length structure (Myers G 1996, Strazza, Pirrone et al. 2011). 
 Tat consists of six major functional domains (Figure 1.1) as determined by 
mutational analysis, with the first five being encoded by exon 1 (Kuppuswamy, 
Subramanian et al. 1989). Located at the N-terminus of the protein are the acidic 
domain (residues 1-21), the cysteine-rich domain (residues 22-37), and the core 
domain (residues 38-48). Together, these three domains function as the minimal 
region of Tat required for transactivation of the LTR. While the acidic domain is 
functionally robust with respect to single-residue mutations, changes in positions 
25-40 are generally deleterious to Tat-mediated transactivation, particularly the 
conserved cysteine residues at positions 22, 25, 27, and 37 (Li, Li et al. 2009, Li, 
Dahiya et al. 2012). Of importance to posttranslational modifications of Tat in this 
region is the lysine residue at position 28, which functions in the stabilization of the 
Tat-cyclinT1-TAR (transactivation response element) complex in the early stages 
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of transactivation (D'Orso and Frankel 2009). Furthermore, position 31 of Tat 
mediates neurotoxicity, as the cysteine residue at this position is involved in 
binding of neuronal N-methyl-D-aspartate (NMDA) glutamate receptors (Li, Huang 
et al. 2008).  Importantly, the cysteine region has been shown to play a role in 
synaptodendritic injury (Bertrand, Aksenova et al. 2013). The fourth domain 
(residues 49-57) contains the well-conserved arginine-rich motif 49RKKRRQRRR57 
that functions as the TAR binding domain (Dingwall, Ernberg et al. 1989, Roy, 
Delling et al. 1990). This domain has also been referred to as the basic domain 
and has been shown to be required for uptake of extracellular Tat (residues 48-60) 
as well as nuclear localization (Vives, Brodin et al. 1997, Jeang, Xiao et al. 1999). 
The fifth domain (residues 58-72) is a glutamine-rich region that demonstrates the 
greatest amount of genetic variability and functions in both nuclear localization and 
Tat-mediated apoptosis of T cells (Li, Dahiya et al. 2012).  
The sixth domain (residues 73-101) of Tat has been shown to be the only 
domain encoded by the second exon and has gained attention for a variety of 
functions (Lopez-Huertas, Callejas et al. 2010). Most relevant to this Chapter is the 
enhancement of HIV-1 replication in cells of the monocyte-macrophage lineage 
(Neuveut, Scoggins et al. 2003). Additionally, the sixth domain contains a RGD 
motif and a highly conserved ESKKKVE motif, which are thought to function in 
integrin binding and optimal in vivo replication, respectively (Barillari, Gendelman 
et al. 1993, Smith, Pentlicky et al. 2003). Tat exon II also contains conserved 
glutamic acid and lysine residues that are believed to function in the activation of 
nuclear factor-κB (NF-κB) in T cells (Mahlknecht, Dichamp et al. 2008). Finally, it 
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has been proposed that Tat exon II plays a role in the dysregulation of the blood–
brain barrier (BBB) resulting in increased levels of inflammatory cytokines and toxic 
viral proteins in the CNS (Strazza, Pirrone et al. 2011). 
 Although the sequence of Tat is relatively well conserved, as an HIV-1 
protein it still has demonstrated a significant amount of genetic variation that 
impacts its function and role in HIV-1 neuropathogenesis (Li, Dahiya et al. 2012). 
Tat is also a flexible and inherently disordered protein, allowing it to spatially adapt 
to a wide variety of binding partners (Debaisieux, Rayne et al. 2012). The crystal 
structure of Tat complexed with positive transcription elongation factor b (P-TEFb) 
demonstrates extensive surface contact at the protein interface made possible by 
the plasticity of Tat and induced conformational changes to P-TEFb (Tahirov, 
Babayeva et al. 2010). Structural changes as a result of Tat contact are likely 
present in other Tat binding partners as well, possibly providing an assortment of 
potential drug targets that can mitigate Tat-induced pathogenesis. 
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Figure 1.1.  Functional comparison of HIV-1 Tat and HTLV-1 Tax protein 
primary structures and features. 
 
The major functional and protein–protein interaction domains of HIV-1 Tat (blue) 
and HTLV-1 Tax (red) are highlighted, with the common features of the two 
proteins displayed in the middle. Important amino acid residues and sequences 
are designated, as well as sites of posttranslational modifications. 
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Figure 1.1 
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1.3.2 Tax structure and functional domains 
Tax is an HTLV-1 protein consisting of 353 amino acids that has been 
shown to function predominantly as a transactivator protein, but also interfaces 
with a variety of cellular proteins, pathways, and processes (Ng, Iha et al. 2001, 
Boxus, Twizere et al. 2008). In parallel with functional analyses of Tat, Tax has 
also been studied via mutational analysis demonstrating that most mutations do 
not significantly alter Tax function (Semmes and Jeang 1992). The major functional 
regions of HTLV-1 Tax (Figure 1.1) are more loosely annotated than Tat and are 
generally referred to as the amino-terminal, central, and carboxy-terminal 
domains. To date, no crystal structure of HTLV-1 Tax or its complexes has been 
reported. 
 The amino-terminus of Tax is cysteine- and histidine-rich, resulting in the 
formation of overlapping zinc-finger motifs essential for transactivation of the 
HTLV-1 LTR (Semmes and Jeang 1992). Also functioning in transactivation in this 
region are domains facilitating the interaction with the transcription factor cyclic 
adenosine monophosphate (cAMP) response element binding protein (CREB), the 
coactivators CREB-binding protein (CBP) and p300 and for contact with DNA 
(Goren, Semmes et al. 1995, Yin, Paulssen et al. 1995, Bex, Yin et al. 1998, 
Harrod, Tang et al. 1998, Kimzey and Dynan 1999, Georges, Giebler et al. 2003). 
The amino-terminal domain of Tax has largely been shown to be responsible for 
cellular localization as well and has been shown to contain a unique nuclear 
localization signal (NLS) (residues 18-52) required for Tax to locate to the nucleus 
(Gitlin, Lindholm et al. 1991, Smith and Greene 1992). Studies have also shown 
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the central domain of Tax to contain a leucine-rich sequence region that can also 
function as the nuclear export signal (NES) (residues 188-202), allowing the 
protein to travel between the nucleus and cytoplasm (Alefantis, Barmak et al. 
2003). Importantly, the Tax NES is concealed in the context of the full-length 
protein, suggesting a mechanism by which posttranslational modifications or 
interaction with other proteins may be required for nuclear export (Alefantis, 
Barmak et al. 2003, Lodewick, Lamsoul et al. 2011). The carboxy-terminus of Tax 
has been shown to host additional domains required for transcriptional activation 
(residues 289-322) (Semmes and Jeang 1995). This includes domains responsible 
for the interaction with CBP and p300/CBP-associated factor (p/CAF) (Bex, Yin et 
al. 1998, Jiang, Lu et al. 1999). The secretory signals of Tax are also present in 
the carboxy-terminal domain and these signals are critical to the demonstrated 
functional role of Tax as an extracellular and neurotoxic protein (Jain, Mostoller et 
al. 2007, Irish, Khan et al. 2009). Finally, proper in vivo function of Tax has been 
shown to be dependent upon dimerization of the protein for processes such as 
assembly of the transcriptional machinery at the HTLV-1 LTR and nuclear 
transport (Tie, Adya et al. 1996, Fryrear, Durkin et al. 2009). Dimer formation has 
been shown to be largely dependent upon the zinc-binding domain in the amino-
terminus in addition to three distinct sequences located throughout the central 
domain (Basbous, Bazarbachi et al. 2003). 
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1.4 Viral replication and transactivation of the HIV-1 and HTLV-1 promoters 
Chronic retroviral infection and disease is dependent on continuous or 
intermittent viral replication and/or production of viral proteins that can induce 
pathologic consequences. In the case of HTLV-1, some of the pathologic 
consequences may involve an oncogenic state induced by the activity of Tax and 
other proteins produced during the course of viral replication in the T-cell 
population. Accordingly, the mechanisms of viral promoter transactivation remain 
important in the understanding of retroviral pathogenesis. Both Tat and Tax are 
categorized as transactivator proteins and facilitate the binding of cellular 
transcription factors to their respective LTRs in order to fuel processive and 
productive viral replication (Figure 2.1). Productive HIV-1 and HTLV-1 infection 
can also occur beyond the primary target of CD4+ T cells. The susceptible cell 
populations extend to CD34+ bone marrow progenitor cells, dendritic cells (DCs), 
astrocytes, microglia, and cells of the monocyte-macrophage lineage (Persidsky 
and Poluektova 2006, Lepoutre, Jain et al. 2009).  
1.4.1 Tat-mediated transactivation of the HIV-1 LTR 
HIV-1 transcription is controlled principally by Tat, and consists of an early, 
Tat-independent phase and a late, Tat-dependent phase (Rosen, Terwilliger et al. 
1988, Brady and Kashanchi 2005). Initially, viral transcription produces 
predominantly short, aborted RNA transcripts of 30-50 nucleotides owing to the 
inefficiency of RNA polymerase II (RNA Pol II) (Parada and Roeder 1996). 
However, in spite of the overall inefficient elongation, longer transcripts are also 
produced at low abundance and encode for early regulatory proteins such as Tat 
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(Yedavalli, Benkirane et al. 2003). As the concentration of intracellular Tat rises 
beyond threshold levels, it fuels a positive feedback mechanism in which the 
protein has been shown to be capable of effectively transactivating the HIV-1 LTR 
and producing full-length transcripts. Therefore, stochastic fluctuations in Tat gene 
expression can be thought of as a molecular switch that works on the level of 
elongation and is responsible for full-length HIV-1 mRNA transcripts (Weinberger, 
Burnett et al. 2005, Karn 2011).  
Tat functions by binding to the “UCU” bulge of the HIV-1 TAR element, a 
cis-acting RNA enhancer and stem-loop structure located at the 5′ end of all viral 
transcripts (Berkhout, Silverman et al. 1989, Dingwall, Ernberg et al. 1989, Laspia, 
Rice et al. 1989, Selby, Bain et al. 1989, Karn and Stoltzfus 2012). The Tat-TAR 
interaction is critically important with respect to tethering Tat and allowing for 
recruitment of the host transcriptional machinery. However, it is important to note 
that in astrocytes Tat has been shown to be capable of transactivating the LTR in 
the absence of the TAR region (Taylor and Khalili 1994). Specifically, Tat 
associates with P-TEFb, a protein kinase complex consisting of cyclin T1 and 
cyclin-dependent kinase 9 (CDK9) (Zhu, Pe'ery et al. 1997, Wei, Garber et al. 
1998). A conformational change to P-TEFb as a result of Tat binding has been 
shown to be responsible for the activation of CDK9 and results in the 
hyperphosphorylation of the carboxy-terminal domain of RNA pol II and the 
promotion of transcription elongation (Zhu, Pe'ery et al. 1997, Wei, Garber et al. 
1998, Zhou, Chen et al. 1998, Deng, Ammosova et al. 2002, Tahirov, Babayeva 
et al. 2010). Transcription from the HIV-1 LTR can be further regulated through 
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interactions with host transcription factors that can enhance or repress this process 
as well as by genetic variation in the HIV-1 LTR (Nonnemacher, Irish et al. 2004, 
Shah, Nonnemacher et al. 2010, Li, Aiamkitsumrit et al. 2011). 
1.4.2 Tax-mediated transactivation of the HTLV-1 LTR 
Congruent with the role of Tat in HIV-1, Tax interfaces with the host 
transcriptional machinery and cellular transcription factors to promote viral gene 
expression and productive viral replication (Park, Haseltine et al. 1988, Giam and 
Xu 1989). Essential to transcriptional transactivation is the binding of Tax to the 
Tax responsive element 1 (TRE-1), which has been shown to consist of three 21-
basepair TREs located in the U3 region of the LTR (Beimling and Moelling 1992, 
Zhao and Giam 1992). Each of the repeating 21-basepair elements is in turn 
composed of three domains, termed A, B, and C. The B domain has been shown 
to be important to transactivation because it contains a conserved core sequence 
(TGACGTCA) and flanking 5′ and 3′ G/C-rich sequences that closely resemble a 
cAMP response element (CRE) (Lenzmeier, Giebler et al. 1998). Tax recruits the 
transcription factors CREB and serum response factor to the CRE-like element of 
the HTLV-1 LTR, resulting in facilitated transcription (Zhao and Giam 1992, Suzuki, 
Fujisawa et al. 1993). The association of Tax with homodimeric CREB results in 
the formation of a stabilizing ternary complex at the binding domains of TRE-1 
(Lenzmeier, Giebler et al. 1998).  
 Tax has been shown to independently recruit the chromatin remodeling 
factors p300/CREB-binding protein (p300/CBP) and p300/CBP-associated factor 
(P/CAF) to the CREB/DNA complex (Harrod, Tang et al. 1998). These co-
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activators bind to two specific Tax regions located at the amino- and carboxy-
termini of the protein, respectively, and are essential in transcription initiation 
(Lenzmeier, Giebler et al. 1998). While CREB is activated via the cAMP-dependent 
protein kinase A signaling pathway, Tax also regulates transcription by activating 
the NF-κB and ATF/CREB cellular signaling pathways, demonstrating that both the 
direct and indirect interaction of Tax with cellular transcription factors may 
influence transactivation of the viral LTR and regulation of cellular transcription 
(Gonzalez and Montminy 1989, Chrivia, Kwok et al. 1993, Sun, Elwood et al. 
1994). Recent studies have demonstrated that Tax reduces histone protein 
transcript levels in addition to mediating the downregulation of microRNAs 
(miRNAs) that function in chromatin remodeling (Rahman, Quann et al. 2012). 
Combined, these studies emphasize the sophisticated coordination of HTLV-1 
Tax, miRNAs, and chromatin remodeling in the regulation of retroviral transcription 
and replication. 
 
1.5 Posttranslational modifications 
Following translation, Tat and Tax are subjected to a variety of 
posttranslational modifications (PTMs) that may alter the tertiary structure and 
activity of the protein. The importance of these alterations in mediating viral 
replication highlights the importance of PTM-associated enzymes in the HIV-1 Tat 
and HTLV-1 Tax interactomes (Hetzer, Dormeyer et al. 2005). Such modifications 
have been demonstrated to be necessary for optimal transcriptional activity of both 
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Tat and Tax, and by extension are relevant to the persistence of 
neuroinflammation.  
1.5.1 HIV-1 Tat posttranslational modifications 
 Acetylation and deacetylation of Tat is a reversible process performed by 
the acetyltransferase activities of p300 and P/CAF, important HIV-1 transcriptional 
co-activators, and the deacetylase activity of class III deacetylase sirtuin 1 (SIRT1) 
(Kiernan, Vanhulle et al. 1999, Ott, Schnolzer et al. 1999, Pagans, Pedal et al. 
2005). These modifications have been found to occur in the arginine-rich and 
cysteine-rich domains of Tat, specifically at lysine positions 28 and 50 (Kiernan, 
Vanhulle et al. 1999, Kaehlcke, Dorr et al. 2003). Importantly, mutations of lysine 
at these positions or inhibition of SIRT1 reduce transactivation ability and inhibit 
HIV-1 replication (Bres, Kiernan et al. 2003, Pagans, Pedal et al. 2005). 
Furthermore, inhibition of SIRT1 has also resulted in a reduction in Tat 
transactivation. The protein–protein interactions of Tat differ according to whether 
Tat is acetylated at lysine position 50 as well. As previously discussed, 
nonacetylated Tat binds with the cyclinT1 component of P-TEFb via the cysteine-
rich domain, and this complex cooperatively binds to TAR RNA using the arginine-
rich domain of Tat. However, once acetylated, Tat dissociates from TAR RNA and 
cyclinT1 and binds instead with RNA pol II and P/CAF (Kiernan, Vanhulle et al. 
1999, Dorr, Kiermer et al. 2002, Mujtaba, He et al. 2002, Kaehlcke, Dorr et al. 
2003). Accordingly, the dynamic acetylation of Tat appears to be essential for Tat 
to function in both the early and late transactivation stages and the manipulation 
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of this process has been considered for the development of new therapeutic 
strategies (Balasubramanyam, Varier et al. 2004, Zeng, Li et al. 2005). 
 Ubiquitination and methylation have also been observed as important 
posttranslational modifications of HIV-1 Tat capable of altering transactivation. Of 
particular importance to the transactivation ability of Tat is lysine 71, a highly 
conserved residue that functions as the principal ubiquitination target site and may 
contribute to cyclinT1 binding in the early stages of HIV-1 transcription rather than 
proteasomal degradation (Bres, Kiernan et al. 2003). Methylation of Tat proceeds 
through the catalytic activity of protein arginine methyltransferases (PRMTs) such 
as PRMT6 in the arginine-rich region, in addition to lysine position 51 by 
methyltransferases Set7/9 (KMT7) (Boulanger, Liang et al. 2005, Pagans, Kauder 
et al. 2010, Pagans, Sakane et al. 2011). Arginine methylation results in reduced 
transactivation, likely as a consequence of disrupted binding with P/CAF. The 
extent of methylation plays a role in determining whether Tat will be recycled or 
tagged for degradation, as the reversibility of this modification has been shown to 
depend on whether an arginine residue is mono- or di-methylated (Hetzer, 
Dormeyer et al. 2005). 
1.5.2 HTLV-1 Tax posttranslational modifications 
 Tax protein also undergoes various posttranslational modifications that can 
influence disease progression and protein functionality. The principal modifications 
observed include sumoylation, ubiquitination, acetylation, and phosphorylation 
(Lodewick, Lamsoul et al. 2011). Five lysine residues within the central domain of 
Tax, designated K4 to K8, are targets for polyubiquitination. Similar to Tat, this 
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modification does not trigger proteasomal degradation and is likely necessary for 
activation of the NF-κB pathway. Alternatively, lysine residues at positions 280 and 
284 of Tax can be monoubiquitinated, leading to nuclear export (Gatza, Dayaram 
et al. 2007). These residues also function as polysumoylation sites and 
polysumoylated Tax likely works in concert with ubiquitinated Tax to activate the 
NF-κB pathway (Lamsoul, Lodewick et al. 2005, Nasr, Chiari et al. 2006). 
Acetylation of Tax occurs via p300 acetyltransferase activity at lysine position 346 
within the C-terminal domain of Tax. This modification has also been demonstrated 
to promote activation of the NF-κB pathway (Lodewick, Lamsoul et al. 2009). Tax 
is also a phosphoprotein, with serine residues 300 and 301 within the 
transactivation domain being the primary phosphorylation targets (Bex, Murphy et 
al. 1999, Durkin, Ward et al. 2006). Phosphorylation of Tax at these positions is 
critical for Tax nuclear localization and transcriptional activity. Notably, Tax 
phosphorylation appears to be a prerequisite for Tax ubiquitination, 
polysumoylation, and acetylation (Lodewick, Lamsoul et al. 2011). 
 
1.6 Cellular localization and secretion 
Tat and Tax are multifunctional proteins that can localize to multiple cell 
compartments. While their role as transactivating proteins requires localization to 
the cell nucleus, both proteins can also be found in the cytoplasm. Most important 
to neuroinflammation, Tat and Tax are also secreted into the extracellular 
environment where they interact with multiple CNS cell types and activate a variety 
of cellular and immune responses. 
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1.6.1 HIV-1 Tat cellular localization 
The role of exogenous Tat is well established, and the protein can enter a 
variety of cell types present in the CNS (Frankel and Pabo 1988, Mann and Frankel 
1991). Both clathrin and caveolar pathways have been proposed for extracellular 
Tat uptake, consistent with the ability of Tat to bind to the endocytic receptors 
CXCR4, heparan sulfate proteoglycans, and lipoprotein receptor–related protein—
the primary receptor involved in internalization (Ghezzi, Noonan et al. 2000, Liu, 
Jones et al. 2000, Tyagi, Rusnati et al. 2001, Ferrari, Pellegrini et al. 2003, 
Fittipaldi, Ferrari et al. 2003, Vendeville, Rayne et al. 2004). Importantly, the 
endocytic pathway utilized by Tat is likely cell-type dependent, as caveolae are 
absent in T cells (Fra, Williamson et al. 1994). 
 It is well established that Tat is required for HIV-1 transcription and therefore 
is capable of reaching the nucleus. The arginine-rich basic domain of Tat is 
responsible for nuclear import as the mutation or deletion of this domain inhibits 
transport to the nucleus as well as HIV-1 transcription (Hauber, Malim et al. 1989, 
Vives, Brodin et al. 1997, Meredith, Sivakumaran et al. 2009). As previously 
reviewed, the majority of mechanistic studies of nuclear import have attached the 
Tat basic domain to β-galactosidase, glutathione S-transferase, or green 
fluorescent protein, demonstrating that the basic domain is not only necessary but 
also sufficient for nuclear import (Debaisieux, Rayne et al. 2012). However, nuclear 
import studies utilizing the full-length Tat protein have yet to be performed, limiting 
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the extent to which these results can be applied to the actions of full-length Tat. 
This shortcoming is critical, as binding partners of Tat, such as NF-κB–α inhibitor 
(IκBα) and human I-mfa domain-containing protein can interfere with nuclear 
import by promoting nuclear export and cytoplasmic sequestration, respectively 
(Gautier, Sheehy et al. 2005, Puca, Fiume et al. 2007). 
1.6.2 HIV-1 Tat secretion 
Tat has been shown to be released by infected monocytes, glial cells, and 
astrocytes in addition to infected lymphocytes (Ensoli, Buonaguro et al. 1993, 
Johnston, Zhang et al. 2001, Bruce-Keller, Chauhan et al. 2003, Chauhan, 
Turchan et al. 2003). Overall, Tat secretion is a productive process, with 
approximately two thirds of cellular Tat being exported over the lifespan of an HIV-
1-infected T-cell (Rayne, Debaisieux et al. 2010). Secreted Tat is biologically active 
and capable of transcellular activation of the HIV-1 LTR in addition to its extensive 
effects as an extracellular protein (Thomas, Dobkin et al. 1994, Rayne, Debaisieux 
et al. 2010). Additionally, release of Tat by infected cells occurs optimally in low-
serum conditions, such as the brain environment (Ensoli, Buonaguro et al. 1993). 
The secretion of Tat occurs via an unconventional mechanism that utilizes neither 
endosomes nor the endoplasmic reticulum (ER)/Golgi apparatus. Tat, however, 
does bind tightly to plasma-membrane embedded PI(4,5)P2 in the cell membrane. 
Most critical to this process is the tryptophan residue at Tat position 11, as it 
functions in membrane insertion. Tat mutants without this residue remain 
predominantly in the cytoplasm and are weakly secreted (Rayne, Debaisieux et al. 
2010). The exact mechanism by which Tat localizes to the cell membrane is 
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unknown, but localization of Tat likely is dependent upon cell type (Rayne, 
Debaisieux et al. 2010, Debaisieux, Rayne et al. 2012). 
1.6.3 HTLV-1 Tax cellular localization 
HTLV-1 Tax localization to the nucleus is well known because of its 
transactivation activity (Park, Haseltine et al. 1988, Giam and Xu 1989). However, 
Tax is also localized in the cytoplasm of infected cells and may shuttle between 
the nuclear and cytosolic compartments (Alefantis, Jain et al. 2005). The shuttling 
of Tax between the nucleus and cytoplasm is predominantly controlled by the 
nuclear localization signal (NLS) found in the amino-terminus of the protein and 
the leucine-rich nuclear export signal (NES) found at the carboxy-terminus, 
respectively (Smith and Greene 1992, Alefantis, Barmak et al. 2003). The balance 
between nuclear localization and export hinges on the masking of the NES by 
protein–protein interactions or posttranslational modifications to Tax, allowing the 
NLS to function as the dominant cellular localization signal (Fontes, Strawhecker 
et al. 1993, Bex, Murphy et al. 1999). 
1.6.4 HTLV-1 Tax secretion 
Previously, Tax has been shown to associate with the ER and Golgi 
apparatus, with cytoplasmic transport progressing via secretory vesicles shuttled 
by kinesin motor proteins along microtubules (Alefantis, Mostoller et al. 2005). In 
contrast to HIV-1 Tat, which lacks a formal secretory pathway, secretion of Tax is 
largely controlled by two putative secretory signals located in the carboxy-terminal 
domain of Tax, DHE and YTNI, that are responsible for the interaction of Tax with 
cellular secretory proteins (Jain, Mostoller et al. 2007). Specifically, DHE functions 
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as a DXE signal required for the concentration of Tax into coat protein complex II 
(COPII) vesicles, which are responsible for mediating transport of proteins from 
the ER to the Golgi (Lippincott-Schwartz, Roberts et al. 2000). Tax has also been 
demonstrated to interact with multiple other proteins associated with secretion 
(Alefantis, Flaig et al. 2007, Jain, Mostoller et al. 2007). Among its other roles, 
secreted Tax interacts with calreticulin (CRT) and is proposed to play a role in the 
axonal degeneration associated with HAM/TSP (Medina, Quintremil et al. 2014). 
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Figure 1.2  HIV-1 Tat- and HTLV-1 Tax-mediated transcription and secretory 
pathways 
Tat mediates processive transcription by binding to the “UCU” bulge of the nascent 
RNA TAR element and recruiting multiple transcription factors and co-factors. Tat 
associates with P-TEFb, a protein complex consisting of cyclin T1 and CDK9 
responsible for the hyperphosphorylation of the carboxy-terminal domain tail of 
RNA Pol II (RNAP). Tat also mediates recruitment of co-activators CBP/p300 and 
the kinase DNA-PK, which interface with cellular transcription factors. Tat secretion 
occurs via an unconventional mechanism that utilizes neither endosomes nor the 
ER/Golgi apparatus. Critical to Tat secretion is the tryptophan at position 11, which 
functions in cellular membrane insertion and results in reduced secretion when 
mutated. Tax-mediated transcription occurs via Tax binding to the TRE-1 domain 
of the LTR and the recruitment of CREB to the CRE-like element of TRE-1. Tax 
also recruits the chromatin remodeling factors p300/CBP, P/CAF, and histone 
deacetylase (HDAC), which are essential for transcriptional regulation. Tax has 
been demonstrated to localize within the ER and Golgi apparatus. Tax secretion 
is controlled by two putative signaling sequences in the carboxy-terminal domain 
(CTD), DHE and YTNI, the first of which mediates concentration of Tax into COPII 
vesicles for transport from the ER to the Golgi. TFIID = transcription factor IID. 
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Figure 1.2 
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1.7 Presence and diversity of Tat and Tax in the CNS 
HIV-1 Tat is pervasive in the brain and has been detected in patients with 
HIVE (Hofman, Dohadwala et al. 1994, Del Valle, Croul et al. 2000, Hudson, Liu 
et al. 2000, Liu, Jones et al. 2000). The protein has also been linked to neurological 
impairment by the observation that Tat mRNA is detectable in patients with HIVE 
but absent in those without dementia (Hudson, Liu et al. 2000). Specifically, Tat 
has been observed in the cytoplasm of microglial cells and perivascular 
macrophages, which are likely HIV-1-infected cells. Importantly Tat is also found 
in the nuclei of neurons and oligodendrocytes, further demonstrating the ability of 
Tat to affect and enter additional cells of the CNS (Del Valle, Croul et al. 2000, Liu, 
Jones et al. 2000). Furthermore, sequence analysis of Tat has demonstrated 
compartmentalization in brain versus lymphoid tissue (Thomas, Dunfee et al. 
2007). Brain-derived sequences demonstrate higher nonsynonymous/ 
synonymous and transversion mutation rates in HAND patients and display 
phylogenetic clustering within clinical groups (Bratanich, Liu et al. 1998). These 
observations are critical, as brain-derived Tat from HAD patients has a decreased 
ability to transactivate the LTR and may exert pathogenic effects as a result of Tat 
mutations (Boven, Noorbakhsh et al. 2007). However, a recent study has shown 
that despite the heterogeneity of Tat in the brain, the transactivation function is 
conserved in Tat relative to the non-CNS compartment (Cowley, Gray et al. 2011). 
Overall, genetic compartmentalization of HIV-1 Tat between CNS and lymphoid 
tissue likely reflects altered requirements for HIV-1 replication in cells of monocytic 
lineage and brain-specific immune surveillance. 
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 Extracellular Tax may be found to accumulate in the peripheral blood and 
CSF of HAM/TSP patients as well (Cartier and Ramirez 2005). Tax expression 
levels have been shown to be higher in CSF cells than in peripheral blood 
mononuclear cells among HTLV-1 patients overall, and HTLV-1 mRNA levels 
correlate with disease severity in HAM/TSP patients, suggesting a role for 
exogenous Tax in HAM/TSP pathogenesis (Moritoyo, Izumo et al. 1999, Yamano, 
Nagai et al. 2002). Multiple subgroups of Tax have been identified, with one group, 
taxA, found to have a higher incidence among HAM/TSP patients (Furukawa, 
Yamashita et al. 2000, Iniguez, Gastaldello et al. 2010). However, these results 
have been disputed by other research, demonstrating the need for greater 
sampling in order to validate the ability to predict disease progression on the basis 
of Tax sequence (Casseb, Fukumori et al. 2006). 
 
1.8 Neuroinflammatory effects of Tat and Tax on CNS cellular targets 
Extracellular Tat and Tax proteins have been thought to play a large role in 
the pathogenesis of both HAND and HAM/TSP, as these proteins can cause both 
direct and indirect damage to cells of the CNS (Irish, Khan et al. 2009, Li, Li et al. 
2009). The effects of Tat and Tax on cells of the CNS include altered gene 
transcription, direct neurotoxicity, induction of neuroinflammatory cytokine 
secretion, increased immune cell trafficking, and disruption of the BBB (Table 1.1). 
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Table 1.1 
 
CNS Cell Type HIV-1 Tat HTLV-1 Tax 
Neurons 
• Dopamine transmission 
and D1 receptors are 
implicated in Tat 
neurotoxicity (Silvers, 
Aksenova et al. 2007) 
• NMDA receptor levels 
correlate with Tat-
induced apoptosis 
Eugenin, King et al. 
(2011) 
• Elevation of intracellular 
calcium, mitochondrial 
calcium uptake, and 
generation of reactive 
oxygen species in 
response to Tat 
(Kruman, Nath et al. 
1998, Haughey, Nath et 
al. 2001) 
• Induction of TNF-α in cells 
exposed to Tax (Cowan, 
Alexander et al. 1997) 
• Axonal degeneration 
accompanies 
demyelination due to 
axonal oligodendrocyte 
damage (Selmaj and 
Raine 1988, Tsunoda and 
Fujinami 2002) 
Astrocytes 
• Dysregulation of 
glutamate homeostasis 
(Fine, Angel et al. 1996) 
• TAR-independent 
transactivation (Taylor 
and Khalili 1994) 
• Induction of nitric oxide 
synthase (Liu, Jana et al. 
2002) 
• Production of 
CCL2/MCP-1 for 
monocyte recruitment 
(Conant, Garzino-Demo 
et al. 1998) 
• Dysregulation of 
glutamate uptake and 
catabolism (Szymocha, 
Akaoka et al. 2000) 
• Tax RNA detected in 
astrocytes (Szymocha, 
Brisson et al. 2000)  
• Induction of 
proinflammatory cytokines 
IL-1α, IL-1β, TNF-α, TNF-
β, and IL-6 in 
astrogliomas (Banerjee, 
Rochford et al. 2007) 
• Sensitization of 
astrocytomas to apoptosis 
(Banerjee, Rochford et al. 
2007) 
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Microglial 
cells 
• Increased secretion of 
chemokines including 
CCL2 (D'Aversa, Yu et 
al. 2004) 
• Induces increase in 
intracellular calcium 
(Sheng, Hu et al. 2000) 
• Induces a migratory 
phenotype via 
CCL2/MCP-1 (Eugenin, 
Dyer et al. 2005) 
• Secretion of 
proinflammatory cytokines 
TNF-α, IL-1β, and IL-6 
(Dhib-Jalbut, Hoffman et 
al. 1994) 
• Upregulation of 
proinflammatory cytokine 
profile (Wrzesinski, 
Seguin et al. 2000) 
Dendritic cells 
• Tat induces chemokine 
expression in dendritic 
cells, resulting in  T-cell 
and macrophage 
recruitment (Izmailova, 
Bertley et al. 2003) 
• Tat enhances 
maturation, function, and 
antigen presentation 
(Fanales-Belasio, Moretti 
et al. 2002) 
• Internalize extracellular 
Tax and mediate the 
priming of the anti-Tax 
CTL response (Manuel, 
Schell et al. 2009) 
• Activation in response to 
Tax, resulting in constant 
antigen presentation and  
T-cell proliferation (Jain, 
Ahuja et al. 2007) 
Monocyte-
macrophages 
• TNF-α production via 
NF-κB pathway in 
response to Tat (Chen, 
Mayne et al. 1997) 
• Tax RNA expression 
detected, suggesting role 
as a possible reservoir 
(Koyanagi, Itoyama et al. 
1993) 
 
Table 1.1  Impact of transactivation proteins HIV-1 Tat and HTLV-1 Tax on 
resident cells of the CNS 
 
 
1.8.1 Effects of extracellular HIV-1 Tat on CNS 
Tat has been shown to cause the loss of neurons both in vitro and in vivo, 
with the greatest neurotoxicity in the brain occurring in the striatum, dentate gyrus, 
and the CA3 region of the hippocampus (Hayman, Arbuthnott et al. 1993, 
Magnuson, Knudsen et al. 1995, Jones, Olafson et al. 1998, Campbell, Watkins et 
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al. 2011). This observation is consistent with the role of NMDA receptors in 
mediating Tat excitotoxicity in neurons, as these brains regions are rich in NMDA 
receptors (Eugenin, King et al. 2011). Importantly, reduced toxicity of subtype C 
Tat has been attributed to a cysteine-to-serine mutation at position 31, although 
this position does not affect binding to NMDA receptors (Li, Huang et al. 2008). 
Accordingly, it has been proposed that the cysteine residue is required for NMDA 
activation, with other regions functioning in receptor binding (Li, Huang et al. 2008). 
Additionally, Tat-induced phosphorylation of the NMDA receptor and dopamine D1 
receptor pathways has also been implicated in Tat neurotoxicity, with Tat 
upregulating proapoptotic signaling pathways mediated via D1/NMDA receptor 
interaction (Haughey, Nath et al. 2001, Silvers, Aksenova et al. 2007). Tat also 
causes excitotoxicity in neurons through the interaction with both NMDA receptors 
and glutamate receptors, with the latter being implicated in the process of neuronal 
death (Irish, Khan et al. 2009).  Studies using a Tat-transgenic mice model have 
shown that the constitutive expression of Tat in brain generates a latent excitatory 
state that may exacerbate the development of HAND (Zucchini, Pittaluga et al. 
2013). In response to Tat, intracellular calcium levels in neurons dramatically rise 
as a result of release by inositol 1,4,5-triphosphate (IP3) and the subsequent influx 
of extracellular calcium via a glutamate receptor–mediated mechanism (Haughey, 
Holden et al. 1999). This increased concentration results in the mitochondrial 
uptake of Tat, the generation of reactive oxygen species, and eventually Tat-
induced toxicity and apoptosis (New, Ma et al. 1997, Kruman, Nath et al. 1998). 
Synaptodendritic damage also is observed in HAND and cognitive decline, with 
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HIV-1 Tat having been demonstrated to increase the frequency of inhibitory 
synaptic connections in rate hippocampal neurons (Hargus and Thayer 2013). 
 The toxic effect of Tat is not limited to neurons, as astrocytes, DCs, 
macrophages, and microglia also produce proinflammatory mediators, reactive 
oxygen and nitrogen species, and excitatory amino acids that contribute to 
neuropathogenesis in response to Tat (Chen, Mayne et al. 1997, Kutsch, Oh et al. 
2000, Sheng, Hu et al. 2000, Kaul, Garden et al. 2001, Izmailova, Bertley et al. 
2003, D'Aversa, Yu et al. 2004). Of great importance is the secretion of tumor 
necrosis factor-α (TNF-α) by these cells in response to Tat, owing to its 
neurotoxicity (New, Maggirwar et al. 1998, Buscemi, Ramonet et al. 2007). One of 
the primary functions of astrocytes is to regulate extracellular glutamate levels in 
the brain, and TNF-α secretion by monocytic cells has been shown to disrupt 
glutamate metabolism, resulting in dysregulated glutamate homeostasis and 
neuronal damage (Fine, Angel et al. 1996). Tat also activates astrocytes and 
induces the production of chemokines and nitric oxide; however, astrocytes do not 
apoptose unless co-cultured with neurons, suggesting that Tat-induced apoptosis 
requires a signal from NMDAR-expressing neurons (McManus, Weidenheim et al. 
2000, Liu, Jana et al. 2002, Eugenin, D'Aversa et al. 2003). Extracellular Tat has 
been shown to induce production of monocyte chemoattractant factor-1 (MCP-
1)/CCL-2 in human fetal astrocytes and microglial cells (Conant, Garzino-Demo et 
al. 1998, Eugenin, Dyer et al. 2005). The MCP-1/CCL-2 functions in the 
recruitment of monocytic cells to sites of inflammation in the CNS and the 
trafficking of monocytes across the BBB. This mechanism is consistent with 
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findings that individuals with HIVE and HAD have elevated levels of CCL2 in CSF 
(Cinque, Vago et al. 1998). Tax also has been shown to promote the maturation 
of DCs, resulting in enhanced antigen presentation (Fanales-Belasio, Moretti et al. 
2002). In astrocytes, CCL5 expression is upregulated by Tat, through a pathway 
that involves AP-1, C/EBPα, and C/EBPβ (Nookala, Shah et al. 2013). Finally, HIV-
1 Tat displays important properties related to HIV-1 co-receptor usage and cell 
tropism. The ability of Tat to bind the CXCR4 chemokine receptor suggests that it 
may function as a virion antagonist pressuring CXCR4-utilizing HIV-1 strains to 
evolve towards CCR5 tropism (Xiao, Neuveut et al. 2000). As a result, Tat 
production may influence increased targeting of cells of the monocyte-macrophage 
lineage in the CNS. Furthermore, Tat can induce CXCR4 expression on both 
lymphocytes and monocyte-macrophages and CCR5 expression on monocyte-
macrophages (Weiss, Nath et al. 1999), which can result in increased viral 
replication. 
1.8.2 Effects of extracellular HTLV-1 Tax on CNS 
Principally, the accumulation of extracellular Tax may result in the cytokine-
mediated destruction of neuronal tissue via both autocrine and paracrine 
mechanisms (Irish, Khan et al. 2009). Proinflammatory cytokines found to exist at 
elevated concentrations in the CNS of HAM/TSP patients include interferon (IFN)-
γ, TNF-α, interleukin (IL)-1, IL-6, and granulocyte-macrophage colony-stimulating 
factor (GM-CSF) (Nishimoto, Yoshizaki et al. 1990, Ohbo, Sugamura et al. 1991, 
Kuroda and Matsui 1993, Kuroda, Matsui et al. 1993). In human neuronal cells 
exposed to Tax, TNF-α has been produced at a concentration similar to that of 
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HTLV-1-infected T cells (Brady 1992, Cowan, Alexander et al. 1997). Within the 
CNS, cytokine secretion is not limited to neurons as adult microglial cells also 
demonstrate a proinflammatory response and produce TNF-α, IL-1β, and IL-6 in 
response to Tax (Dhib-Jalbut, Hoffman et al. 1994, Wrzesinski, Seguin et al. 2000). 
Importantly, HTLV-1-infected microglial cells cannot produce IL-1β, stressing the 
importance of a paracrine mechanism in a Tax-induced inflammatory response 
(Dhib-Jalbut, Hoffman et al. 1994). HTLV-1 Tax RNA has been detected in 
astrocytes as well as monocytes, suggesting that these cells may also be a source 
of extracellular Tax and could potentially serve as a viral reservoir (Koyanagi, 
Itoyama et al. 1993, Lehky, Fox et al. 1995, Szymocha, Brisson et al. 2000, 
Kramer-Hammerle, Rothenaigner et al. 2005). The HTLV-1 Tax oncoprotein 
stimulates reactive oxygen species (ROS) production through multiple 
mechanisms and interactions.  ROS production is normally inhibited by anti-stress 
host factors such as ubiquitin-specific protease 10 (USP10), however this activity 
is attenuated by Tax (Takahashi, Higuchi et al. 2013).Tax also has been found to 
dysregulate glutamate uptake and catabolism in astrocytes, potentially leading to 
neuronal and oligodendrocyte death (Szymocha, Akaoka et al. 2000). As a 
consequence of the various inflammatory responses caused by Tax, the BBB may 
also be altered, resulting in increased lymphocyte trafficking into the CNS 
(Dhawan, Weeks et al. 1993, Furuya, Nakamura et al. 1997). Tax is also an 
important factor in the dysregulation of autophagy in HTLV-1-infected T cells, as it 
leads to the recruitment of autophagic molecular complexes containing Beclin1 
and Bif-1 to lipid raft microdomains (Ren, Takahashi et al. 2013). 
 35 
 Demyelination of neurons is observed among HAM/TSP patients and can 
be directly attributed to extracellular Tax protein (Selmaj and Raine 1988, Cowan, 
Alexander et al. 1997). Myelin functions in the insulation of axons and is 
responsible for the speed and accuracy of neuronal action potential impulses 
(Griffiths, Klugmann et al. 1998). Oligodendrocytes, being the myelinating cell type 
of the CNS, are sensitive to TNF-α but also secrete the proinflammatory cytokines 
IL-1β, TNF-α, TNF-β, and IL-6 in response to HTLV-1 Tax transduction (Selmaj 
and Raine 1988, Selmaj, Raine et al. 1991, D'Souza, Alinauskas et al. 1995, 
Osame 2002, Banerjee, Rochford et al. 2007). Overall, it is unclear whether axonal 
oligodendrocyte damage occurs prior to axonal degeneration (“outside-in theory”) 
or if the opposite scenario occurs (“inside-out theory”) (Tsunoda and Fujinami 
2002, Lepoutre, Jain et al. 2009). Additionally, the expression of Tax causes the 
activation and proliferation of T cells, with increased ratios of T helper 1 (Th1) 
effector cells to regulatory T cells (Tregs) observed in PBMCs of HLTV-1-infected 
patients with HAM (Barros, Risco et al. 2013). CD39 and CD25 co-expression can 
be used to identify regulatory (CD39+CD25+) and effector (CD39+CD25-) T-cell 
subsets, with CD39 upregulation being suggested as a surrogate diagnostic 
marker of HAM/TSP progression potentially attributable to Tax expression (Leal, 
Ndhlovu et al. 2013). 
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1.9 The adaptive immune response in the CNS 
1.9.1 Immune surveillance in the central nervous system 
The CNS is shielded from the free diffusion of circulating molecules, cells, 
and pathogens by the BBB, which has been reviewed in detail previously (Strazza, 
Pirrone et al. 2011, Ousman and Kubes 2012). Importantly, the BBB can be 
disrupted as a result of HIV-1 and HTLV-1 infection and proteins, including Tat and 
Tax. Both circulating lymphocytes and microglia, the resident macrophages of the 
CNS, contribute to the immune surveillance of the CNS in order to maintain optimal 
function and protection. Consistent with the critical role of the BBB, cellular immune 
surveillance can vary according to CNS region, with the highest concentration of 
cells located near areas with reduced tight junctions of the BBB (Hickey, Hsu et al. 
1991). Peripheral immune cells, such as perivascular macrophages and 
meningeal DCs, are strategically located along the BBB and function in antigen 
presentation and surveying the periphery for foreign antigens (Hickey 2001). 
Within the CNS, microglial cells are the principal mediators of homeostasis and the 
primary defenders of the CNS parenchyma against infection and injury (Hayes, 
Woodroofe et al. 1987, Hickey 2001). Because of the minimal overlap and motility 
of microglia, the entire extracellular environment of the CNS is continuously 
sampled even when these microglial cells exist in a presumed resting state 
(Nimmerjahn, Kirchhoff et al. 2005). Despite these inherent immune protections of 
the brain, HIV-1 and HTLV-1 infection of the CNS remains extremely common 
(Gonzalez-Scarano and Martin-Garcia 2005, Gessain and Mahieux 2012). The 
unique microenvironment and immune surveillance within the brain allows viruses 
 37 
to enjoy immune privilege owing to the relative absence of adaptive immune cells, 
such as B and T cells, and inherent mechanisms that limit neuroinflammation in 
order to protect nonrenewable neuronal pathways (Peterlin and Trono 2003, 
Persidsky and Poluektova 2006). Overall, the number of T cells infiltrating the 
healthy CNS is small relative to peripheral organs, owing to reduced interaction 
with endothelial adhesion molecules and leukocyte rolling in the brain (Carvalho-
Tavares, Hickey et al. 2000).  
1.9.2 HIV-1 Tat antibody response 
A Tat-targeting antibody response is found in nearly 50% of seropositive 
HIV-1-infected patients (Campbell, Senkaali et al. 2007). However, this antibody 
response does not appear to prevent disease progression even though anti-Tat 
antibodies have been shown to inhibit viral replication in vitro (Steinaa, Sorensen 
et al. 1994, Re, Furlini et al. 1995). Uninfected individuals have natural IgM 
antibodies against the Tat epitopes located in the cysteine-rich and basic domains 
that contribute to HIV-1 pathogenesis resistance (Rodman, Pruslin et al. 1992). 
Genetic variation likely plays an important role in an anti-Tat antibody response, 
as subtype C Tat variants demonstrate the ability to avoid an antibody response 
via mutation while maintaining transactivation ability (Campbell, Senkaali et al. 
2007). Researchers recently reported that anti-Tat antibody titers are higher in 
individuals without HAND than in those who display neurocognitive impairment, 
even among those with higher viral loads and lower CD4+  T-cell counts (Bachani, 
Sacktor et al. 2013). Tat immune complexes have been shown to interact with 
NMDA receptors and prevent excitotoxicity in a novel host defense mechanism, 
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an effect that does not occur in the presence of either Tat or antibody alone 
(Rumbaugh, Bachani et al. 2012). This observation, in conjunction with the high 
anti-Tat antibody levels detected among patients with long-term nonprogressing 
disease as compared with patients with rapidly progressing disease, has fueled 
continued interest in developing a Tat vaccine for the prevention of HAND 
(Goldstein 1996, Zagury, Sill et al. 1998, Rezza, Fiorelli et al. 2005, Campbell and 
Loret 2009, Goldstein and Chicca 2012). 
1.9.3 HIV-1 Tat cytotoxic T-lymphocyte response 
The natural time course of HIV-1 infection consists of an initial acute stage in 
which viremia peaks, followed by a sharp decline in viral load resulting from the 
natural antiviral CTL response (Borrow, Lewicki et al. 1994, Koup, Safrit et al. 
1994). CTLs recognize and destroy cells that present foreign epitopes in the 
context of class I major histocompatibility complex molecules (MHC-I) molecules 
on the cell surface. These epitopes are created by the cleavage of viral proteins 
by the proteasome, which are then delivered to MHC-I molecules on the cell 
membrane by the transporter associated with antigen processing (TAP) (Blum, 
Wearsch et al. 2013). The diverse population of quasispecies that emerge as a 
result of HIV-1 replication provides an abundant substrate for the selective 
pressures that favor the most genetically fit variants. The CTL component of the 
adaptive immune system is particularly prominent in shaping viral evolution, as 
mutations are selected for that decrease MHC-I binding and CTL recognition 
(Evans, O'Connor et al. 1999, Allen, Altfeld et al. 2005). In principle, viruses could 
rapidly eliminate all of their CTL epitopes. However, this does not occur because 
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the need to evade the immune response is counterbalanced by the need to 
maintain functionality and the ability to replicate (Altman and Feinberg 2004, Li, 
Gladden et al. 2007). These competing influences indicate that toggling mutations 
between more functional sequences that display epitopes, and less functional 
sequences that can evade the host immune response, occur in HIV-1 (Delport, 
Scheffler et al. 2008).  
While the majority of analyses on the HIV-1-specific CTL response initially 
focused on structural proteins, researchers are now exploring early regulatory 
genes such as Tat and Rev in more detail. Significantly, Tat is frequently targeted 
by CTLs, representing a selective pressure after the onset of the asymptomatic 
period of infection (Addo, Altfeld et al. 2001, Guillon, Stankovic et al. 2006). The 
HIV-1 CTL epitope repertoire across multiple HLAs has been analyzed on the 
basis of their “size of immune repertoire” (SIR) score (Vider-Shalit, Almani et al. 
2009). This study demonstrated that HIV-1 removes CD8+ CTL epitopes as an 
evasion strategy, and that regulatory proteins such as Tat have low SIR scores in 
comparison with late virion-associated genes (Vider-Shalit, Almani et al. 2009). 
The evolution of HIV-1 Tat over time may be due either to escape mutations from 
the host immune response or to mutations that confer enhanced viral replication 
ability. One study suggests that the primary determinant is the former, with Tat 
mutants that emerge over time displaying no significant difference in 
transactivation ability (Guillon, Stankovic et al. 2006). The CTL response within the 
brain has been shown to be distinct from that of the peripheral blood in simian 
immunodeficiency virus (SIV) studies (von Herrath, Oldstone et al. 1995). SIV 
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studies have also demonstrated that the persistence of a CTL response in the brain 
is associated with increased levels of IL-15 and the absence of IL-2 (Marcondes, 
Burdo et al. 2007). Accordingly, the anti-Tat CTL response within the brain may 
contribute to a unique cytokine environment.  
1.9.4 HTLV-1 Tax antibody response 
The presence of an anti-Tax antibody response has been well established 
among individuals infected with HTLV-1 (Rudolph, Coligan et al. 1994). The 
percentage of individuals expressing anti-Tax antibody as well as the level of anti-
Tax antibody titers have been demonstrated to be significantly greater in HAM/TSP 
patients compared with asymptomatic HTLV-1 carriers (Rudolph, Coligan et al. 
1994, Burbelo, Meoli et al. 2008). In contrast, anti-Tax levels have been 
demonstrated to be low for HTLV-1-infected patients with a diagnosis of adult T-
cell leukemia, stressing the role of the Tax-specific antibody response in HAM/TSP 
pathogenesis (Hisada, Okayama et al. 1998, Akimoto, Kozako et al. 2007). In 
addition to conferring an increased risk of developing HAM/TSP, the presence of 
anti-Tax antibody has been shown to correlate with increased proviral loads and 
the potential for the virus to replicate (Lydy, Conner et al. 1998). Notably, the 
resistance to apoptosis conferred by HTLV-1 Tax production is reversed by the 
presence of anti-Tax antibodies (Copeland, Haaksma et al. 1994). Together, these 
observations demonstrate that a robust anti-Tax antibody response may be a 
contributing factor in neuropathogenesis. 
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1.9.5 HTLV-1 Tax CTL response 
HTLV-1 Tax and HBZ protein have been associated with HTLV-1 disease 
progression due to their roles in inducing cellular proliferation and the CTL-
mediated immune response.  Accordingly, tax mRNA expression levels have been 
identified as the best marker to estimate risk for HAM/TSP development (Andrade, 
Goncalves Pde et al. 2013).  Tax exists as an extracellular protein within the CNS, 
and as a result it can be internalized and made available for immune recognition 
by antigen-presenting cells. Accordingly, DCs play a major role in directing the 
anti-Tax cellular immune response, and their rapid maturation is associated with 
HAM/TSP stimulation of CD4+ and CD8+ T cells (Ali, Patterson et al. 1993, Makino, 
Shimokubo et al. 1999). Recently DCs have been shown to successfully mediate 
the priming of the anti-Tax CTL response both in vitro and in vivo (Manuel, Schell 
et al. 2009). Tax plays a central role in this process, as DCs exposed to Tax 
undergo activation, resulting in T-cell proliferation (Jain, Ahuja et al. 2007). CTLs 
specific for HTLV-1 Tax are the primary proliferating cell type observed in the CSF 
of HAM/TSP patients (Jacobson, McFarlin et al. 1992, Cartier and Ramirez 2005). 
In particular, the Tax11-19 epitope is recognized and targeted by infiltrating CTLs, 
and the continual activation of these cells suggests that viral replication and 
production of HTLV-1 proteins persist in the CNS (Sakai, Nagai et al. 2001). The 
expanding population of activated CD8+ T cells is believed to contribute to the CNS 
damage via the lysis of Tax-presenting cells and the ensuing release of 
proinflammatory molecules. Additionally, infiltrating CTLs are an important source 
of proinflammatory mediators, including IFN-γ, TNF-α, IL-16, matrix 
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metalloproteinase-9, macrophage inflammatory protein-1α, and macrophage 
inflammatory protein-1β (Biddison, Kubota et al. 1997). Molecular mimicry 
contributes to neuronal damage in HAM/TSP as well, as the CTL response 
directed against Tax also demonstrates cross-reactivity to cells displaying the 
heterogeneous ribonuclear protein-A1 antigen in the CNS (Levin, Lee et al. 2002). 
Although a high frequency of HTLV-1-specific CTLs correlates with risk of HTLV-
1-associated inflammation, host and viral immunogenetics suggest that a strong 
CTL response is associated with a low risk of HAM/TSP. As a result, the avidity of 
the CTL response is essential to controlling HTLV-1 neuropathology, as efficient 
control of HTLV-1 infection depends on the lytic efficiency of HTLV-1-targeting 
CTLs (Kattan, MacNamara et al. 2009). 
1.10 Conclusion 
 HIV-1 Tat and HTLV-1 Tax are analogous proteins in terms of both virologic 
function and the ability to stimulate a neuroinflammatory response as extracellular 
proteins. However, these proteins are also distinct with respect to their role in 
disease progression. Tax is the dominant force in HAM/TSP, whereas Tat-
mediated neuroinflammation comprises only one aspect of HIV-1 
neuroinflammation. The multifaceted and complex interactomes of Tat and Tax 
have been studied in detail, elucidating a vast network of viral and cellular protein 
interactions that control nearly every aspect of Tat- and Tax-induced 
neuropathogenesis, including transcriptional regulation, secretion, 
posttranslational processing, neurotoxicity, and immune recognition (Boxus, 
Twizere et al. 2008, Li, Dahiya et al. 2012). As previously discussed, particular Tat 
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and Tax mutations can significantly alter protein–protein interactions, with the 
effects potentially resonating throughout these intricate protein networks and 
contributing to neuropathogenesis. Given the low fidelity of HIV-1 and HTLV-1 
reverse transcriptase, genetic variation is a pervasive attribute of retroviral proteins 
that influences not only drug resistance but also protein functionality. Accordingly, 
the selection of escape mutations within Tat and Tax epitopes likely affects both 
viral evolution and the extent of the neuroinflammatory response. Future research 
must be cognizant of the differences between the anti-Tat and anti-Tax immune 
responses on either side of the blood–brain barrier, as this will likely shape the 
persistence and selection of particular HIV-1 quasispecies within the brain 
compartment. Accordingly, Tat and Tax variants that are selected for on the basis 
of optimal survival within the cells of the CNS may demonstrate a unique set of 
characteristics that contribute to the progression of HAND and HAM/TSP. 
 
1.11 References 
Addo, M. M., et al. (2001). "The HIV-1 regulatory proteins Tat and Rev are 
frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected 
individuals." Proc Natl Acad Sci U S A 98(4): 1781-1786. 
  
Ahuja, J., et al. (2007). "Induction of pro-inflammatory cytokines by human T-cell 
leukemia virus type-1 Tax protein as determined by multiplexed cytokine protein 
array analyses of human dendritic cells." Biomed Pharmacother 61(4): 201-208. 
  
Akimoto, M., et al. (2007). "Anti-HTLV-1 tax antibody and tax-specific cytotoxic T 
lymphocyte are associated with a reduction in HTLV-1 proviral load in 
asymptomatic carriers." J Med Virol 79(7): 977-986. 
  
Alefantis, T., et al. (2003). "Characterization of a nuclear export signal within the 
human T cell leukemia virus type I transactivator protein Tax." J Biol Chem 
278(24): 21814-21822. 
  
 44 
Alefantis, T., et al. (2007). "Interaction of HTLV-1 Tax protein with calreticulin: 
implications for Tax nuclear export and secretion." Biomed Pharmacother 61(4): 
194-200. 
  
Alefantis, T., et al. (2005). "HTLV-1 Tax nucleocytoplasmic shuttling, interaction 
with the secretory pathway, extracellular signaling, and implications for neurologic 
disease." J Biomed Sci 12(6): 961-974. 
  
Alefantis, T., et al. (2005). "Secretion of the human T cell leukemia virus type I 
transactivator protein tax." J Biol Chem 280(17): 17353-17362. 
  
Ali, A., et al. (1993). "Dendritic cells infected in vitro with human T cell 
leukaemia/lymphoma virus type-1 (HTLV-1); enhanced lymphocytic proliferation 
and tropical spastic paraparesis." Clin Exp Immunol 94(1): 32-37. 
  
Allen, T. M., et al. (2005). "Selective escape from CD8+ T-cell responses 
represents a major driving force of human immunodeficiency virus type 1 (HIV-1) 
sequence diversity and reveals constraints on HIV-1 evolution." J Virol 79(21): 
13239-13249. 
  
Altman, J. D. and M. B. Feinberg (2004). "HIV escape: there and back again." Nat 
Med 10(3): 229-230. 
  
Andrade, A. S., et al. (2012). "Relationships Among Neurocognitive Status, 
Medication Adherence Measured by Pharmacy Refill Records, and Virologic 
Suppression in HIV-infected Persons." J Acquir Immune Defic Syndr. 
  
Andrade, R. G., et al. (2013). "Strong correlation between tax and HBZ mRNA 
expression in HAM/TSP patients: distinct markers for the neurologic disease." J 
Clin Virol 56(2): 135-140. 
  
Araujo, A. Q., et al. (1998). "HTLV-I-associated myelopathy/tropical spastic 
paraparesis in Brazil: a nationwide survey. HAM/TSP Brazilian Study Group." J 
Acquir Immune Defic Syndr Hum Retrovirol 19(5): 536-541. 
  
Araujo, A. Q., et al. (1995). "Progression of neurological disability in HTLV-I-
associated myelopathy/tropical spastic paraparesis (HAM/TSP)." J Neurol Sci 
129(2): 147-151. 
  
Bachani, M., et al. (2013). "Detection of anti-tat antibodies in CSF of individuals 
with HIV-associated neurocognitive disorders." J Neurovirol 19(1): 82-88. 
  
Balasubramanyam, K., et al. (2004). "Curcumin, a novel p300/CREB-binding 
protein-specific inhibitor of acetyltransferase, represses the acetylation of 
histone/nonhistone proteins and histone acetyltransferase-dependent chromatin 
transcription." J Biol Chem 279(49): 51163-51171. 
 45 
  
Banerjee, P., et al. (2007). "Proinflammatory cytokine gene induction by human T-
cell leukemia virus type 1 (HTLV-1) and HTLV-2 Tax in primary human glial cells." 
J Virol 81(4): 1690-1700. 
  
Barillari, G., et al. (1993). "The Tat protein of human immunodeficiency virus type 
1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, 
induces adhesion of the same cell types by using integrin receptors recognizing 
the RGD amino acid sequence." Proc Natl Acad Sci U S A 90(17): 7941-7945. 
  
Barros, N., et al. (2013). "CD4+ T cell subsets and Tax expression in HTLV-1 
associated diseases." Pathog Glob Health 107(4): 202-206. 
  
Basbous, J., et al. (2003). "The central region of human T-cell leukemia virus type 
1 Tax protein contains distinct domains involved in subunit dimerization." J Virol 
77(24): 13028-13035. 
  
Beimling, P. and K. Moelling (1992). "Direct interaction of CREB protein with 21 bp 
Tax-response elements of HTLV-ILTR." Oncogene 7(2): 257-262. 
  
Berkhout, B., et al. (1989). "Tat trans-activates the human immunodeficiency virus 
through a nascent RNA target." Cell 59(2): 273-282. 
  
Bertrand, S. J., et al. (2013). "HIV-1 Tat protein variants: critical role for the 
cysteine region in synaptodendritic injury." Exp Neurol 248: 228-235. 
  
Bex, F., et al. (1999). "Phosphorylation of the human T-cell leukemia virus type 1 
transactivator tax on adjacent serine residues is critical for tax activation." J Virol 
73(1): 738-745. 
  
Bex, F., et al. (1998). "Differential transcriptional activation by human T-cell 
leukemia virus type 1 Tax mutants is mediated by distinct interactions with CREB 
binding protein and p300." Mol Cell Biol 18(4): 2392-2405. 
  
Biddison, W. E., et al. (1997). "Human T cell leukemia virus type I (HTLV-I)-specific 
CD8+ CTL clones from patients with HTLV-I-associated neurologic disease 
secrete proinflammatory cytokines, chemokines, and matrix metalloproteinase." J 
Immunol 159(4): 2018-2025. 
  
Blum, J. S., et al. (2013). "Pathways of Antigen Processing." Annu Rev Immunol. 
  
Borrow, P., et al. (1994). "Virus-specific CD8+ cytotoxic T-lymphocyte activity 
associated with control of viremia in primary human immunodeficiency virus type 
1 infection." J Virol 68(9): 6103-6110. 
  
 46 
Boulanger, M. C., et al. (2005). "Methylation of Tat by PRMT6 regulates human 
immunodeficiency virus type 1 gene expression." J Virol 79(1): 124-131. 
  
Boven, L. A., et al. (2007). "Brain-derived human immunodeficiency virus-1 Tat 
exerts differential effects on LTR transactivation and neuroimmune activation." J 
Neurovirol 13(2): 173-184. 
  
Boxus, M., et al. (2008). "The HTLV-1 Tax interactome." Retrovirology 5: 76. 
  
Brady, J. and F. Kashanchi (2005). "Tat gets the "green" light on transcription 
initiation." Retrovirology 2: 69. 
  
Brady, J. N. (1992). ""Extracellular Tax1 protein stimulates NF-kB and expression 
of NF-kB-responsive Ig kappa and TNF beta genes in lymphoid cells"." AIDS Res 
Hum Retroviruses 8(5): 724-727. 
  
Bratanich, A. C., et al. (1998). "Brain-derived HIV-1 tat sequences from AIDS 
patients with dementia show increased molecular heterogeneity." J Neurovirol 
4(4): 387-393. 
  
Bres, V., et al. (2003). "A non-proteolytic role for ubiquitin in Tat-mediated 
transactivation of the HIV-1 promoter." Nat Cell Biol 5(8): 754-761. 
  
Bruce-Keller, A. J., et al. (2003). "Synaptic transport of human immunodeficiency 
virus-Tat protein causes neurotoxicity and gliosis in rat brain." J Neurosci 23(23): 
8417-8422. 
  
Burbelo, P. D., et al. (2008). "Anti-HTLV antibody profiling reveals an antibody 
signature for HTLV-I-associated myelopathy/tropical spastic paraparesis 
(HAM/TSP)." Retrovirology 5: 96. 
  
Buscemi, L., et al. (2007). "Human immunodeficiency virus type-1 protein Tat 
induces tumor necrosis factor-alpha-mediated neurotoxicity." Neurobiol Dis 26(3): 
661-670. 
  
Campbell, G. R. and E. P. Loret (2009). "What does the structure-function 
relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine?" 
Retrovirology 6: 50. 
  
Campbell, G. R., et al. (2007). "Tat mutations in an African cohort that do not 
prevent transactivation but change its immunogenic properties." Vaccine 25(50): 
8441-8447. 
  
Campbell, G. R., et al. (2011). "Differential induction of rat neuronal excitotoxic cell 
death by human immunodeficiency virus type 1 clade B and C tat proteins." AIDS 
Res Hum Retroviruses 27(6): 647-654. 
 47 
  
Cartier, L. and E. Ramirez (2005). "Presence of HTLV-I Tax protein in 
cerebrospinal fluid from HAM/TSP patients." Arch Virol 150(4): 743-753. 
  
Carvalho-Tavares, J., et al. (2000). "A role for platelets and endothelial selectins 
in tumor necrosis factor-alpha-induced leukocyte recruitment in the brain 
microvasculature." Circ Res 87(12): 1141-1148. 
  
Casseb, J., et al. (2006). "Lack of tax diversity for tropical spastic 
paraparesis/human T-cell lymphotropic virus type 1 (HTLV-I) associated 
myelopathy development in HTLV-I-infected subjects in Sao Paulo, Brazil." Mem 
Inst Oswaldo Cruz 101(3): 273-276. 
  
Chauhan, A., et al. (2003). "Intracellular human immunodeficiency virus Tat 
expression in astrocytes promotes astrocyte survival but induces potent 
neurotoxicity at distant sites via axonal transport." J Biol Chem 278(15): 13512-
13519. 
  
Chen, P., et al. (1997). "The Tat protein of HIV-1 induces tumor necrosis factor-
alpha production. Implications for HIV-1-associated neurological diseases." J Biol 
Chem 272(36): 22385-22388. 
  
Cherner, M., et al. (2007). "Neuropathologic confirmation of definitional criteria for 
human immunodeficiency virus-associated neurocognitive disorders." J Neurovirol 
13(1): 23-28. 
  
Chrivia, J. C., et al. (1993). "Phosphorylated CREB binds specifically to the nuclear 
protein CBP." Nature 365(6449): 855-859. 
  
Churchill, M. and A. Nath (2013). "Where does HIV hide? A focus on the central 
nervous system." Curr Opin HIV AIDS 8(3): 165-169. 
  
Cinque, P., et al. (1998). "Elevated cerebrospinal fluid levels of monocyte 
chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication." 
AIDS 12(11): 1327-1332. 
  
Conant, K., et al. (1998). "Induction of monocyte chemoattractant protein-1 in HIV-
1 Tat-stimulated astrocytes and elevation in AIDS dementia." Proc Natl Acad Sci 
U S A 95(6): 3117-3121. 
  
Copeland, K. F., et al. (1994). "Inhibition of apoptosis in T cells expressing human 
T cell leukemia virus type I Tax." AIDS Res Hum Retroviruses 10(10): 1259-1268. 
  
Cowan, E. P., et al. (1997). "Induction of tumor necrosis factor alpha in human 
neuronal cells by extracellular human T-cell lymphotropic virus type 1 Tax." J Virol 
71(9): 6982-6989. 
 48 
  
Cowley, D., et al. (2011). "Genetic and functional heterogeneity of CNS-derived tat 
alleles from patients with HIV-associated dementia." J Neurovirol 17(1): 70-81. 
  
D'Aversa, T. G., et al. (2004). "Expression of chemokines by human fetal microglia 
after treatment with the human immunodeficiency virus type 1 protein Tat." J 
Neurovirol 10(2): 86-97. 
  
D'Orso, I. and A. D. Frankel (2009). "Tat acetylation modulates assembly of a viral-
host RNA-protein transcription complex." Proc Natl Acad Sci U S A 106(9): 3101-
3106. 
  
D'Souza, S., et al. (1995). "Differential susceptibility of human CNS-derived cell 
populations to TNF-dependent and independent immune-mediated injury." J 
Neurosci 15(11): 7293-7300. 
  
Daenke, S., et al. (1990). "Sequence variants of human T-cell lymphotropic virus 
type I from patients with tropical spastic paraparesis and adult T-cell leukemia do 
not distinguish neurological from leukemic isolates." J Virol 64(3): 1278-1282. 
  
Debaisieux, S., et al. (2012). "The ins and outs of HIV-1 Tat." Traffic 13(3): 355-
363. 
  
Del Valle, L., et al. (2000). "Detection of HIV-1 Tat and JCV capsid protein, VP1, 
in AIDS brain with progressive multifocal leukoencephalopathy." J Neurovirol 6(3): 
221-228. 
  
Delport, W., et al. (2008). "Frequent toggling between alternative amino acids is 
driven by selection in HIV-1." PLoS Pathog 4(12): e1000242. 
  
Deng, L., et al. (2002). "HIV-1 Tat interaction with RNA polymerase II C-terminal 
domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation 
and transcription from HIV-1 promoter." J Biol Chem 277(37): 33922-33929. 
  
Dhawan, S., et al. (1993). "Increased expression of alpha 4 beta 1 and alpha 5 
beta 1 integrins on HTLV-I-infected lymphocytes." Virology 197(2): 778-781. 
  
Dhib-Jalbut, S., et al. (1994). "Extracellular human T-cell lymphotropic virus type I 
Tax protein induces cytokine production in adult human microglial cells." Ann 
Neurol 36(5): 787-790. 
  
Dingwall, C., et al. (1989). "Human immunodeficiency virus 1 tat protein binds 
trans-activation-responsive region (TAR) RNA in vitro." Proc Natl Acad Sci U S A 
86(18): 6925-6929. 
  
 49 
Dorr, A., et al. (2002). "Transcriptional synergy between Tat and PCAF is 
dependent on the binding of acetylated Tat to the PCAF bromodomain." EMBO J 
21(11): 2715-2723. 
  
Durkin, S. S., et al. (2006). "Site-specific phosphorylation differentiates active from 
inactive forms of the human T-cell leukemia virus type 1 Tax oncoprotein." J Biol 
Chem 281(42): 31705-31712. 
  
Ensoli, B., et al. (1993). "Release, uptake, and effects of extracellular human 
immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation." 
J Virol 67(1): 277-287. 
  
Eugenin, E. A., et al. (2003). "MCP-1 (CCL2) protects human neurons and 
astrocytes from NMDA or HIV-tat-induced apoptosis." J Neurochem 85(5): 1299-
1311. 
  
Eugenin, E. A., et al. (2005). "HIV-1 tat protein induces a migratory phenotype in 
human fetal microglia by a CCL2 (MCP-1)-dependent mechanism: possible role in 
NeuroAIDS." Glia 49(4): 501-510. 
  
Eugenin, E. A., et al. (2011). "Differences in NMDA receptor expression during 
human development determine the response of neurons to HIV-tat-mediated 
neurotoxicity." Neurotox Res 19(1): 138-148. 
  
Evans, D. T., et al. (1999). "Virus-specific cytotoxic T-lymphocyte responses select 
for amino-acid variation in simian immunodeficiency virus Env and Nef." Nat Med 
5(11): 1270-1276. 
  
Fanales-Belasio, E., et al. (2002). "Native HIV-1 Tat protein targets monocyte-
derived dendritic cells and enhances their maturation, function, and antigen-
specific T cell responses." J Immunol 168(1): 197-206. 
  
Ferrari, A., et al. (2003). "Caveolae-mediated internalization of extracellular HIV-1 
tat fusion proteins visualized in real time." Mol Ther 8(2): 284-294. 
  
Fine, S. M., et al. (1996). "Tumor necrosis factor alpha inhibits glutamate uptake 
by primary human astrocytes. Implications for pathogenesis of HIV-1 dementia." J 
Biol Chem 271(26): 15303-15306. 
  
Fittipaldi, A., et al. (2003). "Cell membrane lipid rafts mediate caveolar endocytosis 
of HIV-1 Tat fusion proteins." J Biol Chem 278(36): 34141-34149. 
  
Fontes, J. D., et al. (1993). "Phorbol esters modulate the phosphorylation of human 
T-cell leukemia virus type I Tax." J Virol 67(7): 4436-4441. 
  
 50 
Fra, A. M., et al. (1994). "Detergent-insoluble glycolipid microdomains in 
lymphocytes in the absence of caveolae." J Biol Chem 269(49): 30745-30748. 
  
Frankel, A. D. and C. O. Pabo (1988). "Cellular uptake of the tat protein from 
human immunodeficiency virus." Cell 55(6): 1189-1193. 
  
Fryrear, K. A., et al. (2009). "Dimerization and a novel Tax speckled structure 
localization signal are required for Tax nuclear localization." J Virol 83(11): 5339-
5352. 
  
Furukawa, Y., et al. (2000). "Phylogenetic subgroups of human T cell lymphotropic 
virus (HTLV) type I in the tax gene and their association with different risks for 
HTLV-I-associated myelopathy/tropical spastic paraparesis." J Infect Dis 182(5): 
1343-1349. 
  
Furuya, T., et al. (1997). "Heightened transmigrating activity of CD4-positive T cells 
through reconstituted basement membrane in patients with human T-lymphotropic 
virus type I-associated myelopathy." Proc Assoc Am Physicians 109(3): 228-236. 
  
Gatza, M. L., et al. (2007). "Ubiquitination of HTLV-I Tax in response to DNA 
damage regulates nuclear complex formation and nuclear export." Retrovirology 
4: 95. 
  
Gautier, V. W., et al. (2005). "Direct interaction of the human I-mfa domain-
containing protein, HIC, with HIV-1 Tat results in cytoplasmic sequestration and 
control of Tat activity." Proc Natl Acad Sci U S A 102(45): 16362-16367. 
  
Georges, S. A., et al. (2003). "Tax recruitment of CBP/p300, via the KIX domain, 
reveals a potent requirement for acetyltransferase activity that is chromatin 
dependent and histone tail independent." Mol Cell Biol 23(10): 3392-3404. 
  
Gessain, A. and R. Mahieux (2012). "Tropical spastic paraparesis and HTLV-1 
associated myelopathy: clinical, epidemiological, virological and therapeutic 
aspects." Rev Neurol (Paris) 168(3): 257-269. 
  
Ghezzi, S., et al. (2000). "Inhibition of CXCR4-dependent HIV-1 infection by 
extracellular HIV-1 Tat." Biochem Biophys Res Commun 270(3): 992-996. 
  
Giam, C. Z. and Y. L. Xu (1989). "HTLV-I tax gene product activates transcription 
via pre-existing cellular factors and cAMP responsive element." J Biol Chem 
264(26): 15236-15241. 
  
Gitlin, S. D., et al. (1991). "Transdominant human T-cell lymphotropic virus type I 
TAX1 mutant that fails to localize to the nucleus." J Virol 65(5): 2612-2621. 
  
 51 
Goldstein, G. (1996). "HIV-1 Tat protein as a potential AIDS vaccine." Nat Med 
2(9): 960-964. 
  
Goldstein, G. and J. J. Chicca (2012). "Exploratory clinical studies of a synthetic 
HIV-1 Tat epitope vaccine in asymptomatic treatment-naive and antiretroviral-
controlled HIV-1 infected subjects plus healthy uninfected subjects." Hum Vaccin 
Immunother 8(4): 479-485. 
  
Goncalves, D. U., et al. (2010). "Epidemiology, treatment, and prevention of human 
T-cell leukemia virus type 1-associated diseases." Clin Microbiol Rev 23(3): 577-
589. 
  
Gonzalez, G. A. and M. R. Montminy (1989). "Cyclic AMP stimulates somatostatin 
gene transcription by phosphorylation of CREB at serine 133." Cell 59(4): 675-680. 
  
Gonzalez-Scarano, F. and J. Martin-Garcia (2005). "The neuropathogenesis of 
AIDS." Nat Rev Immunol 5(1): 69-81. 
  
Goren, I., et al. (1995). "The amino terminus of Tax is required for interaction with 
the cyclic AMP response element binding protein." J Virol 69(9): 5806-5811. 
  
Grant, C., et al. (2002). "Human T cell leukemia virus type I and neurologic 
disease: events in bone marrow, peripheral blood, and central nervous system 
during normal immune surveillance and neuroinflammation." J Cell Physiol 190(2): 
133-159. 
  
Gray, F., et al. (2001). "Neuropathology and neurodegeneration in human 
immunodeficiency virus infection. Pathogenesis of HIV-induced lesions of the 
brain, correlations with HIV-associated disorders and modifications according to 
treatments." Clin Neuropathol 20(4): 146-155. 
  
Griffiths, I., et al. (1998). "Axonal swellings and degeneration in mice lacking the 
major proteolipid of myelin." Science 280(5369): 1610-1613. 
  
Guerreiro, J. B., et al. (2006). "Levels of serum chemokines discriminate clinical 
myelopathy associated with human T lymphotropic virus type 1 (HTLV-1)/tropical 
spastic paraparesis (HAM/TSP) disease from HTLV-1 carrier state." Clin Exp 
Immunol 145(2): 296-301. 
  
Guillon, C., et al. (2006). "Evidence for CTL-mediated selection of Tat and Rev 
mutants after the onset of the asymptomatic period during HIV type 1 infection." 
AIDS Res Hum Retroviruses 22(12): 1283-1292. 
  
Hargus, N. J. and S. A. Thayer (2013). "Human immunodeficiency virus-1 Tat 
protein increases the number of inhibitory synapses between hippocampal 
neurons in culture." J Neurosci 33(45): 17908-17920. 
 52 
  
Harrod, R., et al. (1998). "An exposed KID-like domain in human T-cell 
lymphotropic virus type 1 Tax is responsible for the recruitment of coactivators 
CBP/p300." Mol Cell Biol 18(9): 5052-5061. 
  
Hauber, J., et al. (1989). "Mutational analysis of the conserved basic domain of 
human immunodeficiency virus tat protein." J Virol 63(3): 1181-1187. 
  
Haughey, N. J., et al. (1999). "Involvement of inositol 1,4,5-trisphosphate-
regulated stores of intracellular calcium in calcium dysregulation and neuron cell 
death caused by HIV-1 protein tat." J Neurochem 73(4): 1363-1374. 
  
Haughey, N. J., et al. (2001). "HIV-1 Tat through phosphorylation of NMDA 
receptors potentiates glutamate excitotoxicity." J Neurochem 78(3): 457-467. 
  
Hayes, G. M., et al. (1987). "Microglia are the major cell type expressing MHC 
class II in human white matter." J Neurol Sci 80(1): 25-37. 
  
Hayman, M., et al. (1993). "Neurotoxicity of peptide analogues of the 
transactivating protein tat from Maedi-Visna virus and human immunodeficiency 
virus." Neuroscience 53(1): 1-6. 
  
Hetzer, C., et al. (2005). "Decoding Tat: the biology of HIV Tat posttranslational 
modifications." Microbes Infect 7(13): 1364-1369. 
  
Hickey, W. F. (2001). "Basic principles of immunological surveillance of the normal 
central nervous system." Glia 36(2): 118-124. 
  
Hickey, W. F., et al. (1991). "T-lymphocyte entry into the central nervous system." 
J Neurosci Res 28(2): 254-260. 
  
Hisada, M., et al. (1998). "Risk factors for adult T-cell leukemia among carriers of 
human T-lymphotropic virus type I." Blood 92(10): 3557-3561. 
  
Hofman, F. M., et al. (1994). "Exogenous tat protein activates central nervous 
system-derived endothelial cells." J Neuroimmunol 54(1-2): 19-28. 
  
Hudson, L., et al. (2000). "Detection of the human immunodeficiency virus 
regulatory protein tat in CNS tissues." J Neurovirol 6(2): 145-155. 
  
Hunt, P. W., et al. (2003). "Continued CD4 cell count increases in HIV-infected 
adults experiencing 4 years of viral suppression on antiretroviral therapy." AIDS 
17(13): 1907-1915. 
  
Iniguez, A. M., et al. (2010). "Correlation of HTLV-1 Tax genetic diversity with 
HTLV-1 associated myelopathy/tropical spastic paraparesis progression and 
 53 
HTLV-1a genotypes in an HTLV-1 endemic region in Argentina." J Med Virol 82(8): 
1438-1441. 
  
Irish, B. P., et al. (2009). "Molecular Mechanisms of Neurodegenerative Diseases 
Induced by Human Retroviruses: A Review." Am J Infect Dis 5(3): 231-258. 
  
Izmailova, E., et al. (2003). "HIV-1 Tat reprograms immature dendritic cells to 
express chemoattractants for activated T cells and macrophages." Nat Med 9(2): 
191-197. 
  
Jacobson, S. (2002). "Immunopathogenesis of human T cell lymphotropic virus 
type I-associated neurologic disease." J Infect Dis 186 Suppl 2: S187-192. 
  
Jacobson, S., et al. (1992). "HTLV-I-specific cytotoxic T lymphocytes in the 
cerebrospinal fluid of patients with HTLV-I-associated neurological disease." Ann 
Neurol 32(5): 651-657. 
  
Jain, P., et al. (2007). "Modulation of dendritic cell maturation and function by the 
Tax protein of human T cell leukemia virus type 1." J Leukoc Biol 82(1): 44-56. 
  
Jain, P., et al. (2007). "Identification of human T cell leukemia virus type 1 tax 
amino acid signals and cellular factors involved in secretion of the viral 
oncoprotein." J Biol Chem 282(47): 34581-34593. 
  
Jeang, K. T., et al. (1999). "Multifaceted activities of the HIV-1 transactivator of 
transcription, Tat." J Biol Chem 274(41): 28837-28840. 
  
Jeffery, K. J., et al. (2000). "The influence of HLA class I alleles and heterozygosity 
on the outcome of human T cell lymphotropic virus type I infection." J Immunol 
165(12): 7278-7284. 
  
Jiang, H., et al. (1999). "PCAF interacts with tax and stimulates tax transactivation 
in a histone acetyltransferase-independent manner." Mol Cell Biol 19(12): 8136-
8145. 
  
Johnston, J. B., et al. (2001). "HIV-1 Tat neurotoxicity is prevented by matrix 
metalloproteinase inhibitors." Ann Neurol 49(2): 230-241. 
  
Jones, M., et al. (1998). "Intraventricular injection of human immunodeficiency 
virus type 1 (HIV-1) tat protein causes inflammation, gliosis, apoptosis, and 
ventricular enlargement." J Neuropathol Exp Neurol 57(6): 563-570. 
  
Kaehlcke, K., et al. (2003). "Acetylation of Tat defines a cyclinT1-independent step 
in HIV transactivation." Mol Cell 12(1): 167-176. 
  
 54 
Kannagi, M., et al. (1992). "Target epitope in the Tax protein of human T-cell 
leukemia virus type I recognized by class I major histocompatibility complex-
restricted cytotoxic T cells." J Virol 66(5): 2928-2933. 
  
Karn, J. (2011). "The molecular biology of HIV latency: breaking and restoring the 
Tat-dependent transcriptional circuit." Curr Opin HIV AIDS 6(1): 4-11. 
  
Karn, J. and C. M. Stoltzfus (2012). "Transcriptional and posttranscriptional 
regulation of HIV-1 gene expression." Cold Spring Harb Perspect Med 2(2): 
a006916. 
  
Kattan, T., et al. (2009). "The avidity and lytic efficiency of the CTL response to 
HTLV-1." J Immunol 182(9): 5723-5729. 
  
Kaul, M., et al. (2001). "Pathways to neuronal injury and apoptosis in HIV-
associated dementia." Nature 410(6831): 988-994. 
  
Kiernan, R. E., et al. (1999). "HIV-1 tat transcriptional activity is regulated by 
acetylation." EMBO J 18(21): 6106-6118. 
  
Kim, J., et al. (2013). "HIV-1 Tat interacts with and regulates the localization and 
processing of amyloid precursor protein." PLoS One 8(11): e77972. 
  
Kimzey, A. L. and W. S. Dynan (1999). "Identification of a human T-cell leukemia 
virus type I tax peptide in contact with DNA." J Biol Chem 274(48): 34226-34232. 
  
Koup, R. A., et al. (1994). "Temporal association of cellular immune responses 
with the initial control of viremia in primary human immunodeficiency virus type 1 
syndrome." J Virol 68(7): 4650-4655. 
  
Koyanagi, Y., et al. (1993). "In vivo infection of human T-cell leukemia virus type I 
in non-T cells." Virology 196(1): 25-33. 
  
Kramer-Hammerle, S., et al. (2005). "Cells of the central nervous system as targets 
and reservoirs of the human immunodeficiency virus." Virus Res 111(2): 194-213. 
  
Kruman, II, et al. (1998). "HIV-1 protein Tat induces apoptosis of hippocampal 
neurons by a mechanism involving caspase activation, calcium overload, and 
oxidative stress." Exp Neurol 154(2): 276-288. 
  
Kuppuswamy, M., et al. (1989). "Multiple functional domains of Tat, the trans-
activator of HIV-1, defined by mutational analysis." Nucleic Acids Res 17(9): 3551-
3561. 
  
Kuroda, Y. and M. Matsui (1993). "Cerebrospinal fluid interferon-gamma is 
increased in HTLV-I-associated myelopathy." J Neuroimmunol 42(2): 223-226. 
 55 
  
Kuroda, Y., et al. (1993). "Granulocyte-macrophage colony-stimulating factor and 
interleukin-1 increase in cerebrospinal fluid, but not in serum, of HTLV-I-associated 
myelopathy." J Neuroimmunol 45(1-2): 133-136. 
  
Kutsch, O., et al. (2000). "Induction of the chemokines interleukin-8 and IP-10 by 
human immunodeficiency virus type 1 tat in astrocytes." J Virol 74(19): 9214-9221. 
  
Lamsoul, I., et al. (2005). "Exclusive ubiquitination and sumoylation on overlapping 
lysine residues mediate NF-kappaB activation by the human T-cell leukemia virus 
tax oncoprotein." Mol Cell Biol 25(23): 10391-10406. 
  
Laspia, M. F., et al. (1989). "HIV-1 Tat protein increases transcriptional initiation 
and stabilizes elongation." Cell 59(2): 283-292. 
  
Leal, F. E., et al. (2013). "Expansion in CD39(+) CD4(+) immunoregulatory t cells 
and rarity of Th17 cells in HTLV-1 infected patients is associated with neurological 
complications." PLoS Negl Trop Dis 7(2): e2028. 
  
Lehky, T. J., et al. (1995). "Detection of human T-lymphotropic virus type I (HTLV-
I) tax RNA in the central nervous system of HTLV-I-associated myelopathy/tropical 
spastic paraparesis patients by in situ hybridization." Ann Neurol 37(2): 167-175. 
  
Lenzmeier, B. A., et al. (1998). "Human T-cell leukemia virus type 1 Tax requires 
direct access to DNA for recruitment of CREB binding protein to the viral promoter." 
Mol Cell Biol 18(2): 721-731. 
  
Lepoutre, V., et al. (2009). "Role of resident CNS cell populations in HTLV-1-
associated neuroinflammatory disease." Front Biosci 14: 1152-1168. 
  
Levin, M. C., et al. (2002). "Autoimmunity due to molecular mimicry as a cause of 
neurological disease." Nat Med 8(5): 509-513. 
  
Li, B., et al. (2007). "Rapid reversion of sequence polymorphisms dominates early 
human immunodeficiency virus type 1 evolution." J Virol 81(1): 193-201. 
  
Li, L., et al. (2011). "Development of co-selected single nucleotide polymorphisms 
in the viral promoter precedes the onset of human immunodeficiency virus type 1-
associated neurocognitive impairment." J Neurovirol 17(1): 92-109. 
  
Li, L., et al. (2012). "Impact of Tat Genetic Variation on HIV-1 Disease." Adv Virol 
2012: 123605. 
  
Li, T. S., et al. (1998). "Long-lasting recovery in CD4 T-cell function and viral-load 
reduction after highly active antiretroviral therapy in advanced HIV-1 disease." 
Lancet 351(9117): 1682-1686. 
 56 
  
Li, W., et al. (2008). "NMDA receptor activation by HIV-Tat protein is clade 
dependent." J Neurosci 28(47): 12190-12198. 
  
Li, W., et al. (2009). "Role of Tat protein in HIV neuropathogenesis." Neurotox Res 
16(3): 205-220. 
  
Lippincott-Schwartz, J., et al. (2000). "Secretory protein trafficking and organelle 
dynamics in living cells." Annu Rev Cell Dev Biol 16: 557-589. 
  
Liu, X., et al. (2002). "Human immunodeficiency virus type 1 (HIV-1) tat induces 
nitric-oxide synthase in human astroglia." J Biol Chem 277(42): 39312-39319. 
  
Liu, Y., et al. (2000). "Uptake of HIV-1 tat protein mediated by low-density 
lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the 
receptor ligands." Nat Med 6(12): 1380-1387. 
  
Lodewick, J., et al. (2011). "Move or die: the fate of the Tax oncoprotein of HTLV-
1." Viruses 3(6): 829-857. 
  
Lodewick, J., et al. (2009). "Acetylation of the human T-cell leukemia virus type 1 
Tax oncoprotein by p300 promotes activation of the NF-kappaB pathway." Virology 
386(1): 68-78. 
  
Lopez-Huertas, M. R., et al. (2010). "Modifications in host cell cytoskeleton 
structure and function mediated by intracellular HIV-1 Tat protein are greatly 
dependent on the second coding exon." Nucleic Acids Res 38(10): 3287-3307. 
  
Lydy, S. L., et al. (1998). "Relationship between anti-Tax antibody responses and 
cocultivatable virus in HTLV-I-infected rabbits." Virology 250(1): 60-66. 
  
Magnuson, D. S., et al. (1995). "Human immunodeficiency virus type 1 tat activates 
non-N-methyl-D-aspartate excitatory amino acid receptors and causes 
neurotoxicity." Ann Neurol 37(3): 373-380. 
  
Mahlknecht, U., et al. (2008). "NF-kappaB-dependent control of HIV-1 transcription 
by the second coding exon of Tat in T cells." J Leukoc Biol 83(3): 718-727. 
  
Makino, M., et al. (1999). "The role of human T-lymphotropic virus type 1 (HTLV-
1)-infected dendritic cells in the development of HTLV-1-associated 
myelopathy/tropical spastic paraparesis." J Virol 73(6): 4575-4581. 
  
Mann, D. A. and A. D. Frankel (1991). "Endocytosis and targeting of exogenous 
HIV-1 Tat protein." EMBO J 10(7): 1733-1739. 
  
 57 
Manuel, S. L., et al. (2009). "Presentation of human T cell leukemia virus type 1 
(HTLV-1) Tax protein by dendritic cells: the underlying mechanism of HTLV-1-
associated neuroinflammatory disease." J Leukoc Biol 86(5): 1205-1216. 
  
Marcondes, M. C., et al. (2007). "Enrichment and persistence of virus-specific CTL 
in the brain of simian immunodeficiency virus-infected monkeys is associated with 
a unique cytokine environment." J Immunol 178(9): 5812-5819. 
  
McArthur, J. C. (2004). "HIV dementia: an evolving disease." J Neuroimmunol 
157(1-2): 3-10. 
  
McManus, C. M., et al. (2000). "Chemokine and chemokine-receptor expression in 
human glial elements: induction by the HIV protein, Tat, and chemokine 
autoregulation." Am J Pathol 156(4): 1441-1453. 
  
Medina, F., et al. (2014). "Tax Posttranslational Modifications and Interaction with 
Calreticulin in MT-2 Cells and Human Peripheral Blood Mononuclear Cells of 
Human T Cell Lymphotropic Virus Type-I-Associated Myelopathy/Tropical Spastic 
Paraparesis Patients." AIDS Res Hum Retroviruses. 
  
Meredith, L. W., et al. (2009). "Potent inhibition of HIV-1 replication by a Tat 
mutant." PLoS One 4(11): e7769. 
  
Moritoyo, T., et al. (1999). "Detection of human T-lymphotropic virus type I p40tax 
protein in cerebrospinal fluid cells from patients with human T-lymphotropic virus 
type I-associated myelopathy/tropical spastic paraparesis." J Neurovirol 5(3): 241-
248. 
  
Mujtaba, S., et al. (2002). "Structural basis of lysine-acetylated HIV-1 Tat 
recognition by PCAF bromodomain." Mol Cell 9(3): 575-586. 
  
Myers G, K. B., Foley BT, Jeang K-T, Mellors JW, Wain-Hobson S. (1996). Human 
Retroviruses and AIDS: A Compilation and Analysis of Nucleic Acid and Amino 
Acid Sequences. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los 
Alamos National Laboratory: III-11–III-26. 
  
Nakagawa, M., et al. (1995). "HTLV-I-associated myelopathy: analysis of 213 
patients based on clinical features and laboratory findings." J Neurovirol 1(1): 50-
61. 
  
Nasr, R., et al. (2006). "Tax ubiquitylation and sumoylation control critical 
cytoplasmic and nuclear steps of NF-kappaB activation." Blood 107(10): 4021-
4029. 
  
Nath, A., et al. (2008). "Evolution of HIV dementia with HIV infection." Int Rev 
Psychiatry 20(1): 25-31. 
 58 
  
Neuveut, C., et al. (2003). "Requirement for the second coding exon of Tat in the 
optimal replication of macrophage-tropic HIV-1." J Biomed Sci 10(6 Pt 1): 651-660. 
  
New, D. R., et al. (1997). "Human immunodeficiency virus type 1 Tat protein 
induces death by apoptosis in primary human neuron cultures." J Neurovirol 3(2): 
168-173. 
  
New, D. R., et al. (1998). "HIV-1 Tat induces neuronal death via tumor necrosis 
factor-alpha and activation of non-N-methyl-D-aspartate receptors by a 
NFkappaB-independent mechanism." J Biol Chem 273(28): 17852-17858. 
  
Ng, P. W., et al. (2001). "Genome-wide expression changes induced by HTLV-1 
Tax: evidence for MLK-3 mixed lineage kinase involvement in Tax-mediated NF-
kappaB activation." Oncogene 20(33): 4484-4496. 
  
Niewiesk, S., et al. (1994). "The transactivator gene of human T-cell leukemia virus 
type I is more variable within and between healthy carriers than patients with 
tropical spastic paraparesis." J Virol 68(10): 6778-6781. 
  
Nimmerjahn, A., et al. (2005). "Resting microglial cells are highly dynamic 
surveillants of brain parenchyma in vivo." Science 308(5726): 1314-1318. 
  
Nishimoto, N., et al. (1990). "Elevated levels of interleukin-6 in serum and 
cerebrospinal fluid of HTLV-I-associated myelopathy/tropical spastic paraparesis." 
J Neurol Sci 97(2-3): 183-193. 
  
Nonnemacher, M. R., et al. (2004). "Specific sequence configurations of HIV-1 LTR 
G/C box array result in altered recruitment of Sp isoforms and correlate with 
disease progression." J Neuroimmunol 157(1-2): 39-47. 
  
Nookala, A. R., et al. (2013). "HIV-1 Tat-mediated induction of CCL5 in astrocytes 
involves NF-kappaB, AP-1, C/EBPalpha and C/EBPgamma transcription factors 
and JAK, PI3K/Akt and p38 MAPK signaling pathways." PLoS One 8(11): e78855. 
  
Ohbo, K., et al. (1991). "Interleukin-6 in cerebrospinal fluid of HTLV-I-associated 
myelopathy." Neurology 41(4): 594-595. 
  
Osame, M. (2002). "Pathological mechanisms of human T-cell lymphotropic virus 
type I-associated myelopathy (HAM/TSP)." J Neurovirol 8(5): 359-364. 
  
Ott, M., et al. (1999). "Acetylation of the HIV-1 Tat protein by p300 is important for 
its transcriptional activity." Curr Biol 9(24): 1489-1492. 
  
Ousman, S. S. and P. Kubes (2012). "Immune surveillance in the central nervous 
system." Nat Neurosci 15(8): 1096-1101. 
 59 
  
Pagans, S., et al. (2010). "The Cellular lysine methyltransferase Set7/9-KMT7 
binds HIV-1 TAR RNA, monomethylates the viral transactivator Tat, and enhances 
HIV transcription." Cell Host Microbe 7(3): 234-244. 
  
Pagans, S., et al. (2005). "SIRT1 regulates HIV transcription via Tat deacetylation." 
PLoS Biol 3(2): e41. 
  
Pagans, S., et al. (2011). "Characterization of HIV Tat modifications using novel 
methyl-lysine-specific antibodies." Methods 53(1): 91-96. 
  
Parada, C. A. and R. G. Roeder (1996). "Enhanced processivity of RNA 
polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal 
domain." Nature 384(6607): 375-378. 
  
Park, R. E., et al. (1988). "A nuclear factor is required for transactivation of HTLV-
I gene expression." Oncogene 3(3): 275-279. 
  
Parker, C. E., et al. (1992). "Activated, HTLV-1-specific cytotoxic T-lymphocytes 
are found in healthy seropositives as well as in patients with tropical spastic 
paraparesis." Virology 188(2): 628-636. 
  
Persidsky, Y. and L. Poluektova (2006). "Immune privilege and HIV-1 persistence 
in the CNS." Immunol Rev 213: 180-194. 
  
Peterlin, B. M. and D. Trono (2003). "Hide, shield and strike back: how HIV-infected 
cells avoid immune eradication." Nat Rev Immunol 3(2): 97-107. 
  
Pillat, M. M., et al. (2011). "HTLV-1-associated myelopathy/tropical spastic 
paraparesis (HAM/TSP): still an obscure disease." Cent Nerv Syst Agents Med 
Chem 11(4): 239-245. 
  
Puca, A., et al. (2007). "IkappaB-alpha represses the transcriptional activity of the 
HIV-1 Tat transactivator by promoting its nuclear export." J Biol Chem 282(51): 
37146-37157. 
  
Rafatpanah, H., et al. (2007). "Association between HLA-DRB1*01 and HLA-
Cw*08 and outcome following HTLV-I infection." Iran J Immunol 4(2): 94-100. 
  
Rahman, S., et al. (2012). "HTLV-1 Tax mediated downregulation of miRNAs 
associated with chromatin remodeling factors in T cells with stably integrated viral 
promoter." PLoS One 7(4): e34490. 
  
Rayne, F., et al. (2010). "Phosphatidylinositol-(4,5)-bisphosphate enables efficient 
secretion of HIV-1 Tat by infected T-cells." EMBO J 29(8): 1348-1362. 
  
 60 
Re, M. C., et al. (1995). "Effect of antibody to HIV-1 Tat protein on viral replication 
in vitro and progression of HIV-1 disease in vivo." J Acquir Immune Defic Syndr 
Hum Retrovirol 10(4): 408-416. 
  
Ren, T., et al. (2013). "HTLV-1 Tax deregulates autophagy by recruiting 
autophagic molecules into lipid raft microdomains." Oncogene. 
  
Rezza, G., et al. (2005). "The presence of anti-Tat antibodies is predictive of long-
term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of 
HIV-1 seroconverters." J Infect Dis 191(8): 1321-1324. 
  
Rodman, T. C., et al. (1992). "Human immunodeficiency virus (HIV) Tat-reactive 
antibodies present in normal HIV-negative sera and depleted in HIV-positive sera. 
Identification of the epitope." J Exp Med 175(5): 1247-1253. 
  
Rosen, C. A., et al. (1988). "Intragenic cis-acting art gene-responsive sequences 
of the human immunodeficiency virus." Proc Natl Acad Sci U S A 85(7): 2071-
2075. 
  
Roy, S., et al. (1990). "A bulge structure in HIV-1 TAR RNA is required for Tat 
binding and Tat-mediated trans-activation." Genes Dev 4(8): 1365-1373. 
  
Ruben, S., et al. (1989). "Structural and functional characterization of human 
immunodeficiency virus tat protein." J Virol 63(1): 1-8. 
  
Rudolph, D. L., et al. (1994). "Detection of antibodies to trans-activator protein 
(p40taxI) of human T-cell lymphotropic virus type I by a synthetic peptide-based 
assay." Clin Diagn Lab Immunol 1(2): 176-181. 
  
Rumbaugh, J. A., et al. (2012). "HIV immune complexes prevent excitotoxicity by 
interaction with NMDA receptors." Neurobiol Dis 49C: 169-176. 
  
Sabouri, A. H., et al. (2005). "Differences in viral and host genetic risk factors for 
development of human T-cell lymphotropic virus type 1 (HTLV-1)-associated 
myelopathy/tropical spastic paraparesis between Iranian and Japanese HTLV-1-
infected individuals." J Gen Virol 86(Pt 3): 773-781. 
  
Sacktor, N., et al. (2002). "HIV-associated cognitive impairment before and after 
the advent of combination therapy." J Neurovirol 8(2): 136-142. 
  
Sakai, J. A., et al. (2001). "In vitro spontaneous lymphoproliferation in patients with 
human T-cell lymphotropic virus type I-associated neurologic disease: 
predominant expansion of CD8+ T cells." Blood 98(5): 1506-1511. 
  
 61 
Selby, M. J., et al. (1989). "Structure, sequence, and position of the stem-loop in 
tar determine transcriptional elongation by tat through the HIV-1 long terminal 
repeat." Genes Dev 3(4): 547-558. 
  
Selmaj, K., et al. (1991). "Cytokine cytotoxicity against oligodendrocytes. 
Apoptosis induced by lymphotoxin." J Immunol 147(5): 1522-1529. 
  
Selmaj, K. W. and C. S. Raine (1988). "Tumor necrosis factor mediates myelin and 
oligodendrocyte damage in vitro." Ann Neurol 23(4): 339-346. 
  
Semmes, O. J. and K. T. Jeang (1992). "HTLV-I Tax is a zinc-binding protein: role 
of zinc in Tax structure and function." Virology 188(2): 754-764. 
  
Semmes, O. J. and K. T. Jeang (1992). "Mutational analysis of human T-cell 
leukemia virus type I Tax: regions necessary for function determined with 47 
mutant proteins." J Virol 66(12): 7183-7192. 
  
Semmes, O. J. and K. T. Jeang (1995). "Definition of a minimal activation domain 
in human T-cell leukemia virus type I Tax." J Virol 69(3): 1827-1833. 
  
Shah, S., et al. (2010). "Innate and adaptive factors regulating human 
immunodeficiency virus type 1 genomic activation." J Neuroimmune Pharmacol 
5(3): 278-293. 
  
Sheng, W. S., et al. (2000). "Activation of human microglial cells by HIV-1 gp41 
and Tat proteins." Clin Immunol 96(3): 243-251. 
  
Shibasaki, H., et al. (1988). "Clinical picture of HTLV-I associated myelopathy." J 
Neurol Sci 87(1): 15-24. 
  
Silvers, J. M., et al. (2007). "Neurotoxicity of HIV-1 Tat protein: involvement of D1 
dopamine receptor." Neurotoxicology 28(6): 1184-1190. 
  
Smith, M. R. and W. C. Greene (1992). "Characterization of a novel nuclear 
localization signal in the HTLV-I tax transactivator protein." Virology 187(1): 316-
320. 
  
Smith, S. M., et al. (2003). "An in vivo replication-important function in the second 
coding exon of Tat is constrained against mutation despite cytotoxic T lymphocyte 
selection." J Biol Chem 278(45): 44816-44825. 
  
Steinaa, L., et al. (1994). "Antibody to HIV-1 Tat protein inhibits the replication of 
virus in culture." Arch Virol 139(3-4): 263-271. 
  
Strazza, M., et al. (2011). "Breaking down the barrier: the effects of HIV-1 on the 
blood-brain barrier." Brain Res 1399: 96-115. 
 62 
  
Sun, S. C., et al. (1994). "Human T-cell leukemia virus type I Tax activation of NF-
kappa B/Rel involves phosphorylation and degradation of I kappa B alpha and 
RelA (p65)-mediated induction of the c-rel gene." Mol Cell Biol 14(11): 7377-7384. 
  
Suzuki, T., et al. (1993). "The trans-activator tax of human T-cell leukemia virus 
type 1 (HTLV-1) interacts with cAMP-responsive element (CRE) binding and CRE 
modulator proteins that bind to the 21-base-pair enhancer of HTLV-1." Proc Natl 
Acad Sci U S A 90(2): 610-614. 
  
Szymocha, R., et al. (2000). "Human T-cell lymphotropic virus type 1-infected T 
lymphocytes impair catabolism and uptake of glutamate by astrocytes via Tax-1 
and tumor necrosis factor alpha." J Virol 74(14): 6433-6441. 
  
Szymocha, R., et al. (2000). "Long-term effects of HTLV-1 on brain astrocytes: 
sustained expression of Tax-1 associated with synthesis of inflammatory 
mediators." J Neurovirol 6(4): 350-357. 
  
Tahirov, T. H., et al. (2010). "Crystal structure of HIV-1 Tat complexed with human 
P-TEFb." Nature 465(7299): 747-751. 
  
Takahashi, M., et al. (2013). "HTLV-1 Tax oncoprotein stimulates ROS production 
and apoptosis in T cells by interacting with USP10." Blood 122(5): 715-725. 
  
Taylor, J. P. and K. Khalili (1994). "Activation of HIV-1 transcription by Tat in cells 
derived from the CNS: evidence for the participation of NF-kappa B--a review." Adv 
Neuroimmunol 4(3): 291-303. 
  
Thomas, C. A., et al. (1994). "TAT-mediated transcellular activation of HIV-1 long 
terminal repeat directed gene expression by HIV-1-infected peripheral blood 
mononuclear cells." J Immunol 153(8): 3831-3839. 
  
Thomas, E. R., et al. (2007). "High frequency of defective vpu compared with tat 
and rev genes in brain from patients with HIV type 1-associated dementia." AIDS 
Res Hum Retroviruses 23(4): 575-580. 
  
Tie, F., et al. (1996). "Interaction of the human T-lymphotropic virus type 1 Tax 
dimer with CREB and the viral 21-base-pair repeat." J Virol 70(12): 8368-8374. 
  
Tsunoda, I. and R. S. Fujinami (2002). "Inside-Out versus Outside-In models for 
virus induced demyelination: axonal damage triggering demyelination." Springer 
Semin Immunopathol 24(2): 105-125. 
  
Tyagi, M., et al. (2001). "Internalization of HIV-1 tat requires cell surface heparan 
sulfate proteoglycans." J Biol Chem 276(5): 3254-3261. 
  
 63 
Vendeville, A., et al. (2004). "HIV-1 Tat enters T cells using coated pits before 
translocating from acidified endosomes and eliciting biological responses." Mol 
Biol Cell 15(5): 2347-2360. 
  
Vider-Shalit, T., et al. (2009). "The HIV hide and seek game: an immunogenomic 
analysis of the HIV epitope repertoire." AIDS 23(11): 1311-1318. 
  
Vives, E., et al. (1997). "A truncated HIV-1 Tat protein basic domain rapidly 
translocates through the plasma membrane and accumulates in the cell nucleus." 
J Biol Chem 272(25): 16010-16017. 
  
von Herrath, M., et al. (1995). "Simian immunodeficiency virus (SIV)-specific CTL 
in cerebrospinal fluid and brains of SIV-infected rhesus macaques." J Immunol 
154(10): 5582-5589. 
  
Walker, B. D. and D. R. Burton (2008). "Toward an AIDS vaccine." Science 
320(5877): 760-764. 
  
Wei, P., et al. (1998). "A novel CDK9-associated C-type cyclin interacts directly 
with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA." 
Cell 92(4): 451-462. 
  
Weinberger, L. S., et al. (2005). "Stochastic gene expression in a lentiviral positive-
feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity." Cell 122(2): 169-
182. 
  
Weiss, J. M., et al. (1999). "HIV-1 Tat induces monocyte chemoattractant protein-
1-mediated monocyte transmigration across a model of the human blood-brain 
barrier and up-regulates CCR5 expression on human monocytes." J Immunol 
163(5): 2953-2959. 
  
Wrzesinski, S., et al. (2000). "HTLV type 1 Tax transduction in microglial cells and 
astrocytes by lentiviral vectors." AIDS Res Hum Retroviruses 16(16): 1771-1776. 
  
Xiao, H., et al. (2000). "Selective CXCR4 antagonism by Tat: implications for in 
vivo expansion of coreceptor use by HIV-1." Proc Natl Acad Sci U S A 97(21): 
11466-11471. 
  
Yamano, Y., et al. (2002). "Correlation of human T-cell lymphotropic virus type 1 
(HTLV-1) mRNA with proviral DNA load, virus-specific CD8(+) T cells, and disease 
severity in HTLV-1-associated myelopathy (HAM/TSP)." Blood 99(1): 88-94. 
  
Yedavalli, V. S., et al. (2003). "Tat and trans-activation-responsive (TAR) RNA-
independent induction of HIV-1 long terminal repeat by human and murine cyclin 
T1 requires Sp1." J Biol Chem 278(8): 6404-6410. 
  
 64 
Yin, M. J., et al. (1995). "Protein domains involved in both in vivo and in vitro 
interactions between human T-cell leukemia virus type I tax and CREB." J Virol 
69(6): 3420-3432. 
  
Zagury, J. F., et al. (1998). "Antibodies to the HIV-1 Tat protein correlated with 
nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine." 
J Hum Virol 1(4): 282-292. 
  
Zeng, L., et al. (2005). "Selective small molecules blocking HIV-1 Tat and 
coactivator PCAF association." J Am Chem Soc 127(8): 2376-2377. 
  
Zhao, L. J. and C. Z. Giam (1992). "Human T-cell lymphotropic virus type I (HTLV-
I) transcriptional activator, Tax, enhances CREB binding to HTLV-I 21-base-pair 
repeats by protein-protein interaction." Proc Natl Acad Sci U S A 89(15): 7070-
7074. 
  
Zhou, Q., et al. (1998). "Transcription elongation factor P-TEFb mediates Tat 
activation of HIV-1 transcription at multiple stages." EMBO J 17(13): 3681-3691. 
  
Zhu, Y., et al. (1997). "Transcription elongation factor P-TEFb is required for HIV-
1 tat transactivation in vitro." Genes Dev 11(20): 2622-2632. 
  
Zucchini, S., et al. (2013). "Increased excitability in tat-transgenic mice: role of tat 
in HIV-related neurological disorders." Neurobiol Dis 55: 110-119. 
  
 
 	
65 
CHAPTER II 
  
Utilization of HIV-1 envelope V3 to identify X4- and R5-specific  
Tat and LTR sequence signatures 
 
 
 
Gregory C. Antell, Will Dampier, Benjamas Aiamkitsumrit,  
Michael R. Nonnemacher, Jeffrey M. Jacobson, Vanessa Pirrone, Wen Zhong,  
Katherine Kercher, Shendra Passic, Jean W. Williams, Gregory Schwartz,  
Uri Hershberg, Fred C. Krebs, and Brian Wigdahl 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is published as: 
Antell G.C., Dampier W., Aiamkitsumrit B., Nonnemacher M.R., Jacobson J.M., 
Pirrone V., Zhong W., Kercher K., Passic S., Williams J.W., Schwartz G., 
Hershberg U., Krebs F.C., and Wigdahl B. Utilization of HIV-1 envelope V3 to 
identify X4- and R5-specific Tat and LTR sequence signatures. Retrovirology 
2016. 
 
GA, BA, WD, MN, UH and BW conceived and designed the study. GA, WD, and 
UH designed and performed the bioinformatic and statistical analyses. BW, MN, 
VP, JJ, KK, JW, WZ, BA, GA and SP managed the Drexel Medicine CARES Cohort 
and/or obtained sequences from patient PBMC samples. GA, UH, MN, FK, and 
BW prepared and designed the figures and drafted the manuscript. All authors 
read and approved the final manuscript. 
 
  
 	
66 
2.1 Abstract 
Human immunodeficiency virus type 1 (HIV-1) entry is a receptor-mediated 
process directed by the interaction of the viral envelope with the host cell CD4 
molecule and one of two co-receptors, CCR5 or CXCR4. The amino acid sequence 
of the third variable (V3) loop of the HIV-1 envelope is highly predictive of co-
receptor utilization preference during entry, and machine learning predictive 
algorithms have been developed to characterize sequences as CCR5-utilizing 
(R5) or CXCR4-utilizing (X4). It was hypothesized that while the V3 loop is 
predominantly responsible for determining co-receptor binding, additional 
components of the HIV-1 genome may contribute to overall viral tropism and 
display sequence signatures associated with co-receptor utilization. 
The accessory protein Tat and the HlV-1 long terminal repeat (LTR) were 
analyzed with respect to genetic diversity and compared by Jensen-Shannon 
divergence to identify R5- and X4-genome specific trends. The LTR sequences 
were further analyzed for putative transcription factor binding sites using the 
JASPAR transcription factor binding profile database. Sequences containing a full-
length V3 loop in addition to a co-linear Tat or LTR were obtained from the Los 
Alamos National Laboratory (LANL) HIV Sequence Database and supplemented 
with additional sequences from the Drexel University College of Medicine (Drexel 
Medicine) CNS AIDS Research and Eradication Study (CARES) Cohort.  
It was determined that Jensen-Shannon divergence was correlated with 
both mean genetic diversity as well as the absolute difference in genetic diversity. 
As expected, the V3 domain of the gp120 protein was enriched with statistically 
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divergent positions. Statistically divergent positions were identified in Tat amino 
acid sequences within the transactivation and TAR-binding domains, and in 
nucleotide positions throughout the LTR. We found several putative differences in 
transcription factor binding sites between R5 and X4 HIV-1 genomes, specifically 
identifying the C/EBP sites I and II, and Sp site III to differ with respect to sequence 
configuration for R5 and X4 LTRs. These observations support the hypothesis that 
co-receptor utilization coincides with specific genetic signatures in HIV-1 Tat and 
the LTR, likely due to differing transcriptional regulatory mechanisms and selective 
pressures applied within specific cellular targets during the course of productive 
HIV-1 infection. 
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2.2 Introduction 
Human immunodeficiency virus type 1 (HIV-1) entry is a receptor-mediated, 
pH-independent process occurring via the direct interaction between viral 
envelope glycoprotein (gp)120 and the host cell CD4 receptor molecule, as well as 
one of the two most commonly encountered co-receptor molecules, CCR5 or 
CXCR4 (Arrildt, Joseph et al. 2012). The HIV-1 gp120 entry protein consists of five 
variable regions (V1-V5), which are highly modified by insertion, deletion, and 
substitution mutations, interspersed among five constant regions (C1-C5). 
Regardless of this sequence hypervariability, the overall structure and function of 
gp120 is highly conserved. Of particular importance to the HIV-1 entry mechanism 
is the third variable loop (V3), which has been shown to consist of 34-36 amino 
acid residues (most commonly 35 residues). The V3 domain has been extensively 
studied as it has been identified as the principal neutralizing domain (PND) on the 
viral envelope gp120 (Goudsmit, Debouck et al. 1988, Javaherian, Langlois et al. 
1989, Sirois, Sing et al. 2005) and the viral partner in selective interactions with 
the different co-receptors (Sharon, Kessler et al. 2003). 
The V3 region is a major determinant in predicting HIV-1 entry phenotype, 
distinguishing non-syncytium inducing (NSI) from syncytium inducing (SI) strains 
and macrophage tropic from non-macrophage tropic strains (De Jong, De Ronde 
et al. 1992, Fouchier, Groenink et al. 1992, Cormier and Dragic 2002, Sharon, 
Kessler et al. 2003). In this regard, it was discovered that a T-cell tropic (T-tropic) 
isolate, or SI virus, preferentially uses the co-receptor CXCR4, and has 
consequently been referred to as an X4 virus. In contrast, a primary macrophage 
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tropic (M-tropic) isolate, or NSI virus, was found to preferentially use the co-
receptor CCR5 for entry and therefore referred to as an R5 virus (Deng, Liu et al. 
1996, Feng, Broder et al. 1996). Previously, viral tropism based on co-receptor 
usage was used interchangeably with tropism defined by cellular target; however, 
several studies have shown that while co-receptor usage can at times be linked 
with cellular tropism, it is important to discuss viral infection in terms of utilization 
of a co-receptor in conjunction with the phenotype of the target cell (Gonzalez-
Scarano and Martin-Garcia 2005, Swanstrom and Coffin 2012). As an example, 
recent investigations have shown that HIV-1 infectious molecular clones 
containing transmitted/founder (T/F) genome sequences preferentially utilized 
CCR5 as a co-receptor during entry and were able to replicate efficiently in primary 
CD4+ T cells (Keele, Giorgi et al. 2008, Ochsenbauer, Edmonds et al. 2012). These 
molecular clones also exhibited reduced replication efficiency in monocyte-derived 
macrophages (MDMs), in contrast to the prototypic M-tropic strains of HIV-1 
(Ochsenbauer, Edmonds et al. 2012). 
For high-throughput applications, co-receptor utilization predictions can be 
performed on Env-V3 sequences computationally (Sierra, Kaiser et al. 2007, 
Verhofstede, Brudney et al.). To this end, the internet-based bioinformatic method, 
position-specific scoring matrices (Web-PSSM), utilizes sequences of known entry 
phenotype to determine if an Env-V3 sequence is CCR5- or CXCR4-utilizing (R5 
or X4 Env-V3 sequences). This algorithm indicates the propensity of the virus to 
utilize CXCR4 at both high sensitivity (84%) and specificity (96%), with X4 virus 
sequences exhibiting high scores and R5 sequences exhibiting low scores, while 
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intermediate Web-PSSM scores indicates both R5 and X4 virus sequences as well 
as dual tropic X4/R5 virus sequences (Jensen, Li et al. 2003). Typically, X4 viruses 
emerge gradually in a subset of patients due to accumulation of amino acid 
changes within the V3 loop, particularly at positions 11 and 25. While HIV-1 co-
receptor usage has been demonstrated to be directly associated with the genotype 
of V3 loop, as described above, other amino acid residues within gp120 V1, V2, 
C4, and a number of regions of gp41, have also been associated with co-receptor 
usage (Koito, Stamatatos et al. 1995, Carrillo and Ratner 1996, Labrosse, 
Treboute et al. 2001, Pastore, Nedellec et al. 2006, Suphaphiphat, Essex et al. 
2007, Huang, Toma et al. 2008, Thielen, Sichtig et al. 2010, Coetzer, Nedellec et 
al. 2011, Dimonte, Mercurio et al. 2011, Aiamkitsumrit, Dampier et al. 2014). As 
conformational changes within the V3 loop occur upon the binding of gp120 and 
CD4, it is possible that the co-receptor usage-associated amino acid residues 
within other regions of envelope participate in the structural rearrangement of 
gp120 (Kwong, Wyatt et al. 1998). 
The overall goal of this study was to identify and characterize genetic 
differences between CCR5- and CXCR4-utilizing HIV-1 sequences beyond the V3 
loop of envelope as defined by genotypic prediction. Specifically, HIV-1 gp120 and 
Tat amino acid sequences and the HIV-1 long terminal repeat (LTR) nucleotide 
sequences were selected for this analysis. The HIV-1 Tat protein derives its name 
from the fact that its primary function during viral replication is to serve as the trans-
activator of transcription. While not directly involved in HIV-1 entry, Tat has a 
multitude of intracellular host binding partners and functions. The HIV-1 LTR 
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contains an abundance of transcription factor binding sites upstream of the 
transcription start site that alter levels of HIV-1 transcription, often in a cell type-
dependent manner. Importantly, these binding sites can work independently, in 
concert, or antagonistically, with a single nucleotide polymorphism capable of 
producing dramatic changes in binding, including the complete abrogation of 
transcription factor binding (Roy, Delling et al. 1990, Nonnemacher, Irish et al. 
2004).  
We hypothesized that co-evolved R5- or X4-associated genetic signatures 
emerge in viral genes and proteins that are not directly associated with entry, and 
suggest that these differences are reflective of evolutionary constraints applied by 
different cellular milieus that associate, co-evolve, or co-adapt with co-receptor 
usage and may collectively guide tissue- and/or cell type-specific replication 
patterns, as well as organ-specific disease pathogenesis. The validity of this 
hypothesis is supported by the association of X4 virus with depleted CD4+ T-cell 
levels and enhanced disease progression, as well as the tendency of R5 virus to 
infect cells of the monocyte-macrophage lineage and to be found at the time of 
transmission (Sturdevant, Joseph et al. 2015). However, the full extent of the 
underlying changes in the viral genome that could underlie such a shift remains 
unknown.  
To remedy this, we have taken a genetic approach with functional 
underpinnings that have centered on dividing HIV-1 co-linear sequences (gp120, 
Tat, and LTR) into two co-receptor utilization groups using genotypic prediction 
methods. Subsequently, these two groups of sequences were used to explore the 
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differences in the remainder of gp120 sequences outside of Env-V3 as well as co-
linear Tat and LTR sequences (Table 2.1). Sequence alignments of each co-
receptor usage-defined population of co-linear gp120, Tat, or LTR sequences were 
quantitatively evaluated at each amino acid (gp120 and Tat) or nucleotide (LTR) 
position utilizing first-order diversity and Jensen-Shannon divergence. Together, 
diversity and divergence provide metrics to characterize the position-specific 
variation of amino acids or nucleotides, as well as provide a quantitative method 
to compare this information between R5- and X4-defined sequences. This strategy 
has provided a straightforward genetic approach to define specific sequences in 
Tat and the LTR, or potentially any other HIV-1 sequence, that are co-selected 
with CXCR4- and CCR5-dependent entry. 
 
2.3 Methods 
2.3.1 HIV-1 sequence collection 
HIV-1 sequences containing the Env-V3 region in addition to a co-linear Tat 
or LTR were collected and annotated from the Los Alamos National Laboratory 
(LANL) HIV Sequence Database as of October 2014, while additional sequences 
from the Drexel Medicine CNS Research and AIDS Eradication Study (CARES) 
Cohort were added to supplement the total number of sequences publicly 
available. The Drexel Medicine CARES Cohort is a subtype B patient cohort from 
Philadelphia, Pennsylvania and has been previously described (Li, Aiamkitsumrit 
et al. 2011, Aiamkitsumrit, Dampier et al. 2014, Parikh, Dampier et al. 2014, 
Nonnemacher, Pirrone et al. 2016).  The sequences from the Drexel Medicine 
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CARES Cohort have been submitted to Genbank under BioProject sub1322660. 
To reduce the effect of regional and subtype differences, the LANL database query 
was limited to include only subtype B sequences isolated from North America. The 
query was further limited to a single sequence per patient using the LANL query 
tool which specifically excludes laboratory strain sequences or those used for 
functional studies.  Table 2.1 shows the breakdown of sequences for each region. 
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Table 2.1.  HIV-1 amino acid sequences for gp120 and Tat and nucleotide 
sequences for LTR were classified as being derived from CCR5- or CXCR4-
utilizing genomes according to Web-PSSM prediction scores utilizing the Env-V3 
sequence. Sequences with intermediate scores PSSM scores are derived from 
R5, X4, or dual-tropic X4/R5 viruses and were not included in further analysis. 
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Table 2.1.  Identification of HIV-1 Tat and LTR sequences co-linear to CCR5- 
and CXCR4-utilizing Env-V3 sequences defined by Web-PSSM scoring.   
 
Genomic Region CCR5 CXCR4 
gp120 1678 52 
Tat 504 31 
LTR 615 35 
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2.3.2 Co-receptor usage classification 
The in silico co-receptor usage prediction tool Web-PSSM was used to 
classify all sequences as CCR5- or CXCR4-utilizing based on the score of the co-
linear Env-V3 amino acid sequence (Jensen, Li et al. 2003). Numerous exclusion 
methods were utilized to reduce noise introduced by Web-PSSM predictions as 
discussed previously (Aimkitsumrit 2014). Sequences were excluded from the 
study if the V3 region was not 35 amino acid residues in length, if the V3 percentile 
determined by Web-PSSM was greater than 0.95 (indicating that a given sequence 
may not be a V3 sequence), or if the V3 PSSM score was in the ‘indeterminate 
range’ (using scoring cutoffs of > -2.88 and < -6.96 for X4 and R5 Env-V3 
sequences, respectively), which was defined as a scoring range consisting of 
sequences with R5 and/or X4 properties including sequences that are dual tropic 
(X4/R5).  Using these cutoffs, this predictor has an 84% sensitivity and 96% 
specificity, indicating its ability to detect X4 binding sequences and non-binding 
sequences, respectively (Jensen, Li et al. 2003). This filtering method allowed the 
genetic analysis to focus on sequences with the highest confidence classification 
in the PSSM-derived distribution, definitively signifying CCR5- or CXCR4-utilizing 
Env-V3 sequences. Following classification as R5 or X4, the co-linear gp120, Tat, 
and LTR sequences were aligned to the HXB2 reference sequence (K03455) using 
Multiple Sequence Comparison by Log-Expectation (MUSCLE), (version 5.05) 
(Tamura, Peterson et al. 2011) utilizing default parameters; insertions relative to 
the reference were removed to simplify the analysis. This pipeline resulted in R5- 
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and X4-associated and multiple sequence alignments for each gp120, Tat, and 
LTR sequence (Table 2.1). 
2.3.3 Genetic diversity and rarefaction 
The diversity of each amino acid or nucleotide position of the respective 
multiple sequence alignments was calculated using a window length, w, of 1 and 
an order of 1 [equivalent to exp(Shannon entropy with base e)] according to 
equation 1 (Schwartz and Hershberg 2013).  
Diversity at order = 1 calculates the effective number of species (amino 
acids or nucleotides) in a population while giving greater weight to neither rare nor 
abundant species. The maximum possible diversity is 20 for amino acid sequences 
(gp120 and Tat) and 4 for nucleotide sequences (LTR), with gaps regarded as 
missing data. In general, positions of high structural or functional importance are 
evolutionarily constrained in their use of amino acids or nucleotides and therefore 
demonstrate low diversity, while positions more permissive to variation in amino 
acid or nucleotide usage displayed higher genetic diversity (Ashkenazy, Erez et al. 
2010). Rarefaction curves for each position were generated in order to ensure that 
sufficient sample sizes existed for each comparison being made. 
 
Equation 2.1 .  First-order genetic diversity 
D",$ = exp − p*+, ln	 p*+,0+,*12  
Equation 2.1.  Diversity, D, weighs the abundance of all variants, p, at a given 
position, i, in the protein.  A window length, w, is applied, with w = 1 used in order 
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to independently assess the diversity of each position within a multiple sequence 
alignment. At an order, or Hill number, of q = 1, D does not exist; however, the limit 
as q approaches 1 can be computed as shown here. 
 
2.3.4 Application of Jensen-Shannon divergence 
 Jensen-Shannon divergence is a measure of the similarity between two 
probability distributions that can be applied to profile-to-profile multiple sequence 
alignment comparisons, with the divergence score bound by 0 (similar) and 1 
(dissimilar) (Yona and Levitt 2002, Wang and Dunbrack 2004). Multiple sequence 
alignments (MSA) generated from R5- and X4-classified sequence populations 
were used to generate position frequency matrices (PFMs). Each PFM contains 
the relative abundance of each residue (amino acid or nucleotide) for each position 
(N) of the multiple sequence alignment, resulting in 20 x N or 4 x N matrices for 
amino acid or nucleotide sequences, respectively. Residues that are not present 
in any of the sequences at a particular position of the MSA were represented with 
a pseudo-count of 1x10-7, equivalent to a relative abundance of 1 instance per ten 
million sequences, which ranges from approximately 1x104-fold to 1x106-fold lower 
abundance than being present in a single sequence. PFMs derived from R5- and 
X4-classified sequences were used to calculate the Jensen-Shannon divergence 
between populations according to Equation 2.2.  
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Equation 2.2 .  Jensen-Shannon divergence 
D34 = 12 Q82log; Q82Q8< + Q8;;<812 log; Q8;Q8<	;<812  
where:   Q8< = 2; Q82 +	Q8;  
Equation 2.2.  Jensen-Shannon divergence, DJS, is determined according to the 
abundance of each amino acid variant, Qa, in populations 1 and 2, using an 
information theory-based calculation. The value Q0 is calculated for each amino 
acid variant, and a pseudo-count is utilized for amino acid variants absent in both 
populations.  
 
Statistically significant positions were identified by applying a Monte Carlo 
permutation test, which randomly re-grouped the total pool of sequences into 
groups of size M and N iteratively (n = 1000), where M and N are equivalent to the 
number of sequences in the X4 and R5 groups, and generated a probability density 
function (PDF) of the Jensen-Shannon divergence values of the randomized model 
using a Gaussian kernel density estimator implemented in SciPy. Numerical 
integration was used to determine the probability of finding a random value greater 
than or equal to the true Jensen-Shannon divergence. 
 
2.3.5 Statistical analysis 
Statistical analysis was recorded in custom IPython Notebooks and 
performed using the SciPy Python library (version 0.14.0). Spearman’s rank 
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correlation coefficient was used to evaluate the relationship between R5 and X4 
diversity, as well as the relationship of Jensen-Shannon divergence to mean 
genetic diversity and the absolute difference in genetic diversity, respectively. 
gp120 domain enrichment analysis of statistically divergent positions utilized a 
hypergeometric test, with a null hypothesis of equal distribution of divergent 
positions. Enrichment of consensus amino acids within statistically divergent Tat 
positions was performed using a Fisher’s exact test. 
 
2.3.6 Two sequence logos 
Experimentally validated transcription factor bindings sites C/EBP-II (HXB2 
positions 281-289), ATF-CREB (330-337), C/EBP-I (338-349), NF-κB-II (350-359), 
NF-κB-I (363-373), Sp-III (377-386), Sp-II (388-398), and Sp-I (399-408), as well 
as the RNA stem loop (454-518), were evaluated using Two Sample Logo (Vacic, 
Iakoucheva et al. 2006). Two Sample Logo is a web-based application that 
calculates and visualizes the differences between two sets of aligned sequences. 
Each nucleotide was represented with a different color, and the height of the one-
letter nucleotide code was scaled according to the magnitude of the difference in 
abundance of the nucleotide at a given position, with the largest difference in each 
comparison represented by the maximum height in the logo. 
 
2.3.7 Identification of putative transcription binding sites  
Position frequency matrices (PFMs) were downloaded from the JASPAR 
redundant vertebrate database for C/EBP, Sp, NFkB, and CREB. Each PFM was 
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converted into a position weight matrix (PWM) as previously described (Wang and 
Dunbrack 2004). Each LTR sequence was scanned along its entirety to score 
every potential binding site using each of the PWMs. Each score was then 
compared to the maximum possible score for the PWM being used in order to 
determine a percentile score. Only binding sites with a mean percentile score > 
0.30 in either the R5- or X4-classified LTR sequences were considered for 
statistical analysis. Binding affinities as defined by PWM score show a non-
Gaussian distribution (data not shown). As such, the Kolmogorov-Smirnov (KS) 
test was used to compare affinities between different groups. The PWM was 
applied to each LTR and then the R5 and X4 distributions were compared. The p-
values were adjusted using the Benjamini-Hochberg procedure.  
 
2.4 Results 
Given the goal of this research was to determine if genetic signatures co-evolved 
between different regions of the HIV genome, it was first necessary to find patients 
that had sequences from the genomic areas of interest.  From the Los Alamos 
National Library (LANL) database, sequences derived from patient samples were 
downloaded and aligned to the HXB2 genome. In total more than 2500 samples 
were isolated, which included a full V3 of 35 amino-acids and at least one other 
co-linear sequence in the Tat or LTR regions. This also included 1730 full gp120 
sequences. Table 2.1 shows the breakdown of sequences for each region and the 
selection criteria are further described in the Methods. For all results discussed 
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below, we have analyzed the diversity/divergence of the amino acid sequences of 
gp120 and Tat proteins while the nucleotides of the LTR have been analyzed.  
 
2.4.1 Genetic diversity is correlated in R5- and X4-classified HIV-1 
gp120, Tat, and LTR sequence populations.  
Spearman’s rank correlation was performed to assess the correlation 
between R5 and X4 diversity for gp120 (ρ = 0.8678, P = 2.00 x 10-156), Tat (ρ = 
0.8873, P = 4.67 x 10-35), and LTR (ρ = 0.7021, P = 4.06 x 10-78) (Figure 2.1). In 
all cases, R5 and X4 diversity were well-correlated, with the P-value indicating 
support for the alternative hypothesis that X4 and R5 diversity is unrelated. 
Because first-order diversity was utilized in this analysis rather than richness (order 
= 0), and further supported by rarefaction analysis of the sample sizes, it is unlikely 
that differences in diversity are a reflection of the differences in sample size 
between the R5 and X4 sequence groups. This result indicates that, in general, 
corresponding amino acid (gp120 and Tat) or nucleotide (LTR) positions are 
similarly constrained in their usage with respect to R5 and X4 sequences.    
 
2.4.2 Jensen-Shannon divergence correlates with differences in 
diversity in HIV-1 gp120, Tat, and LTR sequences 
Notably, Jensen-Shannon divergence correlates well with both mean 
diversity (ρ = 0.9226, 0.8552, and 0.9295 for gp120, Tat, and LTR) and the 
absolute difference in diversity (ρ = 0.9005, 0.8852, and 0.9685 for gp120, Tat, 
and LTR) (Figure 2.2). Together, these observations indicate that the gain or loss 
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of diversity in one of the populations is closely associated with high Jensen-
Shannon divergence.  
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Figure 2.1.  HIV-1 genetic diversity is highly correlated between 
corresponding positions in R5- and X4-classified gp120, Tat, and LTR 
sequence populations. The genetic diversity (order = 1) of each position of 
gp120, Tat, and LTR was calculated according to Equation 1.  The positions were 
sorted across the x-axis according to the R5 diversity values (red line), with the 
corresponding X4 positions plotted (blue dots). With this visualization, the vertical 
distance between the line and the corresponding dot represents the difference in 
diversity between the R5- and X4-classified sequences at each position. In 
general, the X4 values were found to cluster around the R5 values, with a slight 
skew towards less diversity within the X4 population. Spearman’s rank correlation 
was performed to assess the correlation between R5 and X4 diversity for gp120 
(ρ = 0.8678, P = 2.00 x 10-156), Tat (ρ = 0.8873, P = 4.67 x 10-35), and LTR (ρ = 
0.7021, P = 4.06 x 10-78). In all cases, R5 and X4 diversity were well-correlated.  
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Figure 2.1 
 
 	
86 
Figure 2.2.  Jensen-Shannon divergence is correlated with both mean 
genetic diversity and the absolute difference in genetic diversity. The 
relationship between Jensen-Shannon divergence and genetic diversity (order = 
1) in HIV-1 gp120, Tat, and LTR sequences was evaluated using Spearman’s rank 
correlation. Both the mean diversity of R5- and X4-classified sequences and the 
absolute difference between R5 and X4 diversity correlated with Jensen-Shannon 
divergence. This result indicates that large divergence can be a reflection of not 
only increased amounts of information (as indicated by high mean diversity), but 
also by the loss of information in one of the two groups (as indicated by the 
absolute difference in mean diversity).  
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Figure 2.2 
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2.4.3. Amino acid diversity and Jensen-Shannon divergence 
identified domains in gp120 responsible for CCR5 or CXCR4 co-
receptor utilization  
The HIV-1 envelope protein gp120 was evaluated to detect the effectiveness of 
first-order sequence position diversity and Jensen-Shannon divergence with 
respect to identifying genetic signatures of co-receptor utilization, with the 
expectation that the V3 domain exhibits higher Jensen-Shannon divergence 
between R5- and X4-associated gp120 sequences. Diversity analysis, which as 
stated above was highly correlated between R5 (red) and X4 (blue) sequence 
populations, confirmed that the variable loops of gp120 display the greatest 
amount of amino acid diversity (Figure 2.3A). The V1 and V4 variable domains, in 
particular, contain several positions that display diversity of greater than 10 at order 
= 1, with a large proportion of positions having a diversity > 3. Calculation of 
Jensen-Shannon divergence between the R5 and X4 populations identified 92 
statistically significant positions throughout gp120 (Figure 2.3B). A hypergeometric 
statistical test was used to determine if any domains of gp120 were enriched in 
statistically divergent positions, as opposed to the null hypothesis of equal 
distribution. Overall, the variable domains were enriched in divergent positions 
when compared to the null model, while the conserved domains were depleted, 
although the C3 and V5 domains were in slight opposition to this trend (Figure 2.4). 
Specifically, the V3 loop was very highly enriched [log2(fold change) = 1.89, p = 
1.74 x 10-11] while the C1 domain [log2(fold change) = -1.09, p = 3.03 x 10-4] and 
C2 domain [log2(fold change) = -1.57, p = 1.28 x 10-4] were statistically depleted at 
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P < 0.01 using a Benjamini-Hochberg multiple testing correction. With the 
understanding that gp120 and V3 behaved as  expected  following the application 
of diversity and divergence in this study, Tat and the LTR were investigated for 
similar signatures that may co-evolve with alterations in co-receptor utilization 
patterns exhibited by Env-V3. 
  
 	
90 
Figure 2.3.  HIV-1 gp120 demonstrates high Jensen-Shannon divergence in 
regions with high genetic diversity. HIV-1 gp120 sequences were classified as 
CCR5 (R5) (n = 1681) or CXCR4 (X4) (n = 52) according to the predicted co-
receptor usage of the V3 domain Web-PSSM score (Jensen, Li et al. 2003). A. 
The diversity index at a Hill number of 1 was calculated for each position for both 
R5 (red) and X4 (blue) gp120 amino acid sequence populations. Diversity values 
range from 1 to greater than 10, with the variable domains of gp120 displaying the 
greatest diversity. B. The Jensen-Shannon divergence between R5 and X4 gp120 
sequence populations was computed for each amino acid position and plotted with 
a diamond. Statistically divergent positions (P < 0.01) were plotted in red. A Monte 
Carlo permutation test was performed to iteratively group gp120 sequences into 
random groups and calculate a distribution of expected Jensen-Shannon 
divergence values. The full range of this distribution was plotted in light blue with 
the interquartile range plotted in dark blue. The full range of divergence for 
randomly generated groups is in close agreement with the combined diversity of 
the R5 and X4 populations. 
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Figure 2.3 
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Figure 2.4.  V3 domain of gp120 is enriched with statistically divergent 
positions. The 10 conserved and variable domains of gp120 were evaluated to 
determine if any regions were enriched in statistically divergent sites. A 
hypergeometric test was used to determine enrichment and depletion of 
statistically divergent positions, using the null hypothesis of equal distribution 
amongst domains. The V3 loop was identified as being highly enriched (p = 1.74 x 
10-11), while the C1 domain (p = 3.03 x 10-4) and C2 domain (p =1.28 x 10-4) were 
statistically depleted at P < 0.01 using a Benjamini-Hochberg multiple testing 
correction. 
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Figure 2.4 
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2.4.4 X4 Tat sequences demonstrate purifying selection in amino 
acid usage 
In general, we observed an overall trend for Tat to have higher amino acid 
diversity in the fifth and sixth domains of both groups (Figure 2.5A). When we 
considered Jensen-Shannon divergence, positions 7, 23, 57, and 60 were found 
to be statistically divergent and P < 0.01 when accounting for multiple testing with 
the Benjamini-Hochberg procedure (Figure 2.5B). For all four divergent positions, 
the set of amino acids used in each population was similar, both with regard to the 
amino acids observed as well as the physiochemical properties of these amino 
acids (Figure 2.6, Table 2.2). In all cases, the amino acid diversity of the X4 
population was less than the diversity of the R5 population, demonstrating the 
qualitative trend that a subset of major variants become further enriched within the 
X4 population (Figure 2.7). While there was no adequate statistical methodology 
to test the significance of the difference in diversity at a single position, a Fisher’s 
exact test was used to demonstrate the statistical enrichment of the consensus 
variants R7 (P = 0.00053), T23 (P = 0.0012), and Q60 (P = 0.0158) within the X4 
group that is not a reflection of differences in R5 and X4 group sizes. In contrast, 
Tat variant R57 was not statistically enriched in the X4 population (P = 0.17). 
Regardless, this observation lends support to a mechanism in which the HIV-1 Tat 
X4 genotype undergoes purifying selection in  
Figure 2.5.  Jensen-Shannon divergence identifies positions of differential 
amino acid usage between R5 and X4 HIV-1 Tat sequences. HIV-1 Tat 
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sequences were sorted into R5 (n = 504) and X4 (n = 31) populations according 
to the predicted co-receptor usage of the co-linear V3 domain as determined by 
Web-PSSM score. A. The diversity index at order = 1 was calculated for each 
position for both R5 (red) and X4 (blue) Tat sequence populations. The diversity 
index between R5 and X4 populations displayed high similarity at nearly all 
positions, with the second half of Tat displaying higher diversity values overall for 
both populations. B. The Jensen-Shannon divergence between R5 and X4 Tat 
sequences was computed for each amino acid position and plotted with a diamond. 
Statistically divergent positions 7, 23, 57, and 60 (P < 0.01) were plotted in red and 
consensus changes, positions 40 and 67, were plotted in yellow. A Monte Carlo 
permutation test was performed to iteratively group Tat sequences into random 
groups and calculate a distribution of expected Jensen-Shannon divergence 
values. The full range of this distribution was plotted in light blue with the 
interquartile range plotted in dark blue. 
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Figure 2.5 
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Figure 2.6.  Divergent HIV-1 Tat positions differentially utilize amino acids. 
The amino acid usage in four HIV-1 Tat amino acid positions (7, 23, 57, and 60) 
was plotted for both R5 and X4 groups as a stacked bar chart representing the 
total genetic variation within each population at the respective positions. Amino 
acids were color coded according to physiochemical property using the following 
scheme: positively charged (red), negatively charged (blue), polar uncharged 
(purple), hydrophobic (green), and unclassified (glycine, proline, and cysteine, 
yellow).  The amino acid positions 7, 23, 57, and 60 were selected due to their 
statistically significant Jensen-Shannon divergence.  
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Figure 2.6 
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Figure 2.7.  Statistically divergent Tat positions demonstrate reduced 
diversity within X4-classified sequences. Within HIV-1 Tat, four amino acid 
positions were identified as having statistically significant Jensen-Shannon 
divergence: 7, 23, 57, and 60. In all four cases, it was noted that X4-classified 
variants exhibited a lower overall genetic diversity at an order of 1, largely due to 
the enhanced presence of the most common variant in the X4 population. This 
pattern of diminished diversity within X4 in comparison to R5 suggests that a 
purifying selective force may be present, affecting a subset of HIV-1 Tat variants. 
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Figure 2.7 
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Table 2.2. HIV-1 R5 and X4 Tat amino acid usage 
 
Position AA R5 count R5 % X4 count X4 % 
7 K 95 0.19 0 0.00 
 N 12 0.02 2 0.06 
 S 115 0.23 2 0.06 
 R 281 0.56 27 0.87 
23 N 230 0.46 5 0.16 
 T 274 0.54 26 0.84 
57 A 5 0.01 3 0.10 
 R 400 0.79 28 0.90 
 T 89 0.18 0 0.00 
60 E 87 0.17 1 0.03 
 D 7 0.01 2 0.06 
 K 30 0.06 0 0.00 
 Q 242 0.48 22 0.71 
 P 35 0.07 5 0.16 
 R 86 0.17 0 0.00 
 
The raw counts and relative abundance value of amino acids present in 
statistically divergent Tat positions for both the R5 and X4 sequence groups (7, 
23, 57, and 60). 
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concert with the change in V3 co-receptor usage from R5 to X4, whereas R5 Tat 
may be able to persist within a less constrained sequence space that allows it to 
effectively drive HIV-1 transcription in both T cells and MDMs and perhaps other 
cell lineages. 
The four Tat amino acid positions of interest are located within domains 
responsible for transactivation, cysteine-rich, TAR binding, and nuclear 
localization, respectively (Figure 2.5). In order to further evaluate the amino acid 
usage of these positions, the relative abundance of each variant was plotted 
(Figure 2.6). In both R5 and X4 Tat, arginine is the most common variant at position 
7, although R7 is much more conserved within the X4 population. Previous studies 
have shown that an R7G substitution has only 93.9 +/- 6.5% of the transactivation 
activity of R7 (Yukl, Pillai et al. 2009). While this effect size is small, it may 
contribute to differences in the transactivation activity between R5 and X4 HIV-1. 
Position 23 of Tat also is likely to play an important role in robust transactivation. 
In our data set, threonine was the most common variant observed at position 23, 
although asparagine was a frequent variant in both the R5 (46%) and X4 (16%) 
sequences. The T23N substitution has been shown to increase transactivation of 
the HIV-1 LTR, as well as binding to P-TEFb (Reza, Shen et al. 2003). Accordingly, 
Tat N23 has been suggested to confer an advantage to HIV-1 by compensating 
for deleterious Tat mutations and supporting the replication of less fit drug-resistant 
or immune-evasive quasispecies (Reza, Shen et al. 2003). Furthermore, the 
enrichment of the T23N substitution in the R5 Tat population may relate to the 
ability of R5 HIV-1 to productively infect both T cells and monocytes and the 
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selection of R5 HIV-1 at the time of transmission, as opposed to X4 HIV-1 which 
lacks a strong association with monocyte infection and is selected against at the 
time of transmission. The co-selection and possible synergistic effect of these Tat 
variants remains an area of future investigation. 
 
2.4.5 Predicted transcription factor binding sites have statistically 
different binding affinity scores between X4 and R5 LTR sequences 
Genetic diversity and Jensen-Shannon divergence analyses were 
performed on LTR nucleotide sequences. 518 nucleotide positions spanning the 
HIV-1 U3, R, and U5 regions were evaluated. High levels of nucleotide diversity 
were present throughout the entire LTR and did not display a general pattern 
beyond being low, i.e. more highly conserved, in the approximately 50 nucleotides 
immediately downstream of the transcription start site that correspond to the TAR 
region of the LTR. This observation translated to large numbers of statistically 
significant Jensen-Shannon divergence scores (n = 48) between the two 
populations (Figure 2.8). A number of these statistically divergent positions were 
identified at nucleotide positions within the core enhancer domain, the region of 
the LTR spanning approximately 200 nucleotides upstream of the transcription 
start site, while a high number of divergent positions were also identified in the less 
well characterized modulatory domain further upstream. Due to the high 
concentration of known transcription factor binding sites within the core enhancer 
domain, this region of the LTR was the focus of further analysis. 
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Figure 2.8.  HIV-1 LTR demonstrates high divergence both upstream and 
downstream of the transcription start site. HIV-1 long terminal repeat (LTR) 
sequences were sorted into R5 (n = 615) and X4 (n = 35) populations according 
to the predicted co-receptor usage of the co-linear V3 region. A The diversity index 
at order = 1 was calculated for each position for both R5 (red) and X4 (blue) LTR 
sequence populations, numbered according to the HXB2 reference sequence. B 
Following the same approach applied for amino acid analysis, Jensen-Shannon 
divergence between R5 and X4 LTR sequences was computed for each nucleotide 
position and plotted. Statistically divergent positions were plotted in red and 
identified throughout the LTR, both upstream and downstream of the 
transcriptional start site and within transcription factor binding sites. A Monte Carlo 
permutation simulation was performed to randomly group LTR sequences and 
calculate a distribution of expected Jensen-Shannon divergence values, with the 
full range (light blue) and interquartile range (dark blue) of the distribution plotted 
across each position of the LTR. 
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Figure 2.8 
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Binding of cellular transcription factors to the LTR has been shown to be 
one of the most critical parts of the viral life cycle with respect to acute infection 
but also in controlling the initial phases of genomic activation from latency. 
Throughout the HIV-1 LTR, eight well-known transcription factor binding sites were 
evaluated to determine if differential nucleotide usage exists between R5 and X4 
populations: C/EBP-II (HXB2 positions 281-289), ATF-CREB (330-337), C/EBP-I 
(338-349), NF-κB-II (350-359), NF-κB-I (363-373), Sp-III (377-386), Sp-II (388-
398), and Sp-I (399-408). Additionally, the TAR stem-loop region (HXB2 positions 
454-518) was similarly investigated for R5- and X4-associated differences.  
The difference in nucleotide usage within known transcription factor binding 
sites was visualized using two-sequence logos (Figure 2.9). This visualization 
creates a sequence logo for each transcription factor binding site that indicates 
nucleotides that are enriched within either the R5 or X4 populations, and scaled 
according to the maximum difference in relative abundance, such that nucleotides 
more frequently found in the R5 or X4 population are displayed on the bottom or 
top partition of the two-sequence logo, respectively, while completely conserved 
nucleotides are displayed in the middle. This analysis demonstrated that the 
greatest relative abundance differences in nucleotide usage occurred within sites 
C/EBP-I (54.7%), C/EBP-II (34.8%), and Sp-III (43.2%), as well as in the TAR stem 
loop (31.1%). In contrast, NF-κB-I (11.7%), NF-κB-II (8.6%), Sp-I (13.8%), Sp-II 
(23.8%), and ATF-CREB (11.8%) showed rather modest differences between X4 
and R5 in terms of nucleotide usage. Statistically divergent positions were 
identified within several of these transcription factor binding sites (Figure 2.8), 
 	
107 
specifically sites C/EBP-I (position 346), C/EBP-II (positions 281 and 284), and Sp-
III (position 384), as well as position 477 of the TAR stem loop, in agreement with 
the maximal differences observed in the two-sequence logos. Specifically, when 
comparing R5 to X4 sequences, the aforementioned positions demonstrated a 
propensity for an A-to-G (HXB2 position 346) mutation within C/EBP-I, an A/C-to-
G (HXB2 position 281) and a T-to-C (HXB2 position 284) mutation within C/EBP-
II, and a G-to-A (HXB2 position 384) mutation within Sp-III. Finally, a large T-to-C 
(HXB2 position 477) mutation was observed within the bulge region of the TAR 
stem loop. The bulge region plays a crucial role in Tat recruitment and binding to 
the transcription complex, raising the possibility that X4 HIV-1 may contain a large 
subpopulation of genomes that have altered Tat recruitment and binding relative 
to R5 HIV-1 (Selby, Bain et al. 1989). 
Although R5- and X4-specific nucleotide positions were identified throughout the 
LTR, it was not clear if those changes would result in meaningful differences 
between R5 and X4 in terms of transcription factor binding affinity. In order to 
quantitatively evaluate the difference between R5 and X4 LTR sequence groups, 
analysis was performed using the JASPAR database, a collection of transcription 
factor DNA-binding preferences modeled as matrices (Sandelin, Alkema et al. 
2004, Mathelier, Zhao et al. 2014). Each LTR sequence was scanned for 
transcription factor binding sites by scoring against position weight matrices 
(PWMs), which were converted from JASPAR position frequency matrices (PFMs) 
downloaded from the JASPAR vertebrate database for C/EBP, SP1, NF-κB, and 
CREB. Each score was then compared to the maximum possible score of the 
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corresponding PWM in order to determine a percentile score. Only binding sites 
with a mean percentile score > 0.30 in either the R5- or X4-classified LTR 
sequences were considered for statistical analysis (Table 2.3). The distribution of 
R5- and X4-binding scores was statistically compared using a Kolmogorov-
Smirnov (KS) test to calculate a P-value. 
Using the JASPAR matrices, we were able to correctly identify the locations 
of each of the eight known transcription factor binding sites within the LTR when 
using a percentile scoring threshold of 0.3. At this threshold, the JASPAR matrices 
for C/EBP, Sp1, and CREB also identified several other potential novel binding 
locations (Table 2.3). Statistical analysis identified differential binding scores 
between the R5 and X4 populations at sites C/EBP-I, C/EBP-II, and Sp-III, but not 
at known transcription factor binding sites Sp-I or Sp-II (Table 2.3). This result is in 
agreement with the positions identified using Jensen-Shannon divergence. 
Additionally, novel putative Sp1 and C/EBP binding sites with differential R5/X4 
JAPSAR scores were noted at positions 223 and 150, respectively.  
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Figure 2.9.  R5 and X4 LTR sequences demonstrate signature enriched 
nucleotide variants in transcription factor binding. HIV-1 transcription factors 
that have been confirmed in vitro, C/EBP-II (HXB2 positions 281-289), ATF-CREB 
(330-337), C/EBP-I (338-349), NF-κB-II (350-359), NF-κB-I (363-373), Sp-III (377-
386), Sp-II (388-398), and Sp-I (399-408), as well as the TAR stem loop (454 – 
518), were evaluated to detect enrichment and depletion of nucleotide variants in 
R5 and X4 sets of aligned LTR sequences using two sample logos. Enriched 
nucleotides were plotted proportional to the difference between the populations, 
with the sum of the most differential position plotted on the vertical axis. 
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Figure 2.9 
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Table 2.3.  Predicted transcription factor binding sites in the HIV-1 LTR.  
 
Transcription 
Factor 
JASPAR 
Matrix 
In vitro 
Confirmed 
HXB2 
Index 
Strand 
Direction 
X4 Mean 
Score 
R5 Mean 
Score P-value 
C/EBP MA0102.1-CEBPA  76 Reverse 4.55 4.06 0.3860 
 MA0102.2-CEBPA  79 Reverse 4.94 4.41 0.3860 
 MA0102.2-CEBPA  81 Forward 4.24 3.12 0.2304 
 MA0102.1-CEBPA  150 Reverse 5.16 3.39 <0.0001 
 MA0102.2-CEBPA  153 Reverse 6.35 4.58 <0.0001 
 MA0102.2-CEBPA  154 Forward 4.53 1.83 <0.0001 
 MA0102.1-CEBPA  197 Reverse 5.27 4.63 0.0092 
 MA0102.2-CEBPA  200 Reverse 4.33 4.34 0.0063 
 MA0102.1-CEBPA C/EBP II 278 Reverse 5.84 6.29 0.0005 
 MA0102.2-CEBPA C/EBP II 281 Reverse 5.26 5.70 0.0010 
 MA0102.3-CEBPA C/EBP II 281 Forward 7.65 9.67 0.0008 
 MA0102.2-CEBPA C/EBP I 342 Forward 5.26 4.65 <0.0001 
CREB MA0018.2-CREB1  173 Forward 4.74 3.93 0.1020 
 MA0018.2-CREB1 ATF/CREB 330 Forward 5.25 5.63 0.4547 
 MA0018.2-CREB1  410 Reverse 4.43 4.68 0.8684 
NF-kB MA0105.1-NFKB1 NF-kB II 350 Forward 13.66 14.52 0.9605 
 MA0105.1-NFKB1 NF-kB II 350 Reverse 7.43 8.30 0.9605 
 MA0105.2-NFKB1 NF-kB II 350 Forward 6.67 7.41 0.9605 
 MA0105.3-NFKB1 NF-kB II 350 Forward 12.37 13.41 0.9722 
 MA0105.1-NFKB1 NF-kB II 351 Reverse 4.85 5.31 0.9813 
 MA0105.1-NFKB1 NF-kB I 363 Forward 6.18 6.77 0.8062 
 MA0105.2-NFKB1 NF-kB I 363 Forward 8.20 8.62 0.8062 
 MA0105.2-NFKB1 NF-kB I 363 Reverse 7.60 7.88 0.8345 
 MA0105.1-NFKB1 NF-kB I 364 Forward 14.55 14.35 1.0000 
 MA0105.1-NFKB1 NF-kB I 364 Reverse 8.33 8.26 1.0000 
 MA0105.2-NFKB1 NF-kB I 364 Forward 7.44 7.29 1.0000 
 MA0105.3-NFKB1 NF-kB I 364 Forward 15.66 15.15 0.8907 
 MA0105.1-NFKB1 NF-kB I 365 Reverse 5.34 5.15 1.0000 
 MA0105.2-NFKB1 NF-kB 504 Forward 6.09 6.46 0.9850 
 MA0105.2-NFKB1 NF-kB 504 Reverse 8.56 8.83 0.9881 
 MA0105.1-NFKB1 NF-kB 505 Reverse 6.01 6.30 0.9850 
Sp MA0079.2-SP1  98 Reverse 4.68 5.68 0.0093 
 MA0079.1-SP1  99 Forward 5.01 5.35 0.0093 
 MA0079.1-SP1  223 Forward 4.35 3.31 <0.0001 
 MA0079.1-SP1  224 Forward 4.57 2.05 <0.0001 
 MA0079.1-SP1  266 Reverse 4.36 3.37 0.1034 
 MA0079.2-SP1 Sp-III 373 Reverse 5.30 5.86 0.5696 
 MA0079.1-SP1 Sp-III 374 Forward 4.12 4.82 0.0755 
 MA0079.2-SP1 Sp-III 376 Reverse 5.22 6.46 <0.0001 
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Transcription 
Factor 
JASPAR 
Matrix 
In vitro 
Confirmed 
HXB2 
Index 
Strand 
Direction 
X4 Mean 
Score 
R5 Mean 
Score P-value 
 MA0079.1-SP1 Sp-III 377 Forward 3.86 5.56 <0.0001 
 MA0079.2-SP1 Sp-III 382 Reverse 4.71 5.81 <0.0001 
 MA0079.2-SP1 Sp-II 387 Reverse 6.72 7.11 0.7894 
 MA0079.3-SP1 Sp-II 387 Reverse 10.11 10.46 0.6982 
 MA0079.1-SP1 Sp-II 388 Forward 5.78 6.14 0.2648 
 MA0079.2-SP1 Sp-II 392 Reverse 6.62 7.07 0.1179 
 MA0079.2-SP1 Sp-II 393 Reverse 5.51 6.81 0.0168 
 MA0079.1-SP1 Sp-I 398 Forward 4.35 4.35 0.6176 
 MA0079.2-SP1 Sp-I 398 Reverse 6.69 7.21 0.5383 
 MA0079.1-SP1 Sp-I 399 Forward 4.30 4.47 0.5539 
 MA0079.2-SP1 Sp-I 400 Reverse 5.78 5.83 1.0000 
 MA0079.1-SP1  479 Forward 5.21 5.02 0.9279 
 
LTR sequences classified as either R5 or X4 based on their co-linear Env-V3 
sequence were scanned for potential transcription factor binding sites. All binding 
sites with a percentile score > 0.3 in either of the two groups were included in this 
analysis. The overall score distribution of R5 and X4 binding sites was compared 
using a KS-test, and multiple testing was accounted for using the Benjamini-
Hochberg procedure. Statistically significant sites (P < 0.01) are highlighted in red. 
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Interestingly, the relative magnitude of R5 and X4 mean binding scores of 
C/EBP-I and -II were opposite one another, with X4 LTRs having a greater mean 
binding score than R5 LTRs for C/EBP-I, whereas R5 LTRs have a greater mean 
binding score for C/EBP II. The novel putative C/EBP site followed the trend of 
C/EBP site I, and had a greater mean score among X4 LTRs. This relationship 
may be a compensatory effect by which the diminished binding affinity of C/EBP 
II, as the virus mutates from R5 to X4, leads to greater binding to C/EBP I and 
perhaps other putative C/EBP sites. This overall trend is also reflected among Sp 
binding sites. As the binding affinity of Sp-III diminishes in X4 virus when compared 
to R5, a putative novel Sp site at position 223 gains enhanced binding affinity as 
indicated by JASPAR scoring. Generally, Sp sites have been shown to be more 
important for LTR-driven transcription in T lymphocytes than cells of the monocyte-
macrophage lineage (McAllister, Phillips et al. 2000). Furthermore, transcription 
factor binding at Sp-III varies with respect to the level of differentiation of 
monocytes (Millhouse, Krebs et al. 1998). Overall, we find that LTR-driven 
transcription is modulated by proteins of the Sp family in a manner that is specific 
to cell phenotype. As an important contrast, CREB and NF-κB binding sites did not 
demonstrate a difference in overall binding affinity between the R5 and X4 groups, 
although the analysis identified all known binding sites in both R5 and X4 
populations. This is likely due to the fact that these sites have been shown to be 
essential for both T-lymphocyte and monocyte-macrophage replication (Krebs, 
Goodenow et al. 1997, Rohr, Aunis et al. 1997, Rohr, Sawaya et al. 1999, Palmieri, 
Trimboli et al. 2004).  
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2.5 Discussion 
The V3 domain of the HIV-1 env gene evolves throughout the course of infection, 
often resulting in a switch from an R5 to an X4 swarm. However, the 
characterization of R5 and X4 HIV-1 has not been defined beyond the envelope, 
specifically with respect to the transcriptional regulation of HIV-1. Our findings 
indicate that when comparing X4 HIV-1 to R5 HIV-1 sequences, Tat amino acids 
variants are more strictly selected at several key positions and specific LTR 
nucleotide variants are preferentially present in X4 HIV-1 sequences when 
compared to R5 HIV-1. One particular caveat of our analysis, and any that involves 
historical sequence review, is our choice of functional annotation algorithm. While 
the specific results may differ to some extent with the choice of computational tools 
used in a given study, the overall finding that there is co-evolution between gp120 
and other regions of the HIV-1 genome remains consistent. These results are 
significant because they indicate that the transcriptional phenotype of HIV-1 may 
diverge with respect to co-receptor utilization. Importantly, the HIV-1 amino acid 
positions identified in Tat as different between X4 and R5 play roles in supporting 
robust transactivation, while the LTR nucleotide mutations associated with X4 and 
R5 strains are found within known and putative transcription factor binding sites 
and may affect their occupancy and contributions to the regulation of HIV-1 gene 
expression. We regard the genetic variation between X4 and R5 HIV-1 Tat and 
LTR sequences to be indicative of selection caused by the differential intracellular 
environments of cells preferentially infected by X4 versus R5 HIV-1 quasispecies. 
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Consequently, the evolution of HIV-1 from an R5 to an X4 swarm likely requires 
adaptation at the level of transcriptional control in addition to co-receptor binding 
and entry. 
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3.1 Abstract 
Viral protein R (Vpr) is a 14 kDa human immunodeficiency virus type 1 (HIV-
1) accessory protein that functions in HIV-1 replication and pathogenesis. 
Previously, we identified sequence signatures in Tat and the LTR that associate 
with co-receptor utilization, providing support for the characterization of HIV-1 
tropism beyond the envelope. As such, we have extended our studies to identify 
associations between Vpr variation in HIV-1-infected patients and co-receptor 
usage. Co-linear HIV-1 Vpr and Env-V3 amino acid sequences were collected from 
the LANL HIV-1 sequence database, as well as from well-suppressed patients 
enrolled in the Drexel Medicine CNS AIDS Research and Eradication Study 
(CARES) Cohort. Vpr sequences were grouped as X4 (CXCR4-utilizing) or R5 
(CCR5-utilizng) according to genotypic classification of the co-linear Env-V3 
sequence. The amino acid diversity of each Vpr population was assessed, as was 
the Jensen-Shannon divergence between groups, in order to identify sequence 
signatures associated with co-receptor utilization. Multiple amino acid alphabets 
were utilized in order to better assess the impact of amino acid substitutions with 
similar physiochemical properties. Positions 35-45 and the C-terminus of Vpr 
consistently displayed statistically significant divergence across multiple 
alphabets. Specifically, positions 37 and 41 displayed a consensus amino acid 
switch between R5 and X4 sequence populations. Overall, the results suggest a 
functional link between the evolution of Vpr and gp120 in HIV-1-infected patients. 
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3.2 Introduction 
Human immunodeficiency virus type 1 (HIV-1) entry proceeds via direct 
interaction between the viral envelope glycoprotein (gp)120 and the host cell CD4 
receptor molecule, as well as one of two co-receptor molecules, CCR5 or CXCR4 
(Arrildt, Joseph et al. 2012). The HIV-1 gp120 envelope protein consists of five 
hyper-variable regions (V1-V5) interspersed among five constant regions (C1-C5), 
with the third variable loop (V3) region serving as the major determinant in HIV-1 
co-receptor phenotype. Specifically, V3 consists of 34-36 amino acid residues 
(most commonly 35 residues). However, as conformational changes within the V3 
loop occur upon the binding of gp120 with CD4, it is possible that the co-receptor 
usage-associated amino acid residues within other regions of envelope participate 
in the structural rearrangement of gp120 (Kwong, Wyatt et al. 1998, Antell, 
Dampier et al. 2016). Patients with HIV-1 infections that are not well-suppressed 
by effective antiretroviral therapy will experience some form of co-receptor switch, 
in which CXCR4-utilizing (X4) viruses gradually emerge from a predominantly 
CCR5-utilizing (R5) swarm due to the accumulation of amino acid changes within 
the V3 loop, particularly at amino acid positions 11 and 25. HIV-1 tropism based 
on co-receptor usage was previously used interchangeably with tropism defined 
by cellular target. However, recent studies have concluded that it is more precise 
to discuss viral infection in terms of utilization of a co-receptor alongside the 
phenotype of the target cell (Gonzalez-Scarano and Martin-Garcia 2005, 
Swanstrom and Coffin 2012). For genomic applications, co-receptor utilization 
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prediction algorithms can be effectively used to classify Env-V3 sequences 
computationally, as previously reviewed (Aiamkitsumrit, Dampier et al. 2014).  
Previously, we reported that specific HIV-1 Tat and LTR sequence signatures 
associate with co-receptor utilization, suggesting that selective pressures applied 
within specific cellular targets during the course of HIV-1 infection result in distinct 
transcriptional regulatory mechanisms (Aiamkitsumrit, Dampier et al. 2014, 
Aiamkitsumrit, Dampier et al. 2014, Antell, Dampier et al. 2016). Influenced by this 
result, the overall goal of this study was the identification of genetic signatures of 
the accessory viral protein R (Vpr) with regard to R5 and X4 HIV-1 quasispecies. 
Vpr is a 96 amino acid protein with three characteristic α-helical secondary 
structures, α-helix 1 (positions 17-33), α-helix 2 (positions 38-50), and α-helix 3 
(positions 53-78). The three helices are flanked by two, nonstructural, but 
functional, N- and C-terminal domains (Schuler, Wecker et al. 1999, Wecker and 
Roques 1999, Wecker, Morellet et al. 2002). In general, Vpr has been 
understudied relative to other HIV-1 proteins, despite its multi-faceted roles in the 
replication cycle, activity as an extracellular protein, and contributions to HIV-1-
associated neuropathogenesis. Most critically, Vpr is essential for viral replication 
in macrophages but dispensable in T cells, suggesting strong cell type-specific 
functionality and possible co-evolution with Env-V3 (Westervelt, Henkel et al. 
1992). Accordingly, we hypothesized that co-receptor-associated genetic 
signatures would emerge in Vpr due to cell-type specific selective pressures that 
similarly direct co-receptor usage. The clinical impact of such a phenomenon 
extends to the association of X4 virus with depleted CD4+ T-cell levels and 
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enhanced disease progression, as well as the general but not exclusive tendency 
of R5 viruses to infect cells of the monocyte-macrophage lineage and to be found 
predominantly at the time of transmission (Sturdevant, Joseph et al. 2015). 
However, the variation in Vpr that could contribute to such clinically significant 
events remains unexplored. 
In this study, we extend a genetic approach previously applied to investigate 
gp120, Tat, and LTR associations with co-receptor utilization (Antell, Dampier et 
al. 2016) to the accessory protein Vpr. Aligned Vpr sequences were grouped as 
X4 or R5 according to the predicted co-receptor utilization of the co-linear V3 
region and evaluated independently at each Vpr amino acid position with regards 
to amino acid diversity and Jensen-Shannon divergence between groups. 
Combined diversity and divergence metrics allow for the quantitative 
characterization of position-specific amino acid variation and provide a 
methodology for comparing sequence information between different populations. 
Overall, this strategy has provided a concise genetic approach to define specific 
amino acids and side chain motifs in Vpr that are co-selected with CXCR4 or CCR5 
co-receptor utilization during replication in HIV-1-infected patients. 
 
3.3. Methods  
3.3.1 Collection and sequencing of DNA from HIV-1-infected patients 
Patients enrolled in the Drexel Medicine CNS AIDS Research and Eradication 
Study (CARES) Cohort were recruited from the Partnership Comprehensive Care 
Practice of the Division of Infectious Disease and HIV Medicine in the Department 
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of Medicine at Drexel University College of Medicine (Philadelphia, Pennsylvania, 
USA) and the Center for Clinical and Translational Medicine in the Institute for 
Molecular Medicine and Infectious Disease. Patients in the Drexel Medicine 
CARES Cohort were recruited under protocol 1201000748 (Brian Wigdahl, PI), 
which adheres to the ethical standards of the Helsinki Declaration (1964, amended 
most recently in 2008), which was developed by the World Medical Association. 
All patients provided written consent upon enrollment.  Whole blood collected from 
each patient was processed and assessed as previously described (Li, 
Aiamkitsumrit et al. 2011). Peripheral blood samples were used for drug screening, 
plasma analysis, and PBMC isolation as previously described. Env-V3 and Vpr 
regions were sequenced from 4.4-kb fragments (Li, Aiamkitsumrit et al. 2011, 
Aiamkitsumrit, Dampier et al. 2014) 
3.3.2 Compiling co-linear HIV-1 vpr-env sequences 
HIV-1 sequences from the Los Alamos National Laboratory (LANL) HIV 
Sequence Database that included co-linear env-V3 and vpr coding regions were 
collected and annotated in October 2014, while additional sequences from patients 
in the Drexel Medicine CARES Cohort were included to supplement the publicly 
available dataset. The Drexel Medicine CARES Cohort is a predominantly subtype 
B patient population from Philadelphia, Pennsylvania (Li, Aiamkitsumrit et al. 2011, 
Aiamkitsumrit, Dampier et al. 2014, Parikh, Dampier et al. 2014, Nonnemacher, 
Pirrone et al. 2016). To reduce the effect of regional and subtype differences, the 
LANL database query was limited to include only subtype B sequences isolated 
from North America. The query was further limited to a single sequence per patient 
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using the LANL query tool that specifically excludes laboratory strain sequences 
or those used for functional studies.  
3.3.3 Co-receptor usage classification 
The in silico co-receptor usage prediction tool Web-PSSM was used to classify 
all Vpr sequences as CCR5- or CXCR4-utilizing (R5 or X4) based on the score of 
the co-linear Env-V3 amino acid sequence (Jensen, Li et al. 2003). This algorithm 
classifies CXCR4 co-receptor utilization at both high sensitivity (84%) and 
specificity (96%) (Jensen, Li et al. 2003). Numerous exclusion methods were 
applied to reduce noise introduced by Web-PSSM predictions as discussed 
previously (Aimkitsumrit 2014). Specifically, sequences were excluded from the 
study if the V3 region was not 35 amino acid residues in length, if the V3 percentile 
determined by Web-PSSM was greater than 0.95 (indicating a poor likelihood of 
being a V3 sequence), or if the V3 PSSM score was in the ‘indeterminate range’ 
(using scoring cutoffs of > -2.88 and < -6.96 for X4 and R5 Env-V3 sequences, 
respectively), which was defined as a scoring range consisting of sequences with 
R5 and/or X4 properties, including sequences that were dual tropic (X4/R5). Using 
these cutoffs, this predictor has 84% sensitivity and 96% specificity, indicating its 
ability to detect X4 binding sequences and non-binding sequences, respectively 
(Jensen, Li et al. 2003). This filtering method allowed the genetic analysis to focus 
on sequences with the highest confidence classification in the PSSM-derived 
distribution, definitively signifying CCR5- or CXCR4-utilizing Env-V3 sequences 
(Aiamkitsumrit, Dampier et al. 2014).  
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3.3.4 Reduced amino acid alphabets 
Reduced amino acid alphabets were utilized in order to gain deeper insight 
into the structural and functional consequences of amino acid substitutions. The 
20-letter amino acid alphabet was reduced to smaller alphabets based on 
correlations indicated by the BLOSUM50 similarity matrix (Murphy, Wallqvist et al. 
2000) and implemented in the BioPython version 1.66 (Cock, Antao et al. 2009). 
The resulting alphabets were designated as Murphy-15, Murphy-10, Murphy-8, 
and Murphy-4, referring to the number of letters that make up each alphabet. 
Accordingly, all diversity and divergence calculations were performed on reduced 
amino acid alphabets in addition to the full alphabet containing 20 distinct amino 
acids. Whereas diversity and divergence metrics may be oversensitive to amino 
acid variation between amino acids with similar physiochemical properties (K 
versus R for example), reduced alphabets may overgeneralize and exclude 
important sequence information. Overall, this methodology aims to better focus on 
the truly important regions of a protein by observing trends in diversity and 
divergence across multiple alphabets. 
3.3.5 Positional diversity analysis 
Following classification as R5 or X4, co-linear Vpr sequences were aligned to 
the HXB2 reference sequence (K03455) using Multiple Sequence Comparison by 
Log-Expectation (MUSCLE), (version 5.05) (Tamura, Peterson et al. 2011) utilizing 
default parameters; both insertions and gaps relative to the reference were 
removed to preserve appropriate reference numbering. The diversity of each 
amino acid position was calculated using a window length, w, of 1 and an order of 
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1 [equivalent to exp(Shannon entropy with base e)] according to the following 
equation (Schwartz and Hershberg 2013):  
D",$ = exp − p*+, ln	 p*+,0+,*12  
Diversity, D, weighs the abundance of all variants, p, at a given position, i, in 
the protein. A window length, w, is applied, with w = 1 used in order to 
independently assess the diversity of each position within a multiple sequence 
alignment. At an order, or Hill number, of q = 1, D does not exist; however, the limit 
as q approaches 1 can be computed as shown here. The amino acid diversity at 
order = 1 calculates the effective number of amino acids present at an alignment 
position while giving greater weight to neither rare nor abundant species. In 
general, positions of high structural and functional importance have an 
evolutionarily constrained sequence space and therefore demonstrate low 
diversity, while positions more permissive to variation in amino acid usage display 
higher diversity (Ashkenazy, Erez et al. 2010).  
3.3.6 Positional Jensen-Shannon divergence analysis 
Jensen-Shannon divergence measures the similarity between two probability 
distributions with applications to profile-to-profile multiple sequence alignment 
comparisons (Yona and Levitt 2002, Wang and Dunbrack 2004). Divergence 
scores are bound in the range of 0 (completely similar) and 1 (completely 
dissimilar). Multiple sequence alignments (MSA) generated from R5- and X4-
classified sequence populations were used to generate position frequency 
matrices (PFMs). Each PFM contains the relative abundance of each residue (or 
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residue group in the case of reduced alphabets) for each position of the multiple 
sequence alignment. Residues that are not present in any of the sequences at a 
particular position of the MSA were represented with a pseudo-count of 1x10-7, 
equivalent to a relative abundance of 1 instance per ten million sequences, which 
ranges from approximately 1x104-fold to 1x106-fold lower abundance than being 
present in a single sequence. PFMs derived from R5- and X4-classified sequences 
were used to calculate the Jensen-Shannon divergence between populations 
according to the following equation: 
D34 = 12 Q82log; Q82Q8< + Q8;;<812 log; Q8;Q8<	;<812  
where   Q8< = 2; Q82 +	Q8;  
Jensen-Shannon divergence, DJS, is determined according to the abundance 
of each amino acid variant, Qa, in populations 1 and 2, using an information theory-
based calculation. The value Q0 is calculated for each amino acid variant, and a 
pseudo-count is utilized for amino acid variants absent in both populations.  
3.3.7 Statistical Analysis 
Statistical analysis was performed in custom IPython Notebooks using the 
SciPy Python library (version 0.14.0). Statistically significant positions were 
identified by applying a Monte Carlo permutation test, which randomly re-grouped 
the total pool of sequences into groups of size M and N iteratively (n = 1000), 
where M and N are equivalent to the number of sequences in the X4 and R5 Vpr 
groups. A probability density function (PDF) of the randomized Jensen-Shannon 
divergence distribution was generated using a Gaussian kernel density estimator 
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implemented in SciPy. Numerical integration was used to determine the probability 
of finding a random value greater than or equal to the true Jensen-Shannon 
divergence. 
3.4 Results 
Studies of coordinated amino acid variation between Vpr and gp120 were 
initiated using HIV-1 DNA sequences containing both vpr and env. Sequences of 
clinical origin were derived from blood samples collected from HIV-1-infected 
patients in the Drexel Medicine CNS AIDS Research and Eradication Study 
(CARES) Cohort (Li, Aiamkitsumrit et al. 2011, Aiamkitsumrit, Dampier et al. 
2014, Parikh, Dampier et al. 2014, Shah, Alexaki et al. 2014, Dampier, 
Nonnemacher et al. 2016, Nonnemacher, Pirrone et al. 2016). Co-linear DNA 
was isolated from patient PBMCs and amplified using primers specifically designed 
to encompass the Vpr and gp120 coding sequences. Similarly, DNA sequences 
from the Los Alamos National Laboratory (LANL) HIV-1 Databases 
(http://www.hiv.lanl.gov/) were selected based on the availability of both reading 
frames in a single, co-linear sequence. Sequences derived from patient DNA and 
acquired from the LANL database were first analyzed to determine the putative co-
receptor phenotype of the encoded gp120 glycoprotein. Sequences were analyzed 
using WebPSSM, an established and recognized online tool for predicting co-
receptor usage from amino acids encoded by HIV-1 gp120 V3 sequences 
(Jensen, Li et al. 2003). Of the 1010 co-linear sequences included in the final 
analysis, 969 were found to contain V3 sequences that scored as R5 genotypes. 
In contrast, only 41 sequences were scored as X4 genotypes (Table 3.1). The total 
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set of sequences analyzed included 29 samples from Drexel CARES Cohort, 20 
of which were classified as R5. 
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Table 3.1. Identification of HIV-1 Vpr sequences co-linear to Env-V3 
sequences defined as R5 or X4. A total of 1010 Vpr sequences were classified 
according to co-receptor utilization using Web-PSSM (Jensen, Li et al. 2003). 
 
Source CCR5 CXCR4 
LANL 949 32 
CARES 20 9 
Total 969 41 
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3.4.1. HIV-1 Vpr amino acid diversity is concentrated in two regions of Vpr 
In order to quantitatively assess the meaningful amount of variation occurring 
within R5- and X4-associated Vpr sequences at the amino acid level, the amino 
acid diversity for each Vpr position was independently calculated. Furthermore, a 
series of reduced amino acid alphabets (Murphy-15, Murphy-10, Murphy-8, and 
Murphy-4) were utilized to assess amino acid diversity (Murphy, Wallqvist et al. 
2000). These alphabets hierarchically group amino acids that have similar 
physiochemical properties (Table 3.2). As a general trend, the magnitude of the 
greatest diversity values decreased in concert with reduction of the amino acid 
alphabet size in both the R5 and X4 Vpr populations. However, the most diverse 
positions tended to be robustly persistent against the reduction in alphabet size for 
all alphabets except the highly generalized Murphy-4 alphabet (Figure 3.1). 
 
 
  
 134 
Table 3.2. Reduced alphabets utilized for analysis of Vpr amino acid 
variation.  The 20 standard amino acids were grouped according to BLOSUM50 
correlations in a hierarchical manner as previously reported (Murphy, Wallqvist et 
al. 2000). The resulting alphabets were designated as Murphy-15, Murphy-10, 
Murphy-8, and Murphy-4. 
 
AA M15 M10 M8 M4 
L L L L L 
V L L L L 
I L L L L 
M L L L L 
C C C L L 
A A A A A 
G G G A A 
S S S S A 
T T S S A 
P P P P A 
F F F F F 
Y F F F F 
W W F F F 
E E E E E 
D D E E E 
N N E E E 
Q Q E E E 
K K K K E 
R K K K E 
H H H H E 
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Figure 3.1 Position-specific Vpr amino acid diversity is generally consistent 
across multiple amino acid alphabets but different between R5- and X4-
associated sequences. The amino acid diversity was calculated across all 
positions of Vpr for both the R5 (red) and X4 (blue) sequence populations. While 
the overall levels of variation tended to be consistent between the two populations, 
there were notable differences in amino acid diversity between the R5 and X4 
populations that persisted across multiple alphabets at positions 28, 37, 55, and 
89. Diversity values for amino acid positions at which at least one diversity value 
was greater than 2 in the full amino acid alphabet are listed in Table 3.3. 
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Figure 3.1 
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A diversity value of 2 in either the R5 or X4 group, using the standard 20 amino 
acid alphabet, was used as a threshold to define highly diverse positions. The 
identified positions were located at residues 28, 37, 41, 45, 55, 77, 84, 85, 89, and 
93 (Table 3.3), spanning all three major helical structures of Vpr. Overall, there 
was no clear trend for either the X4 or R5 populations to consistently display 
greater diversity across all positions, and most positions displayed approximately 
equal diversity in the respective populations. However, a subset of positions (28, 
37, 55, and 89) displayed noteworthy diversity trends that persisted across multiple 
alphabets. In almost all cases, Vpr amino acid diversity was reduced to less than 
2 when using the Murphy-4 alphabet, indicating the strong propensity for amino 
acid substitutions to be contained within the same physiochemical groups once the 
group sizes become sufficiently large. 
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Table 3.3. Diversity values at amino acid positions in Vpr. Each position in the 
table had at least one diversity value greater than 2 in the full amino acid alphabet. 
A diversity value greater than 2 (blue shading) indicates a diverse amino acid 
position. 
Position Co-receptor 
All 
Residues 
Murphy-
15 
Murphy-
10 
Murphy-
8 
Murphy-
4 
28 X4 4.45 4.45 3.18 3.18 1.99 R5 3.37 3.37 2.95 2.95 1.76 
37 X4 5.46 2.27 2.27 2.27 1.94 R5 4.97 3.14 2.93 2.92 2.16 
41 X4 2.88 2.88 2.65 2.65 1.45 R5 2.63 2.63 2.55 2.55 1.64 
45 X4 2.20 2.20 2.20 2.20 2.20 R5 2.14 2.14 2.14 2.14 2.08 
55 X4 1.87 1.87 1.87 1.87 1.00 R5 2.78 2.76 2.74 2.74 1.38 
77 X4 2.07 2.07 2.07 2.07 1.00 R5 2.31 2.31 2.31 2.31 1.02 
84 X4 2.94 2.20 2.20 2.20 2.20 R5 2.97 2.55 2.38 2.38 2.15 
85 X4 2.71 2.71 2.71 2.71 1.78 R5 2.68 2.66 2.66 2.66 1.68 
89 X4 1.97 1.97 1.83 1.83 1.00 R5 3.42 3.24 3.06 3.02 1.50 
93 X4 2.23 2.23 1.83 1.83 1.00 R5 1.94 1.94 1.82 1.82 1.00 
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Position 28 displayed considerably greater diversity in X4 Vpr when using the 
full and Murphy-15 alphabets (4.45 versus 3.37 in both cases), but the difference 
narrowed considerably using the Murphy-10 and Murphy-8 alphabets (3.18 versus 
2.95 in both cases). This difference was primarily due to the R5 population being 
dominated by three variants (R28, N28, and S28) while the X4 population 
displayed a more even distribution. Positions 55 and 89 both displayed similar 
trends, in which the R5 diversity was considerably larger across all alphabets but 
Murphy-4. This was largely due to the presence of an E55 variant in the R5 
population that was entirely absent among X4 Vpr sequences. Similarly, the 
differential diversity of position 89 was attributed to variant A89 being more highly 
conserved in the X4 population, with an A89T substitution having no influence on 
diversity in the Murphy-4 alphabet. Finally, position 37 was unique in that the more 
diverse group switched with the amino acid alphabet utilized. While the X4 group 
was more diverse using the standard 20 amino acid alphabet, R5 diversity was 
greater for each of the four reduced alphabets. This position is extremely 
polymorphic, the diversity trend attributed to the most common X4 variants L37, 
V37, I37, and M37 being collapsed into one group in the Murphy-15 alphabet, while 
common R5 variants such as P37, S37, and E37 persisted in distinct amino acid 
groups as the alphabet was reduced. 
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3.4.2 Divergence in amino acid utilization between X4 and R5 Vpr is highly 
consistent across reduced amino acid alphabets 
Jensen-Shannon divergence was calculated between amino acid distributions 
at each position in R5- and X4-associated Vpr sequences (Figure 2), using both 
the standard amino acid alphabet and reduced alphabets (Figure 1). Statistically 
divergent positions (P < 0.01) were highly consistent across all alphabets, 
indicating that the amino acid variation driving Jensen-Shannon divergence was 
maintained across amino acid categories with increasingly generalized 
physiochemical properties. Vpr positions 36, 37, 41, 89, and 96 were identified in 
multiple levels of analysis (Table 4). These positions are concentrated near the 
second alpha helix of Vpr (36, 37 and 41) and the C-terminal domain (89 and 96).  
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Figure 3.2. Jensen–Shannon divergence identifies positions with differential 
amino acid profiles between R5 and X4 Vpr sequences. The Jensen–Shannon 
divergence between R5 and X4 Vpr sequences was computed for each amino acid 
position and plotted with a black circle. Statistically divergent positions, as 
determined by a one-tailed Monte Carlo permutation test (1000 iterations), are 
indicated by a red star (P < 0.05).  This methodology was repeated for each of the 
reduced alphabets, Murphy-15, -10, -8, and -4. 
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Figure 3.2 
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Table 3.4. HIV-1 Vpr positions with high Jensen-Shannon divergence 
between R5- and X4-associated sequences. The calculated Jensen-Shannon 
divergence, along with the associated P-value in parentheses (in red when P < 
0.01), are displayed for positions 36, 37, 41, 89, and 96. 
 
Position All Residues Murphy-15 Murphy-10 Murphy-8 Murphy-4 
36 0.0346 0.0341 0.0341 0.0341 0.0331 (0.0367) (0.0205) (0.0143) (0.0271) (0.0068) 
37 0.1612 0.0950 0.0715 0.0709 0.0656 (0.0053) (0.0322) (0.0555) (0.0389) (0.0026) 
41 0.1012 0.1012 0.0735 0.0735 0.0072 
(0.0013) (0.0005) (0.0024) (0.0034) (0.4613) 
89 0.1094 0.1094 0.1048 0.1034 0.0704 (0.0103) (0.0029) (0.0027) (0.0013) (0.0034) 
96 0.0623 0.0623 0.0623 0.0623 0.0000 (0.0051) (0.0029) (0.0030) (0.0030) (0.5005) 
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3.4.3 Specific amino acid substitutions are signatures of X4 and R5 Vpr 
Sequence logos were utilized to visualize the two regions of HIV-1 Vpr that 
generally displayed high levels of both diversity and Jensen-Shannon divergence 
between X4 and R5 Vpr sequences (Figure 3). Vpr regions 36-45 and 87-96 were 
selected for further analysis and encompass all four positions with statistically 
significant Jensen-Shannon divergence scores. Positions 37 and 41 displayed 
consistently high and statistically significant Jensen-Shannon divergence. The 
diversity of these positions was also considerably high, with several amino acids 
being used at appreciable levels across both populations. In accordance with large 
Jensen-Shannon divergence, positions 37 and 41 both featured a consensus 
change between the R5 and X4 populations, with R5 featuring I37/S41 and X4 
featuring P37/G41. Additionally, position 45 was highly polymorphic, displaying a 
diversity greater than 2 regardless of alphabet, attributable to H45 and Y45. 
However, these two variants did not show a trend with respect to X4 and R5. Within 
the C-terminal region, positions 89 and 96 displayed significant Jensen-Shannon 
divergence, but did not exhibit consensus changes. The difference can be 
attributed to an increased presence of T89 and P96, respectively. Finally, position 
77 displayed a consensus difference between the X4 (Q77) and R5 (R77) 
populations, although this position did not display a statistically different Jensen-
Shannon divergence between groups. 
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Figure 3.3. Sequence logos for Vpr regions 36-45 and 87-96. Both regions 
within the Vpr amino acid sequence included several peaks in amino acid diversity 
across multiple alphabets. They also contained all positions found to be statistically 
divergent using Jensen-Shannon divergence (positions 36, 37, 41, 89, and 96). 
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Figure 3.3 
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3.5 Discussion 
The role that genetic variation beyond the HIV-1 envelope plays in viral tropism 
and replication remains a largely unexplored domain. Vpr specifically was 
hypothesized to have differential co-receptor-associated sequence signatures due 
to its strong requirement for HIV-1 replication in monocytes-macrophages, but 
expendability in T lymphocytes (Levy, Refaeli et al. 1995). HIV-1 Vpr has been 
shown to exist in cell-associated, virion-associated, and virus-free extracellular 
forms; implicating the protein in multiple aspects of the HIV-1 lifecycle (Tungaturthi, 
Sawaya et al. 2003). In particular, the virion-associated form of Vpr points to a role 
for the protein in the early stages of HIV-1 entry and infection, perhaps in the later 
stages of the viral life cycle as progeny virions are assembled, and with respect to 
the structural integrity of the final infectious virion, at least with virus produced 
within cells of the monocyte-macrophage lineage (Poon and Chen 2003). Vpr 
associated with virions has been demonstrated to enable the translocation of the 
pre-integration complex (PIC) into the nucleus of cells such as macrophages (Zhao 
and Zhu 2004).  
The combined use of diversity and divergence analysis allowed us to not only 
survey the total amount of variation in Vpr, but to also test the hypothesis that 
variation is different between co-receptor-defined sequence groups at specific 
positions. As such, this methodology allows us to independently assess 
differences at each amino acid position that may be under selection, a result not 
afforded by standard phylogenetic analysis. Due to the presence of high diversity 
at many amino acid positions throughout Vpr (Figure 1), observation of consensus 
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changes may not always be statistically meaningful with respect to Jensen-
Shannon divergence. Alternatively, it is also possible for significantly divergent 
positions to not demonstrate a consensus change in Vpr amino acid usage 
between R5 and X4. This is because a change in the relative presence of variants 
in a polymorphic position, although indicative of a consensus switch, may fall within 
the limits of uncertainty if the magnitude of the change is modest. In order to better 
focus our understanding of amino acid substitutions on potentially functional 
changes, we expanded our analysis to include a series of reduced amino acid 
alphabets. While larger alphabets preserve more information from the original 
amino acid sequence, they can also overemphasize variation among amino acids 
with similar physiochemical properties. Alternatively, although reduced alphabets 
exclude potentially meaningful information contained in the original sequence, they 
maintain differences between physiochemically disparate residues.  
The functional impact of the specific amino acid substitutions identified in this 
study is difficult to infer precisely in the absence of specific mutagenic studies. 
Nevertheless, positions with differential amino acid occupancy in X4 and R5 
sequences were found in regions of Vpr functionally associated with viral 
packaging, G2 arrest, nuclear localization, and alterations in disease severity or 
progression (Re and Luban 1997, Goh, Rogel et al. 1998, Mologni, Citterio et al. 
2006, Guenzel, Herate et al. 2014). Of the specific positions observed in this study, 
positions 36 and 37 are regarded as essential for Vpr oligomerization (Zhao, Wang 
et al. 1994) while position 89 is possibly correlated with clinical manifestations of 
HIV-1 disease (Chen, Zheng et al. 2011). Structurally, both glycine and proline 
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substitutions may play large roles in altering Vpr secondary structure, especially in 
alpha helices. Position 37, which is occupied by a proline in consensus R5 Vpr, 
could potentially lead to the formation of a kink and unwinding of the alpha helix at 
that position. This effect could be further propagated at position 41 by the presence 
of a glycine residue, leading to the loss of the helical conformation of helix-2. The 
C-terminal domain, which includes the divergent position 96, is regarded to play 
an important role in protein stability (Mahalingam, Patel et al. 1995). Furthermore, 
position S96 is often phosphorylated and involved in inducing apoptosis, 
mitochondrial depolarization, nuclear localization, and transduction of cells by Vpr. 
While not a statistically significant change with regards to Jensen-Shannon 
divergence, position 77 showed high diversity in both the R5 and X4 groups, and 
the consensus sequences both indicated a Q versus R polymorphism at this 
position. In clinical studies comparing HIV-1 progressor and non-progressor 
patients, an R77Q variation was correlated with slower disease progression (long-
term non-progression) (Mologni, Citterio et al. 2006). In vitro studies of Vpr 
demonstrated that the R77Q mutation attenuates Vpr in its ability to induce 
apoptosis in T lymphocytes (Lum, Cohen et al. 2003, Mologni, Citterio et al. 2006). 
Notably, while position 77 of Vpr is part of the third α-helix, the region spanning 
positions 74-78 exhibits a less strictly defined α-helix conformation (Schuler, 
Wecker et al. 1999). 
In parallel studies of Vpr, we showed that four amino acids at three positions 
within the primary sequence of Vpr (I37, N41, S41, and A55) were associated with 
significant differences in patient neuropsychological status (Dampier, Antell et al. 
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2017). Amino acids N41 and A55 were linked to significant increases in patient 
neurocognitive deficits, while I37 and S41 were associated with improvements in 
neurocognitive abilities. The demonstration that positions 37 and 41 are 
specifically linked to both co-receptor usage and neuropathogenesis is interesting 
in light of (i) the role of the HIV-1-infected macrophage (infected by an R5 virus) 
as a “Trojan Horse” that carries HIV-1 into the brain (Fischer-Smith and Rappaport 
2005, Kramer-Hammerle, Rothenaigner et al. 2005) and (ii) the importance of co-
receptor usage in HIV-1-associated neuropathogenesis (Gabuzda and Wang 
1999, Gabuzda and Wang 2000, Vazquez-Santiago and Rivera-Amill 2015). 
The demonstration of coordinated evolution between Vpr and genetic 
determinants of viral co-receptor usage sheds new light on the already complex 
and multi-faceted involvement of Vpr in HIV-1 infection and associated disease. In 
HIV-1-infected T lymphocytes and macrophages, co-selection of Vpr with co-
receptor phenotype may contribute to immunopathogenesis associated with 
productive infection, as well as the establishment and maintenance of long-lived 
viral reservoirs even in the face of highly effective antiretroviral therapies. In the 
brain, co-evolution of Vpr with the predominant R5 phenotype of viruses that infect 
the brain may better position Vpr as a contributor to HIV-1-associated 
neuropathogenesis. Finally, these studies, as do our previous studies of Tat and 
LTR co-evolution with gp120, suggest the distinct possibility that other viral 
proteins also evolve in conjunction with viral co-receptor usage as defined viral 
quasispecies gain access to specific cell populations such as cells of the 
monocyte-macrophage lineage including brain microglial cells. 
 151 
3.6 References 
Aiamkitsumrit, B., et al. (2014). "Bioinformatic analysis of HIV-1 entry and 
pathogenesis." Curr HIV Res 12(2): 132-161. 
  
Aiamkitsumrit, B., et al. (2014). "Defining differential genetic signatures in CXCR4- 
and the CCR5-utilizing HIV-1 co-linear sequences." PLoS One 9(9): e107389. 
  
Aimkitsumrit, B. D., W; Martin-Garcia, J; Nonnemacher, M; Pirrone, V. Ivanova, T; 
Zhong, W; Kilareski, E; Aldigun, A; Frantz, B; Rimbey, M; Wojno, A; Passic, S; 
Williams, J; Shah, S; Blakely, B; Parikh, N; Jacobson, J; Moldover, B; Wigdahl, B; 
(2014). "Defining Differential Genetic Signatures in CXCR4- and the CCR5-
Utilizing HIV-1 Co-Linear Sequences." PLoS One. 
  
Antell, G. C., et al. (2016). "Utilization of HIV-1 envelope V3 to identify X4- and R5-
specific Tat and LTR sequence signatures." Retrovirology 13(1): 32. 
  
Arrildt, K. T., et al. (2012). "The HIV-1 env protein: a coat of many colors." Curr 
HIV/AIDS Rep 9(1): 52-63. 
  
Ashkenazy, H., et al. (2010). "ConSurf 2010: calculating evolutionary conservation 
in sequence and structure of proteins and nucleic acids." Nucleic Acids Res 
38(Web Server issue): W529-533. 
  
Chen, X., et al. (2011). "The Vpr gene polymorphism of human immunodeficiency 
virus type 1 in China and its clinical significance." Curr HIV Res 9(5): 295-299. 
  
Cock, P. J., et al. (2009). "Biopython: freely available Python tools for 
computational molecular biology and bioinformatics." Bioinformatics 25(11): 1422-
1423. 
  
Dampier, W., et al. (2017). "Specific amino acids in HIV-1 Vpr are significantly 
associated with differences in patient neurocognitive status." J Neurovirol 23(1): 
113-124. 
 
Dampier, W., et al. (2016). "HIV-1 genetic variation resulting in the development of 
new quasispecies continues to be encountered in the peripheral blood of well-
suppressed patients." PLoS One, In press. 
  
Fischer-Smith, T. and J. Rappaport (2005). "Evolving paradigms in the 
pathogenesis of HIV-1-associated dementia." Expert Rev Mol Med 7(27): 1-26. 
  
Gabuzda, D. and J. Wang (1999). "Chemokine receptors and virus entry in the 
central nervous system." J Neurovirol 5(6): 643-658. 
  
 152 
Gabuzda, D. and J. Wang (2000). "Chemokine receptors and mechanisms of cell 
death in HIV neuropathogenesis." J Neurovirol 6 Suppl 1: S24-32. 
  
Goh, W. C., et al. (1998). "HIV-1 Vpr increases viral expression by manipulation of 
the cell cycle: a mechanism for selection of Vpr in vivo." Nat Med 4(1): 65-71. 
  
Gonzalez-Scarano, F. and J. Martin-Garcia (2005). "The neuropathogenesis of 
AIDS." Nat Rev Immunol 5(1): 69-81. 
  
Guenzel, C. A., et al. (2014). "HIV-1 Vpr-a still "enigmatic multitasker"." Front 
Microbiol 5: 127. 
  
Jensen, M. A., et al. (2003). "Improved coreceptor usage prediction and genotypic 
monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency 
virus type 1 env V3 loop sequences." J Virol 77(24): 13376-13388. 
  
Kramer-Hammerle, S., et al. (2005). "Cells of the central nervous system as targets 
and reservoirs of the human immunodeficiency virus." Virus Res 111(2): 194-213. 
  
Kwong, P. D., et al. (1998). "Structure of an HIV gp120 envelope glycoprotein in 
complex with the CD4 receptor and a neutralizing human antibody." Nature 
393(6686): 648-659. 
  
Levy, D. N., et al. (1995). "Extracellular Vpr protein increases cellular 
permissiveness to human immunodeficiency virus replication and reactivates virus 
from latency." J Virol 69(2): 1243-1252. 
  
Li, L., et al. (2011). "Development of co-selected single nucleotide polymorphisms 
in the viral promoter precedes the onset of human immunodeficiency virus type 1-
associated neurocognitive impairment." J Neurovirol 17(1): 92-109. 
  
Lum, J. J., et al. (2003). "Vpr R77Q is associated with long-term nonprogressive 
HIV infection and impaired induction of apoptosis." J Clin Invest 111(10): 1547-
1554. 
  
Mahalingam, S., et al. (1995). "The carboxy-terminal domain is essential for 
stability and not for virion incorporation of HIV-1 Vpr into virus particles." Virology 
214(2): 647-652. 
  
Mologni, D., et al. (2006). "Vpr and HIV-1 disease progression: R77Q mutation is 
associated with long-term control of HIV-1 infection in different groups of patients." 
AIDS 20(4): 567-574. 
  
Murphy, L. R., et al. (2000). "Simplified amino acid alphabets for protein fold 
recognition and implications for folding." Protein Eng 13(3): 149-152. 
  
 153 
Nonnemacher, M. R., et al. (2016). "HIV-1 promoter single nucleotide 
polymorphisms are associated with clinical disease severity." PLoS One in press. 
  
Parikh, N., et al. (2014). "Cocaine alters cytokine profiles in HIV-1-infected African 
American individuals in the DrexelMed HIV/AIDS genetic analysis cohort." J Acquir 
Immune Defic Syndr 66(3): 256-264. 
  
Poon, B. and I. S. Chen (2003). "Human immunodeficiency virus type 1 (HIV-1) 
Vpr enhances expression from unintegrated HIV-1 DNA." J Virol 77(7): 3962-3972. 
  
Re, F. and J. Luban (1997). "HIV-1 Vpr: G2 cell cycle arrest, macrophages and 
nuclear transport." Prog Cell Cycle Res 3: 21-27. 
  
Schuler, W., et al. (1999). "NMR structure of the (52-96) C-terminal domain of the 
HIV-1 regulatory protein Vpr: molecular insights into its biological functions." J Mol 
Biol 285(5): 2105-2117. 
  
Schwartz, G. W. and U. Hershberg (2013). "Conserved variation: identifying 
patterns of stability and variability in BCR and TCR V genes with different diversity 
and richness metrics." Phys Biol 10(3): 035005. 
  
Shah, S., et al. (2014). "Functional properties of the HIV-1 long terminal repeat 
containing single-nucleotide polymorphisms in Sp site III and CCAAT/enhancer 
binding protein site I." Virol J 11: 92. 
  
Sturdevant, C. B., et al. (2015). "Compartmentalized replication of R5 T cell-tropic 
HIV-1 in the central nervous system early in the course of infection." PLoS Pathog 
11(3): e1004720. 
  
Swanstrom, R. and J. Coffin (2012). "HIV-1 pathogenesis: the virus." Cold Spring 
Harb Perspect Med 2(12): a007443. 
  
Tamura, K., et al. (2011). "MEGA5: molecular evolutionary genetics analysis using 
maximum likelihood, evolutionary distance, and maximum parsimony methods." 
Mol Biol Evol 28(10): 2731-2739. 
  
Tungaturthi, P. K., et al. (2003). "Role of HIV-1 Vpr in AIDS pathogenesis: 
relevance and implications of intravirion, intracellular and free Vpr." Biomed 
Pharmacother 57(1): 20-24. 
  
Vazquez-Santiago, F. J. and V. Rivera-Amill (2015). "Envelope gene evolution and 
HIV-1 neuropathogenesis." J Neuroinfect Dis 6(Suppl 2). 
  
Wang, G. and R. L. Dunbrack, Jr. (2004). "Scoring profile-to-profile sequence 
alignments." Protein Sci 13(6): 1612-1626. 
  
 154 
Wecker, K., et al. (2002). "NMR structure of the HIV-1 regulatory protein Vpr in 
H2O/trifluoroethanol. Comparison with the Vpr N-terminal (1-51) and C-terminal 
(52-96) domains." Eur J Biochem 269(15): 3779-3788. 
  
Wecker, K. and B. P. Roques (1999). "NMR structure of the (1-51) N-terminal 
domain of the HIV-1 regulatory protein Vpr." Eur J Biochem 266(2): 359-369. 
  
Westervelt, P., et al. (1992). "Dual regulation of silent and productive infection in 
monocytes by distinct human immunodeficiency virus type 1 determinants." J Virol 
66(6): 3925-3931. 
  
Yona, G. and M. Levitt (2002). "Within the twilight zone: a sensitive profile-profile 
comparison tool based on information theory." J Mol Biol 315(5): 1257-1275. 
  
Zhao, L. J., et al. (1994). "Biochemical mechanism of HIV-1 Vpr function. 
Oligomerization mediated by the N-terminal domain." J Biol Chem 269(51): 32131-
32137. 
  
Zhao, L. J. and H. Zhu (2004). "Structure and function of HIV-1 auxiliary regulatory 
protein Vpr: novel clues to drug design." Curr Drug Targets Immune Endocr 
Metabol Disord 4(4): 265-275. 
  
 
 
 156 
 
CHAPTER IV 
  
Identification of Subtype B Tat variants that  
associate with HIV cognitive impairment 
 
 
 
Gregory C. Antell, Will Dampier, Vanessa Pirrone, 
Wen Zhong, Katherine Kercher, Shendra Passic, Zsofia Szep, Kim Malone, 
Jeffrey Jacobson, Uri Hershberg, Brian Wigdahl, and Michael R. Nonnemacher 
 								
 
This chapter is in preparation as: 
Antell, G.C., Dampier, W., Pirrione, V., Pirrone, V., Zhong, W., Kercher, K., 
Passic, S., Malone, K., Szep, Z., Jacobson, J., Hershberg, U., Wigdahl, B., and 
Nonnemacher, M.R. Subtype B HIV-1 Tat next generation DNA sequencing 
reveals genetic associations with HIV-1 associated neurocognitive disorder. 
Scientific Reports. 2017. 
 
GA, WD, MN, UH and BW conceived and designed the study. GA and WD 
designed and performed the bioinformatic and statistical analyses. BW, MN, VP, 
KK, WZ, GA, SP, ZS, JJ managed the Drexel Medicine CARES Cohort and/or 
obtained sequences from patient PBMC samples. GA, UH, MN, and BW 
prepared and designed the figures and drafted the manuscript. All authors read 
and approved the final manuscript. 
 
 157 
4.1 Abstract 
Despite the advent of antiretroviral therapy (ART) for the treatment of 
human immunodeficiency type 1 (HIV-1) infection, approximately 50% of 
therapeutically adherent patients continue to present with mild neurological 
deficits, collectively referred to as HIV-associated neurocognitive disorders 
(HAND). As a potentially important component in the development of HAND, 
genetic variation in the HIV-1 accessory protein Tat has been demonstrated to 
result in altered protein structure and function. This study evaluates the 
relationship between HIV-1 Tat amino acid substitutions and HIV-1-associated 
neurocognitive impairment (NI) in the Drexel CNS AIDS Research and 
Eradication Study (CARES) cohort in Philadelphia, PA. NI was assessed using a 
Comprehensive Neuropsychological Assessment (CNPA) to distinguish between 
impaired and non-impaired individuals. PBMC-derived HIV-1 Tat exons 1 and/or 
2 sequenced from amplified integrated proviral DNA were sequenced using 
Illumina-based next generation sequencing (NGS) for 117 patients (66 impaired, 
51 non-impaired). Amino acid diversity was calculated at both the intrapatient 
and interpatient level, indicating a largely homogenous HIV-1 Tat population 
within patients but substantial amino acid variation between patients. The 
performance of machine learning-based screening algorithms based on HIV-1 
genetic features were compared against algorithms using only standard clinical 
features. These algorithms utilized regularized logistic regression, and were 
validated using 5-fold cross validation. An algorithm including both the top clinical 
and genetic features was also developed and achieved a mean area under the 
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ROC curve (AUC) of 0.74 +/- 0.03, outperforming the top baseline models 
incorporating only genetic or clinical features. This performance provides strong 
preliminary support that integration of NGS data of HIV-1 Tat and other genes 
may yield improvements to clinical screening tools, as well as allow the statistical 
inference of genetic variants associated with NI. 
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4.2 Introduction 
Since the widespread adoption of antiretroviral therapy (ART) in the 
United States, the symptomology of HIV-1 disease has been increasingly 
transformed to a chronic disease that involves pathogenesis in the central 
nervous system (CNS) with an increase in prevalence in HIV-associated 
neurocognitive disorder (HAND) overall but a decrease in the most severe form 
of HAND, HIV-1-associated dementia (HAD) (McArthur 2004, Nath, Schiess et al. 
2008, Cysique and Brew 2009, Heaton, Clifford et al. 2010).  HIV-1 neuro-
invasion is hypothesized to occur largely via the transmigration of infected cells 
of the monocyte-macrophage lineage from peripheral circulation, across the 
blood brain barrier (BBB), and into the CNS (Strazza, Pirrone et al. 2011). 
However, additional recent studies have also suggested a role for HIV-1-infected 
T cells (Chahroudi, Silvestri et al. 2015, Fu, Ward et al. 2016). 
The HIV-1 Tat protein is present in the CNS and has been detected in 
patients with HIV-1 encephalitis (HIVE) (Hofman, Dohadwala et al. 1994, Del 
Valle, Croul et al. 2000, Hudson, Liu et al. 2000, Liu, Jones et al. 2000). The 
protein has also been linked to neurological impairment by the observation that 
Tat mRNA is detectable in patients with HIVE but absent in those without 
dementia (Hudson, Liu et al. 2000).  Specifically, Tat has been observed in the 
cytoplasm of microglial cells and perivascular macrophages, which are likely HIV-
1-infected cells.  Importantly Tat is also found in the nuclei of uninfected neurons 
and oligodendrocytes, further demonstrating the ability of Tat to affect and enter 
additional cells of the CNS (Del Valle, Croul et al. 2000, Liu, Jones et al. 2000).  
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Tat has also been shown to be released by infected monocytes, microglial cells, 
and astrocytes in addition to infected lymphocytes (Ensoli, Buonaguro et al. 
1993, Johnston, Zhang et al. 2001, Bruce-Keller, Chauhan et al. 2003, Chauhan, 
Turchan et al. 2003). 
Secreted Tat is biologically active and capable of transcellular activation of 
the HIV-1 LTR in addition to its extensive effects as an extracellular protein 
(Thomas, Dobkin et al. 1994, Rayne, Debaisieux et al. 2010).  Additionally, 
release of Tat by infected cells occurs optimally in low-serum conditions, such as 
the brain environment (Ensoli, Buonaguro et al. 1993).  Tat can be continually 
produced by HIV-1-infected cells located in the CNS despite the widespread use 
of ART, demonstrating that neurologic vulnerability to this protein persists in the 
HAART era (Li, Li et al. 2009). In addition to its role in regulating transcription of 
the HIV-1 provirus, Tat also impacts a variety of cells within the CNS and may 
contribute to neuropathology through multiple mechanisms. 
The HIV-1 genotype is an important variable in viral replication and 
evolves throughout the course of infection due to the inaccuracy of viral 
polymerase and reverse transcriptase, recombination, rates of viral production, 
and cell- or tissue-specific selection pressures.  Both single nucleotide 
polymorphisms (SNPs) and amino acid substitutions can have an immense 
impact on the fitness and biological activity of HIV-1, potentially impacting the 
disease progression of an infected individual. Sequence analysis of Tat has 
demonstrated compartmentalization in brain versus lymphoid tissue (Thomas, 
Dunfee et al. 2007). Brain-derived sequences demonstrate higher 
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nonsynonymous/synonymous and transversion mutation rates in HAND patients 
and display phylogenetic clustering within clinical groups (Bratanich, Liu et al. 
1998). These observations are critical, as brain-derived Tat from HAD patients 
exhibited a decreased ability to transactivate the LTR but still maintained the 
capability of exerting pathogenic effects by inducing proinflammatory cytokine 
genes as a result of Tat genetic variation (Boven, Noorbakhsh et al. 2007).  The 
exact opposite was observed with Tat-derived from non-dementia brain samples, 
where Tat transactivation function was more conserved.  These observations are 
consistent with more recent studies that have shown that despite the overall 
increased heterogeneity of Tat in the brain across all those autopsied, that the 
transactivation function was generally more conserved in Tat relative to the non-
CNS compartment (Cowley, Gray et al. 2011).  Additionally, in studies comparing 
the genetic diversity of Tat between the cerebrospinal fluid and the peripheral 
blood it was determined that not only are there specific residues within Tat that 
can differentiate between CSF- and PB-derived virus, but increased diversity in 
CSF was also associated with neurocognitive impairment (Choi, Hightower et al. 
2012).  Overall, genetic compartmentalization of HIV-1 Tat between CNS and 
lymphoid tissue likely reflects altered requirements for HIV-1 replication in cells of 
the monocyte lineage and brain-specific immune surveillance. 
Functional differences between HIV-1 subtype infection have been 
identified with respect to replication rate, drug resistance, and overall disease 
progression (Li, Dahiya et al. 2012, Dahiya, Irish et al. 2013). These phenotypic 
differences are driven by the unique biological properties of each subtype and 
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encoded by the genetic constitution of each subtype. Consistent with this trend, 
the incidence and manifestation of neurocognitive impairment in HIV-infected 
individuals has also been shown to demonstrate differences between subtypes, 
specifically between subtypes B and C, which are most common in North 
America, and South Africa and India, respectively (Wainberg 2004, Desfosses, 
Solis et al. 2005). The development of neurological impairment in individuals 
infected with subtype B HIV-1 has been well established and remains relevant in 
the antiretroviral treatment (ART) era, although the forms of neurologic 
impairment observed are significantly less severe. In contrast, subtype C 
infection was initially reported to lead to markedly low incidence of HIV-
associated dementia (HAD) (Ranga, Shankarappa et al. 2004). Overall, the 
difference in cognitive impairment was attributed to subtype B HIV-1 being more 
neurovirulent than subtype C. Specifically, the enhanced neurovirulence of 
subtype B HIV-1 is theorized to stem from the Tat C30C31 dicysteine motif, 
which is prominently substituted in Indian subtype C patient-derived Tat samples 
as C30S31. Experimental studies has provided evidence for the reduced 
chemotaxis of monocytes and diminished activation of proinflammatory cytokines 
in monocytes as a result of the C31S substitution (Gandhi, Saiyed et al. 2009). 
Additionally, the C30C31 dicysteine motif has been linked to NMDA receptor 
activation and excitotoxicity, with the C31S substitution yielding reduced NMDA 
receptor activity (Li, Huang et al. 2008). A reduction in neurocognitive impairment 
has also been observed in studies using a mouse model of HIV-1 brain infection 
in which mice were exposed to the C31S Tat variant (Rao, Neogi et al. 2013). 
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More recently, the impact of the C30C31 motif on the development of HAND has 
been questioned, with a study of the impact of the C31S substitution in a South 
African subtype C cohort concluding that there was no significant difference in 
cognitive performance between C31S and C30C31 individuals (Paul, Joska et al. 
2014). 
 While experimental studies have provided strong evidence that a single 
amino acid substitution at C31 in Tat can yield dramatically different biological 
activity, the impact of this substitution in an epidemiological context remains an 
area of debate and further research. Importantly, previous genetic studies have 
exclusively focused on the presence of the C30C31 dicysteine motif of Tat exon 
1 while disregarding the enormous amount of variation that persists in HIV-1 Tat 
at other positions, domains, and exons. Furthermore, despite increasing 
evidence that neurocognitive impairment in HIV-1-infected individuals is similar 
across subtypes, these studies have been focused on comparisons between 
subtypes, or HAND within subtype C exclusively (Paul, Joska et al. 2014). This 
study, the largest of its kind in this area of investigation, leverages targeted 
sequencing of both exons of HIV-1 Tat using next generation sequencing (NGS) 
technology in order to assess the association of all Tat amino acid substitutions 
across a vast majority of quasispecies in a subtype B HIV-1-infected patient 
population with neurocognitive impairment. Within the context of this 
experimental approach, knowledge of how the Tat sequence may play a role in 
HIV-1 cognitive impairment may shed light on why peripheral viral load alone is 
not an accurate marker of HAND risk and could lead to the development of Tat 
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sequence indicators of HAND and provide information useful in prevention and 
treatment of direct and indirect Tat-induced damage of the BBB and cells of the 
CNS. 
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4.3 Methods 
4.3.1 HIV-1-infected patient enrollment and PBMC collection 
Patients in the Drexel CNS AIDS Research and Eradication Study 
(CARES) Cohort were recruited from the Partnership Comprehensive Care 
Practice of the Division of Infectious Disease and HIV Medicine at Drexel 
University College of Medicine (Drexel Medicine), located in Philadelphia, 
Pennsylvania. Patients in the Drexel Medicine CARES Cohort were recruited 
under protocol 1201000748 (Brian Wigdahl, PI), which adheres to the ethical 
standards of the Helsinki Declaration (1964, amended most recently in 2008), 
which was developed by the World Medical Association as described (Li, 
Aiamkitsumrit et al. 2011). All patients provided written consent upon enrollment.  
Following enrollment, patient clinical data is collected and entered onto 
individual Case Report Forms with anonymous identifiers. Clinical information 
collected directly from the patient included age, year of birth, gender, ethnic 
group, race, HIV exposure category, tobacco and alcohol use history, illicit drug 
use history, potential pregnancy, and approximate year of seroconversion and 
mode of transmission. Additional clinical information was gathered directly from 
the patient chart, including initial, nadir, and current CD4+ T-cell counts; initial, 
nadir, and current CD8+ T-cell counts; peak and latest viral loads; disease status; 
current ART status; current ART regimen; past ART treatments; AIDS-defining 
illnesses; admission of illicit drug, alcohol, and tobacco; any notations on mental 
health history including inpatient stays for mental health reasons, any history of 
depression, schizophrenia, and other neurological diseases; and any notations 
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on other complicating conditions related to HIV-1 infection. After the clinical 
information was collected and the neurological status of the patient was 
assessed, blood samples (~50 mL) were drawn from each patient enrolled in the 
study and blood samples were used for drug screening, serum analysis, and 
PBMC isolation as previously described (Li, Aiamkitsumrit et al. 2011).  
 
4.3.2 Comprehensive Neuropsychological Assessment (CNPA) 
A subset of patients recruited into the Drexel Medicine CARES Cohort 
undergo a yearly Comprehensive Neuropsychological Assessment (CNPA). To 
date, 191 HIV-1-infected cohort patients have been evaluated using the CNPA. 
The CNPA includes (i) assessment of global cognition using the Mini-Mental 
State Examination (MMSE) and premorbid general intellectual functions using 
the Wide Range Achievement-4 single word reading test and Wechsler Adult 
Intelligence Scale-IV Information subset; (ii) a self-reported assessment of 
everyday cognitive and functional status; and (iii) assessment of seven primary 
neuropsychological domains using the Spanish and English versions of the 
Neuropsychological Assessment Scales (SENAS) (Mungas, Reed et al. 2000) 
and other tests controlled for key demographic variables. Approximately 85%-
90% of our participants are modestly educated African-Americans. The 
neuropsychological literature clearly underscores the need to use 
educational/cultural norms in order to obtain an accurate assessment of putative 
NPI (Antinori, Arendt et al. 2007). Although SENAS norms were obtained from 
participants in a single region of the country, the psychometric benefits of the 
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SENAS outweigh the putative influence of geographic region on test scores. For 
these reasons, the SENAS and other neuropsychological parameters under 
consideration were selected because their outcome measures are controlled for 
key demographic variables, including age, education, race, and gender. Another 
advantage of SENAS is that these tests were constructed using item response 
techniques to match test scores on important demographic factors, such as age, 
race, and education, to produce demographically-adjusted standard scores. 
Secondarily, patient NPI is assessed every visit using a modified version of the 
Hopkins Dementia (MHD) Test (Power, Selnes et al. 1995, Li, Aiamkitsumrit et al. 
2011). 
 
4.3.3 Next generation DNA sequencing  
Illumina deep sequencing of PBMC-derived DNA was performed by using 
a PCR amplification technique in which the tat exon1 and tat exon 2 regions are 
flanked by primers that produce a ~1 Kb segment (Henn, Boutwell et al. 2012). 
Primer sites were selected such that they exactly matched >95% of the subtype 
B sequences in the Los Alamos National Library (LANL) HIV database. HIV-1 tat 
was amplified from patient-derived genomic DNA samples by performing a PCR 
for each exon of tat independently. This reaction contained Phusion High-Fidelity 
Polymerase (0.5 U), HF buffer, MgCl2 (1.5 mM), dNTPs (350 µM), and forward 
and reverse primers, with 100 ng of genomic DNA in a total volume of 25 μl. For 
exon 1, primers Frag-37-L (AAAGCCACCTTTGCCTAGTG) and Frag-37-R 
(ACACATGGCTTTAGGCTTTG) were used. For exon 2, primers Frag-26-L 
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(CCATACATTATTGTGCCCCG) and Frag-26-R (AGGTATCTTTCCACAGCCAG) 
were used. The reaction was performed at 95°C for 2 minutes, and then 40 
cycles of 94°C for 30 seconds, 58°C for 30 seconds, and 72°C for 1 minute 
followed by a 10 minute extension at 72°C. Samples were then purified using the 
QIAquick PCR Purification procedure (Qiagen, catalog number 28104) as 
described by the manufacturer and eluted in water. Post PCR-amplification, the 
Nextera XT DNA Library Preparation Guide (Illumina, catalog number FC-131-
1096) was followed, as described by the manufacturer, except where specified. 
Amount of input DNA was changed from 0.2ng/uL to 0.4ng/uL. Tagmentation 
reaction was shortened from 5 minutes at 55°C to 4 minutes and 30 seconds to 
avoid over-fragmenting the shorter PCR fragments. PCR clean-up was 
completed using 90uL per sample of AxyPrep™ Mag PCR Clean-Up procedure 
(Axygen®, catalog number MAG-PCR-CL-5). Libraries were normalized using the 
Quant-iT™ dsDNA Assay Procedure, High Sensitivity (Invitrogen, catalog 
number Q33120), and validated on an Agilent Technology 2100 Bioanalyzer 
using the Agilent High Sensitivity DNA Procedure (Agilent Technologies, catalog 
number 5067-4626).  Based on the average size of 500bp, libraries were 
clustered using the equation 1ng/ul = 3nM. Samples were pooled together to 
reach a final concentration of 1nM, and sequenced using the NextSeq® 500/550 
Mid Output Reagent Cartridge v2 300 cycles (Illumina, catalog number FC-404-
2003) on the Illumina NextSeq 500 Desktop Sequencer. 
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4.3.4 Illumina sequencing analysis 
NGS Tat sequences were processed first by using Trimmomatic (Bolger, 
Lohse et al. 2014) to remove poor quality ends and trim off primer sequences 
using default settings. Cleaned paired-end reads were then aligned to the HXB2 
HIV-1 genome using the bwa mem tool (Li and Durbin 2009) and duplicate reads 
from the same lane were removed using the samblaster tool (Faust and Hall 
2014). Pysam (Li, Handsaker et al. 2009) was used to extract each read with a 
mapping quality greater than a PHRED score of 60 and Biopython (Cock, Antao 
et al. 2009) was used to translate the read in the proper open reading frame and 
extract the amino acid at each position along the read for downstream statistical 
analysis. Final sequences have been submitted to the short read archive and all 
samples were linked under a single Bioproject ID. 
 
4.3.5 Diversity and Enrichment Analysis 
For each NGS sample, each amino acid position of Tat was independently 
analyzed. The amino acid diversity was then calculated for each position 
according to the following equation: 
D",$ = exp − p*+, ln	 p*+,0+,*12  
The resulting intrapatient diversity value was rounded to the nearest 
integer and all but the most common variants were removed from the population, 
yielding only the predominant amino acid variants for each sample. The 
intrapatient diversity was compared between impaired and non-impaired samples 
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at corresponding positions using Welch’s t-test. The resulting top amino acids at 
each position were used to calculate the interpatient diversity, D, for both the 
total sample population as well as each of the impairment-defined groups. The 
top amino acids were evaluated in order to identify variants exclusive to either 
impaired or non-impaired samples. The prevalence of each amino acid variant 
was defined as the proportion of samples that contain the particular variant 
following diversity filtering. Both the difference in prevalence and the ratio in 
prevalence between the impaired and non-impaired groups was calculated for 
each of the top amino acids at each position. A Monte Carlo permutation test of 
10,000 iterations was applied to scramble the top amino acids among the two 
groups and compare to the observed prevalence, yielding a Z-score indicative of 
variant enrichment within the impaired or non-impaired group. 
 
4.3.6 Next generation sequencing data analysis 
NGS data for HIV-1 Tat was compiled into a feature matrix containing the 
relative abundance data of all potential variants for all samples. The initial feature 
matrix consisted of 2020 features (101 positions x 20 amino acids). HIV-1 Tat 
consists of two exons, and features from both exons were included for each 
sample. However, in cases where only 1 of 2 exons were sampled, the median 
abundance value of the data set was used to impute values for features 
representing missing genetic variation data. Overall, 23 samples were missing 
genetic information for exon 1, while 16 samples were missing genetic 
information for exon 2. Additionally, empty features and features with zero 
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variance were removed. In order to develop a generalizable model, rare variants 
were excluded from the final analysis and was assessed by requiring each 
genetic variant to have at least 10% abundance in 10% of the total samples. This 
reduced the total genetic feature space from 2020 to 148, and also greatly 
reduced the sparsity of the data set. The final features were represented by their 
normalized abundance value.  
 
4.3.7 Feature selection methodologies 
Recursive feature elimination (RFE) was utilized to select for the optimal 
combination of clinical features, with regularization strength evaluated as a 
hyper-parameter. In order to determine feature importance and reduce the 
dimensionality of the potential genetic features considered in a final model, a 
randomized lasso approach was applied. In response to highly correlated 
features, lasso methods typically select one of the features while ignoring the 
others. With regards to ranking features by importance, this can ultimately result 
in missing important features. In the stability selection method, a subsample of 
the data is fit to a L1-penalized model where the penalty of a random subset of 
coefficients has been scaled according to the following equation: 
𝑤4 = argmin 12𝑛4 (𝑦? − 𝑥?A𝜔	)D?	∈4 + 𝛼 |𝜔I|𝑠I
K
I12  
The assumption of such a model is that the underlying truth should be 
sparse, which fits the current data well. In this study, many potential genetic 
variants are either absent, entirely conserved, or demonstrate very little variance 
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between samples. The end result allows features to be ranked according to how 
often they are selected across 100 iterations. Feature importance can also be 
plotted as a function of the regularization parameter. These methodologies were 
implemented with scikit-learn version 0.17.  
 
4.3.8 Logistic regression model training and validation 
Logistic regression was performed for sets of both clinical and genetic 
features, as well as for a model incorporating both genetic and clinical data. 
Model performance was evaluated using the mean area under the receiver 
operating characteristic (ROC) curve (AUC) for 5-fold cross validation. The mean 
AUC was calculated 100 times, with each calculation performed on a randomized 
subset of the total data set. However, a balanced split was maintained for each 
iteration to maintain a consistent ratio of impaired and impaired samples. L2-
regularization was applied in the training and cross-validation of the logistic 
regression model.  
 
4.4 Results 
The Drexel Medicine CARES cohort has continually enrolled patients 
since late 2006, with patients scheduled to return for additional visits at six-month 
intervals. The focus of the current study were patients that have had a 
Comprehensive Neuropsychological Assessment (CPNA). In general, patients in 
the CARES Cohort are adherent to therapy and their disease status is well-
suppressed by ART with respect to current CD4+ T-cell counts and viral loads, 
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as previously reported (Dampier, Nonnemacher et al. 2016, Nonnemacher, 
Pirrone et al. 2016). In order to assess the impact of Tat amino acid substitutions 
on neurocognitive impairment with greater granularity than previously utilized 
Sanger technology, next generation sequencing (NGS) was performed on a 
subset of patient samples from the Drexel Medicine CARES Cohort (Table 4.1). 
This set of patients was 98% adherent to therapy at the time of the visit sampled 
in this study. Additionally, 86 out of 118 (72.9%) demonstrated a CD4+ T-cell 
count >500 cells/mL, and 98 out of 118 (83.1%) had a viral load <100 copies/ml. 
Despite overall healthy indicators of HIV disease control, 66 out of 118 patients 
(55.9%) were assessed to be neurocognitively impaired according to GDS score 
(Figure 4.1). Of note, the current study used a GDS threshold of 0.5 to classify 
samples as either impaired or non-impaired, in agreement with the original 
screening methodology (Blackstone, Moore et al. 2012).  Consistent with 
previous studies of ART-suppressed patients, patients ranged from normal to 
mild impairment (0 to 2.5 GDS).  
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Table 4.1. Demographic and clinical data of NGS samples from the Drexel 
Medicine CARES Cohort.  ART= antiretroviral therapy; VL = viral load; GDS 
= global deficit score 
Patient	 Visit	 Age	 Gender	 ART	 CD4	 VL	 GDS	
A0001	 R09	 59	 Male	 on	 797	 20	 0.58	
A0004	 R10	 65	 Male	 on	 749	 30	 0.27	
A0008	 R07	 58	 Male	 on	 723	 20	 0.50	
A0010	 R08	 59	 Male	 on	 1167	 20	 1.42	
A0012	 R02	 63	 Male	 on	 881	 34	 0.58	
A0013	 R09	 68	 Male	 on	 771	 20	 0.00	
A0015	 R10	 54	 Male	 on	 561	 20	 1.33	
A0017	 R09	 37	 Female	 on	 356	 22	 2.00	
A0017	 R10	 38	 Female	 on	 906	 26	 2.25	
A0018	 R02	 48	 Male	 on	 653	 11310	 0.91	
A0019	 R12	 46	 Female	 on	 1130	 20	 0.25	
A0025	 R08	 57	 Male	 on	 347	 20	 0.92	
A0026	 R09	 55	 Male	 on	 137	 67859	 0.58	
A0032	 R05	 39	 Female	 on	 1229	 20	 1.58	
A0034	 R04	 48	 Female	 on	 599	 310	 0.67	
A0037	 R10	 48	 Female	 on	 1418	 20	 1.00	
A0038	 R06	 45	 Female	 on	 1385	 20	 1.67	
A0044	 R10	 50	 Male	 on	 800	 20	 1.78	
A0045	 R03	 51	 Female	 on	 560	 20	 0.17	
A0046	 R10	 63	 Male	 on	 122	 20	 0.08	
A0052	 R05	 50	 Female	 on	 684	 20	 0.08	
A0056	 R06	 51	 Male	 on	 882	 20	 0.83	
A0059	 R08	 47	 Male	 on	 350	 426	 0.25	
A0075	 R07	 49	 Female	 on	 1486	 20	 0.17	
A0078	 R04	 66	 Female	 on	 795	 21	 1.58	
A0080	 R09	 49	 Female	 on	 929	 62	 1.17	
A0082	 R06	 48	 Male	 on	 606	 20	 0.58	
A0083	 R06	 54	 Male	 on	 719	 200	 1.17	
A0086	 R04	 57	 Male	 on	 417	 20	 0.25	
A0091	 R04	 35	 Male	 on	 776	 20	 1.10	
A0095	 R09	 56	 Male	 on	 787	 20	 0.08	
A0097	 R03	 51	 Male	 on	 626	 20	 2.17	
A0100	 R08	 40	 Female	 on	 1185	 20	 1.58	
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A0101	 R02	 61	 Male	 on	 674	 20	 0.42	
A0103	 R06	 49	 Male	 on	 602	 20	 0.00	
A0109	 R11	 46	 Female	 on	 606	 20	 0.00	
A0111	 R05	 63	 Male	 on	 941	 20	 1.17	
A0117	 R09	 45	 Female	 on	 399	 77100	 0.25	
A0119	 R02	 54	 Male	 non-
adherent	
302	 4650	 0.00	
A0120	 R08	 52	 Female	 on	 823	 20	 0.29	
A0127	 R06	 62	 Male	 on	 416	 35	 1.08	
A0132	 R09	 60	 Female	 on	 1336	 30	 0.92	
A0139	 R10	 56	 Male	 on	 933	 20	 1.50	
A0143	 R03	 58	 Male	 on	 418	 20	 0.17	
A0145	 R08	 57	 Male	 on	 874	 80	 0.42	
A0146	 R07	 47	 Female	 on	 639	 20	 1.30	
A0147	 R04	 57	 Male	 on	 94	 89420	 1.83	
A0148	 R04	 56	 Female	 on	 865	 20	 1.00	
A0151	 R03	 56	 Male	 on	 695	 20	 0.00	
A0156	 R06	 51	 Male	 on	 724	 20	 1.17	
A0164	 R07	 56	 Male	 on	 696	 20	 0.00	
A0165	 R05	 62	 Male	 on	 733	 20	 0.17	
A0171	 R05	 54	 Male	 on	 626	 20	 2.08	
A0178	 R03	 50	 Male	 on	 837	 20	 2.27	
A0184	 R06	 54	 Female	 on	 1284	 20	 2.42	
A0185	 R02	 43	 Male	 on	 494	 20	 1.33	
A0195	 R01	 50	 Male	 on	 694	 20	 1.17	
A0208	 R05	 42	 Male	 on	 638	 20	 1.17	
A0209	 R07	 50	 Male	 on	 788	 20	 0.08	
A0218	 R04	 44	 Male	 on	 318	 54	 1.92	
A0220	 R02	 39	 Male	 on	 718	 20	 0.17	
A0227	 R04	 38	 Male	 on	 129	 54988	 0.17	
A0237	 R03	 52	 Male	 on	 13	 20	 1.75	
A0239	 R05	 40	 Female	 on	 459	 119	 0.25	
A0241	 R03	 64	 Male	 on	 511	 73	 0.75	
A0247	 R08	 48	 Female	 on	 615	 20	 1.08	
A0249	 R02	 49	 Male	 on	 257	 1760	 1.42	
A0254	 R03	 43	 Male	 on	 469	 20	 0.50	
A0256	 R05	 47	 Male	 on	 474	 180	 0.33	
A0257	 R05	 53	 Female	 on	 593	 239	 0.17	
A0258	 R04	 50	 Male	 on	 744	 20	 1.67	
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A0259	 R06	 58	 Male	 on	 371	 20	 0.25	
A0263	 R03	 48	 Male	 on	 415	 20	 0.25	
A0268	 R02	 33	 Female	 on	 1201	 40	 0.25	
A0274	 R06	 48	 Female	 on	 1039	 20	 0.58	
A0278	 R05	 56	 Female	 on	 625	 20	 1.36	
A0284	 R09	 65	 Female	 on	 592	 100	 0.42	
A0285	 R04	 51	 Male	 on	 552	 20	 0.27	
A0285	 R05	 52	 Male	 on	 637	 20	 0.33	
A0303	 R02	 53	 Male	 on	 653	 20	 1.75	
A0309	 R02	 51	 Female	 on	 505	 162	 0.17	
A0310	 R04	 56	 Male	 on	 125	 31	 0.17	
A0312	 R04	 37	 Male	 on	 513	 20	 0.33	
A0323	 R08	 51	 Female	 on	 522	 120	 1.67	
A0325	 R03	 51	 Male	 on	 437	 50	 0.00	
A0333	 R06	 51	 Female	 on	 653	 20	 0.42	
A0335	 R03	 53	 Female	 on	 3269	 20	 2.50	
A0338	 R01	 37	 Transgender	 on	 591	 20	 0.25	
A0342	 R03	 56	 Male	 on	 931	 20	 1.33	
A0343	 R05	 72	 Male	 on	 803	 20	 0.36	
A0349	 R04	 57	 Female	 on	 138	 1380	 0.08	
A0357	 R04	 54	 Male	 on	 589	 20	 1.67	
A0359	 R07	 49	 Female	 on	 777	 67	 1.00	
A0364	 R03	 51	 Female	 on	 471	 30	 0.50	
A0367	 R07	 50	 Male	 on	 645	 20	 0.25	
A0378	 R05	 60	 Male	 on	 540	 20	 0.08	
A0379	 R06	 55	 Female	 on	 302	 18292	 0.08	
A0380	 R05	 47	 Male	 on	 379	 20	 0.08	
A0383	 R06	 48	 Male	 on	 914	 26	 0.08	
A0384	 R05	 52	 Female	 on	 1304	 50	 1.50	
A0388	 R04	 62	 Female	 on	 921	 20	 1.00	
A0389	 R07	 51	 Male	 on	 653	 20	 0.00	
A0411	 R01	 40	 Male	 on	 242	 57271	 0.58	
A0413	 R07	 33	 Female	 on	 1008	 20	 0.89	
A0415	 R04	 44	 Male	 on	 528	 20	 1.33	
A0417	 R03	 47	 Male	 on	 409	 20	 1.25	
A0421	 R04	 63	 Male	 on	 532	 20	 0.00	
A0429	 R04	 64	 Male	 on	 860	 20	 0.67	
A0433	 R04	 51	 Female	 on	 157	 60	 2.33	
A0448	 R04	 56	 Female	 non- 40	 568860	 0.00	
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adherent	
A0451	 R03	 41	 Male	 on	 616	 40	 1.33	
A0465	 R03	 46	 Female	 on	 687	 20	 0.25	
A0467	 R01	 41	 Female	 on	 1277	 20	 0.83	
A0470	 R02	 44	 Female	 on	 602	 23	 0.25	
A0490	 R02	 47	 Male	 on	 1129	 20	 1.25	
A0500	 R03	 47	 Female	 on	 734	 20	 0.50	
A0501	 R02	 60	 Male	 on	 262	 30	 0.50	
A0505	 R02	 57	 Male	 on	 644	 40	 0.17	
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Figure 4.1. Global Deficit Scores distinguishes patients as being impaired 
or non-impaired. Patients (117 in number) were evaluated with a 
Comprehensive Neuropsychological Assessment (CPNA). This exam tests 7 
major domains of cognition that can be summarized into a Global Deficit Score 
(GDS) ranging from 0.0 to 4.0. A threshold of 0.5 is used to classify patients as 
being impaired (GDS > 0.5) or non-impaired (GDS ≤ 0.5) at the time of 
evaluation.  
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Figure 4.1 
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4.4.1 Patients in the Drexel CARES Cohort tend to have suppressed viral 
loads and CD4+ T-cell counts within the healthy range. 
Both clinical and demographic as well as genetic features were evaluated 
for their ability to accurately screen for cognitive impairment in HIV-1-infected 
patients without the application of neuropsychiatric evaluation. In order to have 
widespread application, only the most common clinical/demographic attributes 
were utilized: age, gender, current and peak viral load, current and nadir CD4+ T-
cell count, and current and nadir CD8+ T-cell count. The distribution of these 
values for the Drexel Medicine CARES Cohort samples used in this study was 
visualized using a box plot, and identified only current CD4+ T-cell count to be 
statistically significant (P < 0.05) between impaired and non-impaired samples 
(Figure 4.2). Furthermore, pairwise Pearson correlation between clinical and 
demographic features was assessed in order to select feature combinations that 
were not strongly correlated.  Consistent with previous studies, strong positive 
correlations existed between different time points of the same parameter, for 
example viral load and peak viral load, CD4 count and nadir CD4 count, and CD8 
count and nadir CD8 count. Also consistent with previous studies of HIV-1 
disease progression, strong negative correlations exist between measurements 
of viral load and CD4 count (Figure 4.3) (Mellors, Munoz et al. 1997). 
4.4.2 Inclusion of clinical and demographic features with neurological 
screening score improves prediction of cognitive status. 
 Standard HIV-1 clinical features were considered in modeling 
neurocognitive impairment status. In addition to these features, a Modified 
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Hopkins Dementia Score (MHDS) was also included as a baseline for 
comparison. Because MHDS is also a direct measurement of cognitive ability 
that was used as a screening diagnosis, it was anticipated to agree with GDS-
defined impairment at a high rate and regarded as a benchmark for model 
performance. Similarly, the combination of CD4+ T-cell count and log10(viral 
load) were also used to benchmark model performance, given their common 
application in assessing HIV disease severity.  
 Recursive Feature Elimination (RFE) was utilized to select the optimal 
feature set from the total set of features considered. This methodology was 
repeatedly applied using a bootstrapping approach in which 100 out of 117 
samples were randomly selected and the RFE approach was recursively applied 
(Figure 4.4). The model performance and optimal number of features was plotted 
as a function of regularization strength. Similarly, the relative importance of each 
feature was plotted as a function of regularization strength, with four features 
(Age, Years seropostive, CD4+ T-cell count, and MHDS) being selected as the 
optimal feature set to be compared to benchmark models.  
The Receiver Operating Characteristic (ROC) curves for all 3 models was 
plotted as the mean 5-fold cross validation score across 100 randomized subsets 
of the data for different regularization values (Figure 4.5). The three models 
compared in this study were two benchmark models, based solely off the 
Hopkins Dementia Score and current CD4+ T-cell count and viral load, 
respectively, and the RFE-selected model. Our results indicated that the RFE 
model (F1) outperforms the two benchmark models (F2 and F3), and exhibits 
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and AUC of 0.70 +/- 0.03 (Figure 4.5). The coefficients for each model were also 
plotted, to determine their association with neurocognitive status (Figure 4.6). 
  
 183 
Figure 4.2. Commonly used clinical parameters for HIV disease 
management demonstrate similar means and ranges in both impaired and 
non-impaired subjects. The 117 HIV-1-infected patients used in this study were 
classified as either impaired (GDS > 0.5) or non-impaired (GDS ≤ 0.5). CD4+ and 
CD8+ T-cell counts, as well as viral load, at the time of the neuropsychiatric 
assessment were compared. Additionally, nadir CD4+ and CD8+ T-cell counts 
and peak viral loads, based on collected patient history, were compared. Non-
parametric statistical testing only found current CD4 count to be statistically 
different between impaired and non-impaired samples (P < 0.05 marked with an 
asterisk*).  
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Figure 4.3 Identification of correlations between standard clinical 
features. In order to avoid choosing highly correlated features when building 
logistic regression models, the correlation between pairs of clinical features was 
evaluated. Strong positive correlations existed between different time points of 
the same parameter (viral load and peak viral load, CD4 T-cell count and nadir 
CD4 T-cell count, and CD8 T-cell count and nadir CD8 T-cell count). Additionally, 
strong negative correlations exist between measurements of viral load and CD4 
T-cell count, which is consistent with the presentation of HIV-1 disease 
progression. 
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Figure 4.3 
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Figure 4.4. Assessment of model performance and feature importance 
using recursive feature elimination (RFE). Recursive Feature Elimination 
(RFE) was used to select the optimal number of features in a logistic regression 
model of neurocognitive impairment status. RFE was applied on a random 
selection of 100 of the 117 samples for 100 iterations, and the mean and 
standard deviation of the optimal number of features, as well as the performance 
as determined by mean cross-validated AUC, across different regularization 
values were plotted (A). Similarly, the importance of each feature was also 
plotted across different regularization values, with importance determined as the 
number of iterations (max 100) that a given feature was selected as part of the 
optimal set of features (B). 
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Figure 4.4 
A. 
 
B. 
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Figure 4.5 ROC analysis of clinical feature-based logistic regression 
models. Model performance using clinical features was assessed using the 
mean 5-fold cross validation score across 100 randomized subsets of the data. 
Two benchmark models (current viral load and CD4+ T-cell count and Modified 
Hopkins Dementia Test score) were compared against a model selected using 
recursive feature elimination (Age, Years seropostive, CD4+ T-cell count, and 
MHDS). The model selected using RFE (blue) outperformed the benchmark 
models (0.70 +/- 0.03 AUC versus 0.61 +/- 0.03 and 0.64 +/- 0.02). 
  
 190 
Figure 4.5 
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Figure 4.6. Mean coefficients of each parameter in the 5-fold cross-
validated logistic regression clinical models. The coefficient of clinical 
parameters in each model are represented as either red (associated with 
impairment) or blue (association with non-impairment). While each model 
consisted of a different subset of features (F1 = Recursive Feature Selection; 
Age, Years seropositive, CD4+ T-cell count, and MHDS, F2 = current viral load 
and CD4+ T-cell count, F3 = Hopkins Dementia Test), the direction of association 
was consistent between models. Overall, log10(viral load) appears to predict 
neurocognitive status poorly while Modified Hopkins Dementia Score (MHDS) 
and CD4+ T-cell count are much stronger predictors. 
  
 192 
Figure 4.6 
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4.4.3 Next Generation Sequencing of integrated proviral HIV-1 Tat reveals 
measurements of interpatient diversity exceed intrapatient diversity 
Following alignment to the HIV HXB2 reference genome, non-HIV reads 
were removed and correctly mapped reads were translated in the appropriate 
open reading frame of tat for exons 1 and 2. Read coverage was calculated 
independently for each position of Tat for each sample. Samples that did not 
have at least 100X coverage for 80% of the amino acid positions were removed 
from the analysis. The mean and standard deviation of amino acid coverage was 
plotted across all positions of Tat (Figure 4.7). In general, exon 2 of Tat had 
greater coverage than exon 1 of Tat. Additionally, there was a notable decrease 
in coverage at the splice site at positon 72 that did not impact coverage of 
neighboring positions.  
The intrapatient amino acid diversity was calculated independently for 
each position of each sample (Figure 4.8). While minor amino acid substitutions 
are found at very low levels in next generation sequencing data, calculating the 
diversity at each position allows major variants to be distinguished from minor 
variants. The most striking result of this assessment of intrapatient diversity was 
the homogeneity of Tat amino acid variation within a sample at a given position. 
Overall, amino acid diversity tended to be very low for all positions of Tat in both 
the impaired and non-impaired groups. Interpatient diversity was also calculated 
for both impairment groups, as well as the total population, using the distribution 
of variants that survived intrapatient diversity filtering. In general, the interpatient 
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amino acid values were much larger than intrapatient diversity values, regardless 
of the population being evaluated (Figure 4.9).  
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Figure 4.7. Next generation sequencing coverage of HIV-1 Tat exons 1 and 
2. Following read alignment and translation in the appropriate open reading 
frame (ORF), the number of reads that mapped to each position of Tat was 
calculated, with the mean (red) and standard deviation (pink) of the coverage 
plotted. The precise coverage for each individual sample is plotted in gray. 
Overall, the second exon of Tat had greater coverage than exon 1, with a notable 
dip in coverage occurring at position 72, the last amino acid position in exon 1. 
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Figure 4.7 
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Figure 4.8. Comparison of intrapatient amino acid diversity between 
impaired and non-impaired HIV-1 Tat samples. The amino acid diversity at 
each position of Tat was calculated for both impaired and non-impaired samples. 
The mean diversity values for each group, as well as their standard deviations, 
were plotted in red and blue, respectively. Overall, intrapatient diversity was low 
throughout Tat, indicating homogeneity of Tat at the amino acid level within 
patients of the Drexel Medicine CARES Cohort. 
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Figure 4.8 
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Figure 4.9. HIV-1 Tat interpatient diversity is greater than intrapatient 
diversity, which tends to be homogenous within a patient.  First-order 
interpatient amino acid diversity was calculated for each position in HIV-1 Tat for 
both the impaired (blue) and non-impaired (red) populations, as well as for the 
combined groups (gray). Each position was filtered according to its intrapatient 
diversity, d, with the top-d amino acids recorded for each sample and used to 
calculated the interpatient diversity. This result indicates that interpatient variant 
is in general much greater that intrapatient diversity, with many positions 
exceeding a diversity value of 3. The total interpatient diversity values tend to be 
of equivalent magnitude to the impaired and non-impaired groups, indicating that 
the same set of amino acids are generally present in both groups. 
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4.4.4 Utilization of lasso regression allows for the selection of Tat genetic 
variants that improve overall model performance when included as 
features. 
Due to the extremely high number of potential genetic features (2020) 
relative to the number of samples in this study (117), feature selection was 
applied to avoid overfitting and determine the top variants most closely 
associated with neurocognitive impairment. Genetic features that did not have a 
minimum of 10% presence in at least 10% of the total samples were first filtered 
from the dataset, reducing the total number of genetic features from 2020 to 148. 
A randomized lasso approach was used to rank features that were ultimately 
selected for inclusion in the final model (Figure 4.10). Ranking was performed by 
summing the percentage of times a model was selected across regularization 
values ranging from 0.001 to 0.05. Starting with the top ranked feature, 59P, 
features were added to the model and the overall performance was assessed on 
the basis of AUC. Model performance exhibited a maximum AUC value at 7 
features, which were included in the final model (Figure 4.11). Additionally, a 
model using only the top two features (59P and 36V) was evaluated, as these 
two features exhibited much higher importance than all others on the basis of the 
randomized lasso selection approach (Figure 4.12). In this study, variants 36V, 
40T, 63E, and 23Twere negatively associated with neurocognitive impairment, 
while 59P, 74H, and 12K demonstrated a positive correlation (Figure 4.12). The 
top clinical and genetic features were finally joined in a combined model, which 
had an overall performance, as defined by AUC, of 0.74 +/- 0.3, outperforming 
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the best models using only clinical information or only genetic information (Figure 
4.13). 
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Figure 4.10. Stability selection ranks HIV-1 genetic features based on L1-
regularization performance. L1-regularization (lasso regularization) was 
applied to determine feature importance for logistic regression models using only 
genetic variant features. Iterations (100) were performed, in which a random 
subset of 85% of the total features was selected before model training. The 
regularization parameter was altered from 0.001 to 0.05, and the percentage of 
times each feature was selected as a function of the regularization parameter 
was plotted. The top performing features (59P, 36V, 40T, 74H, 63E, 12K, 23T, 
74L, 53R, and 71K) were determined by summing the percent selected value 
across all of the regularization parameters considered. 
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Figure 4.11. Iterative Feature Selection was used to determine the optimal 
number of features to use in the final genetic model. Beginning with the top 
performing feature, 59P, one additional feature was iteratively added and the 
cross-validated model performance was evaluated using AUC. In order to 
maintain at least a 10:1 ratio of samples to features, only the top 10-ranked 
features were considered. Overall, 7 features (AUC = 0.68) were identified as 
exhibiting the top performance from the combinations considered.  
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Figure 4.11 
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Figure 4.12. ROC analysis of genetic feature-based logistic regression 
models. Model performance was assessed using the mean AUC across 5-fold 
cross validation. Receiver Operating Characteristic (ROC) curves were 
generated for two genetic models identified through lasso feature selection (F7 = 
59P, 36V, 40T, 74H, 63E, 12K, 23T, and F2 = 59P and 36V). In general, genetic-
based models performed slightly worse than models using clinical and 
demographic features. Variants 36V, 40T, 63E, and 23T were negatively 
associated with neurocognitive impairment, while 59P, 74H, and 12K 
demonstrated a positive correlation. 
  
 208 
Figure 4.12 
A. 
 
B. 
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Figure 4.13. ROC analysis of top clinical, genetic, and combined logistic 
regression models. Model performance was compared between the top 
performing clinical-only, genetic-only, and combined-feature logistic regression 
models. Receiver Operating Characteristic (ROC) curves were generated and 
performance was assessed using the mean AUC across 5-fold cross validation. 
While the clinical-only model (AUC = 0.70 +/- 0.03) slightly outperformed the top 
performing genetic-only model (AUC = 0.66 +/- 0.04), the combination of genetic 
and clinical features into a combined model achieved an overall improvement in 
performance (AUC = 0.74 +/- 0.03). 
  
 210 
Figure 4.13. 
A. 
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4.5 Discussion 
A substantial number of HIV-1 Tat amino acid substitutions exist between 
and within individuals enrolled in the Drexel Medicine CARES cohort, as 
demonstrated by diversity analysis. Of note, analysis of NGS data indicates the 
amino acid diversity within a single patient tends to be very homogenous across 
the entirety of the Tat protein. However, diversity between individuals shows the 
presence of high diversity at certain positions, with approximately half of Tat (52 
positions out of 101), having an interpatient diversity of 1.5 or greater. This high 
level of interpatient diversity provides the potential for the Tat protein to have a 
variety of physiological effects and clinical manifestations, including the degree of 
neurocognitive impairment.  
The central aim of this analysis was the identification of amino acid 
residues in HIV-1 Tat that associate with neurocognitive impairment status within 
a patient cohort, as well as the development of a proof-of-concept algorithm for 
neurocognitive impairment screening. Currently, a comprehensive 
neuropsychological assessment requires nearly a full day of testing and exams, 
as well as a trained neuropsychologist. However, standard clinical information 
such as CD4+ T-cell count is routinely collected by the healthcare system in the 
management of HIV disease. Previous studies have shown that the risk for 
impairment can be screened with adequate sensitivity (78%) and specificity 
(70%), for use as an adjunct clinical tool (Cysique, Murray et al. 2010). With the 
explosion of next-generation sequencing technologies likely to play a routine role 
in future patient care paradigms, the integration of this abundant and complex 
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viral information may allow such algorithms to be improved even further. 
Additionally, this study can infer the main genetic variants that drive the detection 
of impairment, and inform new hypotheses about the development of HAND. 
The genetic variants that have been identified in this analysis are located 
in both exons and multiple domains of Tat. However, four of these variants are 
found within the cysteine-rich domain of Tat, which has been repeatedly 
implicated in Tat-mediated neurocognitive impairment within subtype C, 
particularly positions 30 and 31. It is worth noting that no cysteine variants were 
identified in this analysis, despite three variants (23T, 36V, and 40T) falling in 
close proximity. The majority of research regarding associations of HIV-1 
subtypes and neurocognitive impairment has focused on substitutions within the 
cysteine-rich domain, specifically the di-cysteine motif at C30C31. Within the 
Drexel Medicine CARES Cohort, both positions C30 and C31 are highly 
conserved, as is expected within an exclusively subtype B cohort. Accordingly, 
model performance based on these two residues is extremely poor. However, 
previous research has indicated the potential for non-cysteine residues within the 
cysteine-rich domain to play an essential role in the full functionality of Tat, and 
indicates the importance of the full sequence of the cysteine-rich domain (Rice 
and Carlotti 1990). 
The transactivation ability of HIV-1 Tat has been shown to massively vary 
with the introduction of single amino acid substitutions. Previously, mutations to 
the lysine residue at position 12, K12, has been shown to result in increased 
binding to p300/CREB-binding protein-associated factor (PCAF), potentially 
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leading to neuronal apoptosis (Wong, Sharma et al. 2005, He, Zhang et al. 
2013). Comparison of Tat mutants suggested that mutation of A21 could 
potentially lead to a reduction in Tat-activated kinase activity as high as 60%, 
yielding a tendency towards post-integration latency (Reza, Rosetti et al. 2003). 
Additionally, much has been reported about the role of threonine 23 in affecting 
Tat transactivation of the HIV-1 promoter. Of note, the substitutions T23Q, T23D, 
T23E, and T23V have been shown to reduce Tat transactivation 30-40% (Reza, 
Shen et al. 2003). In our study, T23 is negatively associated with impairment, 
indicating that reduced transactivation ability may be an advantage in trafficking 
to the CNS and avoidance of the immune response in periphery. Similar to T23, 
T40 also is negatively associated with impairment, with mutations or 
phosphorylation of this variant leading to the loss of Tat-cycling T1 interaction 
(Yoon, Kim et al. 2015). Finally, V36A has been shown to be incapable of LTR-
driven transactivation of HIV-1 transcription, consistent with a trend of reduced 
activation associated with neurocognitive impairment. In the present study, V36 
is strongly negatively associated with non-impairment (Ammosova, Jerebtsova et 
al. 2005, Ammosova, Yedavalli et al. 2011). Position 59 was the site of the most 
prominent amino acid exclusive to one group, with all 7 incidences of 59H 
occurring in impaired samples (25.9% prevalence), with this substitution being 
entirely absent among non-impaired samples. The glutamine-rich domain of Tat 
has been demonstrated to be involved in T-cell apoptosis previously in a study of 
subtype D Tat proteins.   
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This study is the first direct study of genetic associations of HIV-1 Tat with 
neurocognitive impairment in an exclusively subtype B cohort well-suppressed by 
ART and using next generation sequencing technology. The statistical approach 
used in these studies provides further evidence with respect to the role of genetic 
diversity in Tat-mediated neurocognitive impairment, and demonstrates the 
potential for a genetic signature within the peripheral blood compartment of 
therapeutically-suppressed individuals (Choi, Hightower et al. 2012, Rao, Neogi 
et al. 2013). Furthermore, the NGS data analyzed in these studies account for 
intrapatient diversity and minority Tat variants. Overall, these methodologies 
outlined in these studies can be easily extended to other HIV-1 subtypes as well 
as sequences derived from other cohorts.  
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5.1 Abstract 
This thesis has focused on two major areas of research: developing a 
strategy to assess signatures of co-receptor utilization that extend beyond the 
envelope and affect the co-adaptation of HIV accessory proteins such as Tat and 
Vpr to different cellular compartments as enabled by utilization of different co-
receptors (CCR5 and CXCR4), and utilizing the genetic variation of HIV-1 Tat to 
assess the likelihood of neurocognitive impairment and to identify potential 
predictive variants. This Chapter will include a summary of the principle results and 
conclusions, the most important questions yet to be conclusively answered, and 
proposed future studies to address them. This commentary will include current and 
future experimental approaches to deepen the understanding of the 
interrelatedness of HIV-1 entry genotype along with co-adaptive changes in other 
regions of the viral genome such as Vpr and Tat, and the development of 
neurocognitive disorders will be discussed. Furthermore, some preliminary yet 
unpublished observations regarding these future studies have been included, 
although they may lack the scope or precision to be regarded as conclusive 
studies. Finally, the significance and innovation of this research will be discussed 
in the context of the state of the field and the future of HIV-1 disease management 
and cure efforts. 
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5.2 Summary of Major Results 
1. Jensen-Shannon divergence can be applied to compare multiple 
sequence alignments and identify signature positions that are most 
distinct between X4- and R5-utilizing HIV-1 genotypes or 
quasispecies. 
This result is consistent with the observation that Jensen-Shannon 
divergence also strongly correlates with differences in HIV-1 diversity 
between X4 and R5 sequence populations, suggesting that differences in 
amino acid utilization can be attribute to the loss or gain of overall diversity, 
as well as the specific changes in amino acid distributions. This result was 
confirmed to hold true in the well-studied envelope protein of HIV-1, as the 
highly variable and co-receptor-directing V3 region of the envelope gene 
was enriched with statistically divergent positions, while other variable 
regions of envelope were not (Chapter 2). With regards to HIV-1 Tat protein, 
Jensen-Shannon divergence identified positions 7, 23, 57 and 60 to express 
differential amino acid usage when compared on the basis of associated 
co-receptor utilization (Chapter 2). Furthermore, using hierarchically 
clustered alphabets for amino acid representations did not appear to 
introduce variation in the identification of divergent positions, though it did 
allow positions with larger potential impact on function to be confidently 
identified (Chapter 3). 
2. Predicted transcription factor binding sites demonstrate statistically 
different binding affinity scores for X4 and R5 LTR sequences. 
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With regards to the HIV-1 LTR promoter, high divergence between X4 and 
R5 nucleotide sequences extended both upstream and downstream of the 
transcription start site, with each population exhibiting signature 
enrichments in nucleotide abundance (Chapter 2). Consistent with previous 
studies of HIV-1 transactivation, C/EBP and Sp binding sites demonstrated 
variability between populations while NF-kB was most highly conserved 
between the two co-receptor defined groups (Chapter 2). 
3. Standard demographic and clinical measurements demonstrate utility 
as a screening tool in the Drexel Medicine CARES Cohort.  
The simple and time-efficient Hopkins Dementia Test demonstrates some 
capacity to predict GDS-classified impairment status; however, the 
development of a better-performing predictive model that incorporates 
features in addition to neuropsychological testing was the principal goal of 
this study. Among the demographic and clinical metrics considered as 
features in predictive modeling, CD4+ T-cell count, age, and years 
seropositive were included in the optimized model using logistic regression. 
Notably, larger CD4+ T-cell counts, which typically are associated with 
healthier HIV-1 disease status, associated with neurocognitive impairment. 
It is hypothesized that this association may be due to increased trafficking 
of latently-infected CD4+ T-cells to the CNS, and may play an enhanced 
role in the ART era when most individuals have well-suppressed CD4+ T-
cell counts.  
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4. HIV-1 next generation sequencing (NGS) information can be utilized in 
the development of a screening tool for identifying genetic features of 
relevance to HIV disease pathogenesis. 
The depth of coverage enabled by NGS allowed HIV-1 genetic variation to 
be calculated and compared at both an intrapatient, as well as interpatient, 
levels. Interpatient diversity was much greater than intrapatient diversity at 
certain positions, and intrapatient diversity was strikingly low across all 
samples, indicating relative homogeneity within patients as compared to 
between patients. Logistic regression models of neurocognitive impairment 
tended to outperform analogous models built using only standard clinical 
features, indicating the potential for genetic information to enhance overall 
algorithm performance. The genetic variants that most strongly associate 
with neurocognitive impairment include 36V, 40T, 63E, and 23T, while 
variants that strongly associated with non-impairment include 59P, 74H, 
and 12K. Importantly, the inclusion of only the top two features, 59P and 
36V, maintain most of the model performance in a genetic only model (0.66 
+/- 0.04 AUC versus 0.64 +/- 0.03 AUC), and is virtually identical when 
incorporated into the final model including both genetic and clinical features 
(0.73 +/- 0.03 versus 0.74 +/- 0.03). 
 
5.3 Most Pressing Questions and Future Studies 
1. Does the X4/R5 genotype extend beyond the envelope in HIV-1 
enzymatic proteins such as protease and integrase? 
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When assessing genetic differences between the X4 and R5 HIV-1 
genomes, the long-terminal repeat (LTR), tat and vpr were specifically 
evaluated due to their interaction with a vast number of host cellular 
transcription factors (Kamori and Ueno 2017). Although it is now well-
established that X4 and R5 HIV-1 phenotypes do not exclusively infect 
particular cell types, specifically monocytes versus T cells, there is an 
underlying propensity for certain HIV-1 strains to be able to enter certain 
cell types on the basis of co-receptor expression levels (Aiamkitsumrit, 
Dampier et al. 2014, Joseph, Arrildt et al. 2014). In addition to differences 
in co-receptor expression, HIV-1 target cells also exhibit different cellular 
microenvironments, including expression levels of selected transcription 
factors (Kilareski, Shah et al. 2009). Accordingly, it was hypothesized that 
the correlation of transcription factor differences with co-receptor 
expression levels could result in HIV-1 selective pressures that affect TF-
binding proteins such as Tat and Vpr. The data presented in this thesis 
provides support for this hypothesis, specifically with regards to C/EBP and 
SP binding sites, but not for NF-κB sites. 
With regards to HIV-1 enzymatic proteins such as protease and 
integrase, these proteins also must interface with host proteins, and result 
in protein association such as the pre-integration complex (PIC) (Matreyek 
and Engelman 2013). Accordingly, these proteins may likely exhibit co-
linear co-receptor utilization differences resulting in inherent differences in 
their coding sequence and structural architecture due to the same cellular 
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microenvironment dependent pressures as hypothesized for Tat, Vpr, and 
the LTR. In order to test this hypothesis more directly, DNA sequencing of 
the 5’ half of the integrated HIV-1 genome, including co-linearity with the V3 
region of envelope, would need to be performed. Sequencing of this region, 
however, is not as straightforward as sequencing for Tat and Vpr due to the 
increased distance of these genes from the V3 region of env. While 
sequencing platforms, such as Pacific BioSciences, allow for exceptionally 
long read lengths that may be able to address this issue, application of this 
methodology requires prohibitory DNA-input amounts and high error rates 
that make single molecular real time (SMRT) sequencing impractical (Quail, 
Smith et al. 2012).  This limitation likely requires full genome sequencing of 
the HIV-1 genome, with ensuring reconstruction of the HIV-1 quasipecies 
within a given sample. Methods for the reconstruction of full genome 
sequences, using short reads such as those produced by the Illumina 
platform, have been developed and allow for the study of HIV-1 evolution at 
a whole genome level  (Pandit and de Boer 2014). 
 
2. How well does the X4/R5 classification of a genome serve as an 
indication of the cell phenotypes infected with a given HIV-1 type? 
In general, these analyses have investigated viral genetic data on an 
aggregate level, with samples being derived largely from peripheral blood. 
Because peripheral blood is easily accessible with largely non-invasive 
technology, it provides an obvious target for monitoring HIV-1 disease 
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progression and surveying the genetics of the virus. However, HIV-1 has 
been studied extensively at finer granularity, not only at the tissue level but 
also at the cellular level (Symons, Chopra et al. 2017). While current ART 
drug regimens demonstrate efficient clearance of actively replicating HIV-1 
from peripheral blood, sanctuary tissue compartments, including gut, 
lymphoid tissue, and CNS, are believed to sustain low, smoldering levels of 
HIV-1 replication either continuously or intermittently (Poveda and 
Tabernilla 2016). Furthermore, knowledge of these sanctuary sites has 
been used to computationally model CD4+ T-cell count dynamics 
accurately (Wang, Hottz et al. 2015). At a cellular level, recent studies have 
implicated particular CD4+ T-cell subsets, especially memory T cells, as 
harboring latent, integrated provirus (Kulpa and Chomont 2015). 
Applying the methodologies developed in this research to data 
collected at the tissue- or cell-specific level is critical to gaining a deeper 
understanding of HIV pathogenesis and identifying focused targets for new 
interventions. The relationship between X4/R5 HIV-1 classification and cell-
type infection has been demonstrated to exhibit many exceptions 
(Woodham, Skeate et al. 2016). However, a full and thorough accounting 
of both HIV-1 genotype and associated cell type requires extremely 
sensitive sequencing technology and flow cytometry techniques, or an 
extremely large amount of starting material. Furthermore, non-productively 
infected cells must be properly filtered from those cells capable of producing 
potentially infectious virus, a process which requires viral outgrowth assays 
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(Laird, Rosenbloom et al. 2016). These challenges have been explored 
through preliminary studies dedicated to isolating HIV-1 strains from 
particular cellular subsets regarded to play a role in HIV-1 pathogenesis and 
latency (Figure 5.1). 
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Figure 5.1. Flow cytometry strategy for sorting and collecting cells of 
particular interest to HIV-1 infection and latency. This strategy would collect 
both classical and proinflammatory monocytes using the CD14 and CD16 markers, 
as well as T-cell subsets, termed effector memory and central memory, on the 
basis of CD45RA, CCR7, and CD27.  
	 227	
Figure 5.1 
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3. How well does peripheral blood (PBMC)-derived Tat reflect the genetic 
diversity of Tat found in brain tissue? 
A major assumption in these studies is that HIV-1 provirus sequenced from 
the periphery is a useful proxy for the genetic constitution of HIV-1 provirus 
present within the CNS. Previous studies, however, have demonstrated 
varying levels of compartmentalization between the CNS and periphery 
(Bednar, Sturdevant et al. 2015) not to mention between different regions 
of the brain (REF). Regardless of this compartmentalization, however, HIV-
1 quasi-species tend to be more similar within individuals than within 
physiological compartments. That is, there is only limited evidence that 
brain-specific HIV-1 strains exist (Vazquez-Santiago and Rivera-Amill 
2015). In reality, HIV-1 infection within an individual is a dynamic process in 
which cells may traffic between bone marrow, lymphoid tissue, peripheral 
circular, and the CNS (Alexaki and Wigdahl 2008). From this perspective, 
being able to assess a signal within the periphery that is predictive of a 
disease affecting the CNS is a major advantage due to its easy accessibility. 
However, inferring molecular mechanisms within the CNS based on the 
genetic variants found in the periphery are not guaranteed to be accurate 
or applicable. The most direct approach to assess these differences would 
be to repeat the same NGS techniques used in these studies on brain-
isolated tissue paired with peripheral samples and then assess the 
between-group and within-group variance of HIV-1 mutations of interest. 
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Furthermore, phylogenetic methods, such as maximum-likelihood tree 
buildling, can be applied to look for evidence of compartmentalization. 
 
4. Does the co-receptor usage of HIV-1 associate with the development 
or enhanced risk of HIV-associated neurocognitive disorders (HAND)? 
Two of the major conclusions of this research – that HIV-1 exhibits X4- and 
R5-like genotypes and that particular strains of HIV-1 are more likely to be 
associated with HAND – imply that co-receptor utilization may also correlate 
with an increased likelihood for HAND development. In general, X4 HIV-1 
strains have been associated with advanced disease progression, although 
the causality of this relationship has not been determined (Santoro, Armenia 
et al. 2012). Importantly, many infected individuals that develop advanced-
stage HIV disease do not experience a co-receptor switch to X4, indicating 
that X4 infection is not a requirement for advanced disease status (Mortier, 
Dauwe et al. 2013).  
 R5 and X4 HIV-1 strains have also been associated with particular 
cell types, with R5 viruses thought to more likely to infect cells of the 
monocyte-macrophage lineage than X4 (Duncan and Sattentau 2011). It is 
also monocytes, rather than T cells (although this dogma is currently under 
renewed investigation), that are thought to traffic across the blood-brain 
barrier and lead to the development of neurological impairment (Strazza, 
Pirrone et al. 2011). Accordingly, the R5 genotype has been hypothesized 
to be more neurotropic, purely because it is more likely to be found in the 
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CNS and more likely to be associated with cells of the monocyte-
macrophage lineage. Whether or not X4 or R5 variants of Tat, Vpr, and Env 
contribute more to neurotoxicity, either directly or indirectly, is the focus of 
the next question. 
 
5. What is the likely mechanism by which identified HIV-1 amino acid 
polymorphisms contribute to neurocognitive disease progression? 
The precise molecular mechanism of HIV-1-associated neurocognitive 
disorders (HAND) is an area of extensive ongoing studies. However, the 
role of Tat, Vpr, and Env as neurotoxic proteins has been well-established 
(Hategan, Bianchet et al. 2017). With regard to overall disease progression, 
however, it remains unclear if enhanced levels of extracellular viral proteins 
in the CNS are involved impairment, or if particular modifications to the 
protein secondary structure lead to differential protein-protein binding 
interactions or potentially both. Previous studies regarding HIV-1 subtype C 
of Tat in particular suggest the latter may be true (Aralaguppe, Sharma et 
al. 2016). 
 Tat in particular has been evaluated via preliminary studies, as it has 
a wide variety of potential binding partners and is an inherently flexible and 
unstructured protein. The interaction of Tat with the N-methyl-D-aspartate 
(NMDA) receptor may mediate the progression of HAND via the induction 
of proinflammatory cytokine release and neurotoxicity in infected individuals 
(Rumbaugh, Bachani et al. 2013). Molecular modeling studies indicate that 
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single amino acid polymorphisms can greatly alter the interaction between 
Tat and the NMDA receptor, as well as between Tat and positive 
transcription elongation factor b (P-TEFb). While molecular modeling 
studies provide further evidence for the mechanism of Tat neurotoxicity, in 
vitro functional studies using the same mutations would also need to be 
performed for more complete validation of the proposed impact. 
 
6. How may host genetics also contribute to HIV-1 disease progression 
and the development of neurocognitive impairment 
The focus of the proposed studies has been nearly completely on viral 
genetic signatures. However, the interplay of viral genetics with host 
genetics is an important remaining question, and may be responsible for 
much of the variance and noise in the analyzed data. Previous studies have 
indicated that most genetic variation within HIV-1 is driven by selective 
pressures imposed by the host immune system, which is directly 
determined by host genetics (Kloverpris, Leslie et al. 2015). Immune 
evasion, especially from the cytotoxic T lymphocyte (CTL) response, may 
lead to the survival of particular genetic variants, both in the short term as 
well as the long-term survival of the HIV-1 reservoir in well-suppressed 
individuals (Kamori and Ueno 2017).  
The latter phenomenon is particularly important in the antiretroviral 
treatment (ART) era, as the composition of the HIV-1 reservoir and 
persistence of HV-1 comorbidities despite maintenance of viral load and 
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CD4+ T-cell levels are important areas of ongoing research. In order to 
assess the impact of host genetics, HLA-typing of HIV-1-infected patients 
in the Drexel Medicine CARES Cohort would need to be performed. This 
information can then be used to infer the likely epitopes within the HIV-1 
populations, and determine the interplay of host and viral genetics (Figure 
5.2). 
 
  
	 233	
Figure 5.2 Dynamics of the HIV-1 reservoir in response to HIV-1 latency, 
reactivation, CTL-mediated immunity, and protein expression. The HIV-1 T- 
cell reservoir periodically will undergo reactivation and clonal amplification, at 
which point HIV-1 proteins will be expressed. In a therapeutically suppressed 
individual, new infection will not be possible and HIV-1 expression will result in the 
removal of infected cells by the CTL-mediated response. The exception to this 
process would be the expression of HIV-1 quasipecies that are evasive with 
respect to the immune response. Over time, this is expected to result in increased 
homogeneity of the HIV-1 reservoir. 
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Figure 5.2 
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7. How can clinical and genetic information be best integrated to develop 
a HIV-1 neurocognitive impairment tool with both high sensitivity and 
specificity? 
The current model presented in these studies achieves a modest specificity 
and sensitivity that is useful for the inference of important genetic and 
clinical features, but has limited capacity as a predictive clinical tool without 
being extremely permissive of a high false positive rate (FPR). Furthermore, 
the model performance is scored on the basis of cross-validation metrics, 
rather than utilizing a separate and independent validation Cohort. This 
cross-validation approach was utilized due to small sample numbers, and 
also to assess the generalizability of the model across folds. However, this 
approach may also lead to overfitting. 
 Future studies will need to address this shortcoming by testing the 
trained model performance on an independent test set. Ideally, this test set 
could come from a geographically independent test set of infected 
individuals undergoing the same battery of neurocognitive testing. The 
overall model performance may also be improved by combining clinical and 
genetic data into a single model. Alternatively, this could be performed in 
an ensemble approach, in which the predicted output from both models is 
combined and a consensus conclusion is reached. 
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5.4 Significance and Innovation 
As demonstrated by the Drexel Medicine CARES Cohort other 
investigations of HAND and HIV-1 co-morbidities, individuals that respond well to 
therapy (as measured by CD4+ T-cell count and viral load) still remain highly 
vulnerable to an array of additional disease manifestations. The overarching aim 
of these studies is to assess the role HIV-1 genetic diversity plays in disease 
progression in the era of highly active antiretroviral treatment (HAART).  
The consideration of HIV pathogenesis as a direct outcome of HIV-1 viral 
evolution within the context of an infected individual is a paradigm that has been 
largely been ignored beyond studies of HIV-1 drug resistance. While extensive 
databases exist — such as the Stanford HIV Drug Resistance Database — that 
tether HIV-1 SNPs and amino acid polymorphisms to the likelihood of drug 
resistance, such associations have not been thoroughly documented for co-
morbidities such as HIV-1-associated neurocognitive disorders, despite some 
small scale studies being performed (Rhee, Gonzales et al. 2003, Choi, Hightower 
et al. 2012). Additionally, databases such as the HIV Brain Sequence Database 
[http://www.hivbrainseqdb.org/] do not contain sequence regions other than the 
gp120 envelope, and neurocognitive disease status is absent from larger 
databases such as the Los Alamos HIV Sequence Database 
[http://www.hiv.lanl.gov/].  
Accordingly, these studies bridge both shortcomings, as it utilizes data 
collected on neurocognitive impairment and evaluates genes other than the 
envelope. Furthermore, the juxtaposition of these neurocognitive analyses with 
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studies regarding HIV-1 co-receptor utilization provide a broader context for the 
development of neurocognitive impairment with respect to overall HIV-1 selection 
and variation within the peripheral blood. 
The expansiveness of HIV-1 genetic diversity makes it a very difficult 
system to assess and characterize exclusively through in vitro studies. Single 
nucleotide polymorphism (SNPs) and amino acid polymorphisms can greatly alter 
the functionality of a particular protein or promoter region of the LTR. However, 
evaluating all possible polymorphisms, and combinations of polymorphisms, is an 
impossible undertaking. Accordingly, robust statistical techniques that can screen 
and identify the most likely genetic variants that associate with disease progression 
are highly valued. While these associations alone do not establish a causative 
relationship, they do allow particular variants to be prioritized for further evaluation, 
while maintaining a focus only on clinically relevant variants found in a patient 
population. By restricting future studies to patient-derived genetic variants, we can 
more directly test hypotheses related to individuals’ disease progression, and 
potentially make predictions about future risks. 
A major innovation of this study was the use of next generation sequencing 
(NGS) data in the studies of neurocognitive impairment. While there have been a 
few small scale studies that have assessed the role that Tat variation potentially 
plays in the development of HAND, NGS methods have not been utilized. 
Additionally, while NGS DNA-Seq studies have become more common in recent 
years, the vast majority of these studies have performed targeted sequencing of 
either enzymatic targets such as protease, or structural genes such as the 
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envelope. Overall, very few DNA-Seq studies have been performed on the 
accessory gene tat, which was of primary interest in our studies given the results 
of previous research and the underlying hypotheses regarding Tat’s role in 
neurotoxicity. These methods allow us to take into account the distribution of 
genetic variants that exist within individuals, as well as within particular populations 
or groupings of interest. The explosion of next generation sequencing techniques, 
coupled with the rapid descent in pricing for these technologies, suggests a new 
era of personalized medicine on the horizon in which DNA-Seq and RNA-Seq of 
patients could become a routine blood test. This research provides a scalable 
framework that allows the interpretation of the large amounts of data collected from 
a single NGS experiment. 
The statistical methodologies outlined in Chapters 2 and 3 are also 
innovative, as the structural and functional similarities of amino acids are 
incorporated into the analysis. Rather than applying an approach that considers all 
amino acids to be independent, a hierarchical structure based on chemical 
similarity was applied in Chapter 3. Additionally, both Chapters 2 and 3 performed 
analyses at the level of a position, rather than a particular variant, and considered 
the distribution of amino acids encoded by the sequences using a Jensen-
Shannon distance metric to assess the deviation from expectation. This distribution 
approach is a deviation from many genetic studies that simply compare to an 
arbitrary reference genome, and is more applicable to a system more aptly 
modeled as a highly diverse population rather than a single species. Finally, 
although a variety of more complicated machine learning approaches could 
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potentially be applied to assess the risk of neurocognitive impairment in the 
absence of a full neuropsychological examination, regularized logistic regression 
was applied in order to maintain model interpretability as well as deal with the high 
dimensionality of genetic data. 
In summary, these studies evaluate HIV-1 from a population genomics 
perspective, and seek to use genetic information from the peripheral blood to infer 
sophisticated disease processes that ultimately affect the CNS. These studies also 
explicitly evaluate HIV-1 accessory proteins and the LTR, which are most 
responsible for controlling HIV-1 transcription and latency. Within the HAART era, 
it is reasonable that these accessory proteins may need to exhibit qualities that 
allow them to remain latent and evasive of the immune system long-term, which 
may manifest in other affects such as cell-type specific selection and neurotoxicity. 
While many future experimentations will need to be performed, as outlined above, 
these genetic studies lay a strong foundation for how to evaluate additional data 
and target clinically relevant genetic signatures of HIV-1. 
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